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PREFACE
Ointments, creams and o th e r to p ic a l p re p a ra tio n s  a re  
ap p lied  to  th e  broken o r to  th e  in ta c t  sk in . This th e s is  is 
a study o f th e  ab so rp tio n  of drugs through th e  in ta c t  sk in  
o f r a b b i ts ,  s ince  a survey o f the  l i t e r a t u r e  has shorn th a t  
th e  r e s u l t s  and conclusions of many workers a re  bo th  confusing  
and c o n f lic t in g . The degree o f p e n e tra tio n  and ab so rp tio n  o f 
drugs through broken sk in  has not been considered .
In  genera l th e  methods used to  a sse ss  o r ev a lu a te  
th e  e f f ic ie n c y  o f to p ic a l  a p p lic a tio n s  f a l l  in to  two c a te g o rie s , 
namely in  vivo and in  v i t r o  tech n iq u es. The in  vivo techniques 
include h is to lo g ic a l  methods, which fo llow  th e  p a th  o f th e  
ap p lied  drug in to  and th r o u ^  th e  sk in , and blood o r u rin e  
assay  methods, which es tim ate  th e  amount o f drug which p e n e tra te s  
and i s  absorbed in to  o r excre ted  from; th e  blood stream . The 
in  v i t r o  tech n iq u es, on th e  o th e r hand, u su a lly  'Sim ulate th e  
cond itions met w ith  when p re p a ra tio n s  a re  ap p lied  to  th e  
broken sk in  and they  asse ss  th e  r a te  a t  vAiich th e  inco rpo ra ted  
drug d if fu s e s  or i s  l ib e ra te d  from i t s  v eh ic le  o r base.
An in  vivo t e s t  has been designed to  estim ate  th e  
blood le v e ls  o f sev era l drugs when th e se  a re  inco rpo ra ted  
in  a  number of se le c te d  v eh ic le s  and bases and ap p lied  to  th e
c lipped  in ta c t  sk in  o f r a b b its  over a p erio d  o f tim e. The 
t e s t  devised  i s  considered to  be a reasonab le  method o f 
a s se ss in g  th e  degree o f percutaneous ab so rp tio n  encountered 
when d rugs, e a s i ly  and a c c u ra te ly  assayed , a re  used in  t h i s  
way.
INTRODUCTION
T opical p re p a ra tio n s  may be form ulated  w ith  two 
d if f e r e n t  purposes in  view depending upon whether a lo c a l  o r 
system ic e f f e c t  o f  th e  incorpora ted  drug i s  d e s ire d . In  
each o f  th e se  cases th e re  i s  a need fo r  s u i ta b le  methods 
which ev a lu a te  drug re le a s e  from th e  v e h ic le s  o r  bases used .
The number o f v eh ic le s  and bases in  use fo r  th e  p re s e n ta tio n  
o f m edicinal substances to  th e  sk in  i s  la rg e  and th e  recen t 
advances in  form ulation  w ith  th e  modem sy n th e tic s  such as 
th e  s i l ic o n e s  and th e  propylene g ly co ls  and r e la te d  compounds 
have le d  to  th e  in tro d u c tio n  o f new types and form s.
The degree o f p e n e tra tio n  and ab so rp tio n  o f a drug 
from a to p ic a l  a p p lic a tio n  i s  in fluenced  by th e  p ro p e r t ie s  
and s t ru c tu re  o f  th e  sk in . The sk in  c o n s is ts  o f  a  non-vascu lar 
ex te rn a l covering  o f ep ithelium , th e  ep iderm is, and a la y e r  
o f v a sc u la r  connective t i s s u e ,  th e  cerium or derm is. On 
th e  o u te r  su rface  o f th e  epiderm is i s  a th ic k  non-nucleated  
la y e r , th e  stra tum  comeum. Beneath t h i s  i s  th e  stratum  
lucidum a t  th e  base o f  which i s  th e  stra tum  granulosum#
The innerm ost la y e r  o f  th e  epiderm is i s  th e  stra tum  
M a lp i^ i i  o r stra tum  germinatuvum, a la y e r  o f a c t iv e ly  
d iv id in g  c e l l s .  The in n er corium or dermis i s  composed
m ainly o f connective t i s s u e  and i s  w ell supp lied  w ith  hlood 
c a p i l l a r i e s .
The o u te r  epiderm is i s  r ic h  in  l ip o id s  and 
c h o le s te ro l e s te r s  p re se n tin g  a g reasy  la y e r  which delays 
p e n e tra tio n  o f aqueous so lu tio n s  in to  th e  k e ra t in is e d  
la y e rs  o f  th e  stratum  corneum. I t  i s  e l e c t r i c a l ly
p o la r is e d  and behaves l ik e  a membrane w ith  a n eg a tiv e  charge
on th e  o u ts id e . T h e o re tic a lly  t h i s  membrane should be
permeable to  ca tio n s  and impermeable to  an ions. This
accounts fo r  th e  genera l im perm eability  of th e  sk in  to  
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e le c t ro ly te s .
The appendages o f th e  sk in  a re  th e  h a i r  f o l l i c l e s ,  
th e  sebaceous glands and th e  sweat g lands which p e n e tra te  
to  th e  dermal la y e r . The g re a te r  p a r t  o f percutaneous 
p e n e tra tio n  occurs by way o f th e  appendages and when 
p e n e tra tio n  has taken  p la ce  th e  only b a r r ie r  to  system ic 
ab so rp tio n  i s  th e  sebum, a se c re tio n  o f g ly c e r id e s , f a t ty  
ac id s  and c h o le s te ro l .
The p re se n ta tio n  o f medicaments in  th e  form o f 
o in tm ents, creams, lo t io n s ,  e t c . ,  may be considered  from 
th re e  main a s p e c ts . F i r s t ly ,  th e  p e n e tra tio n  of th e  o u te r  
epiderm is o f th e  sk in  by th e  drug in co rp o ra ted  in  a v eh ic le  
o r b ase , secondly, th e  l ib e r a t io n  o f th e  drug from th e
v e h ic le  or h ase , and th i r d ly ,  th e  passage o f th e  drug to  th e
dermal c a p i l la r ie s  and i t s  ab so rp tio n  in to  th e  b loodstream .
The con d itio n s governing each o f th e se  a sp ec ts  v a ry . Among
th e  f a c to rs  in flu en c in g  drug p e n e tra tio n  and ab so rp tio n
through th e  in ta c t  sk in  a re  th e  mode o f a p p l ic a tio n , th e
v e h ic le  o r base employed, th e  l ip o id  s o lu b i l i ty  o f th e  drug,
and th e  p a r t i t io n  c o e ff ic ie n t o f th e  drug between i t s  v e h ic le
o r base and th e  dermal se c re tio n s  such as  sw eat, sebum,
t i s s u e  lip o id s  and th e  e x tra c e l lu la r  f lu id s .
P e n e tra tio n  and ab so rp tio n  r e a d i ly  occur th rough
broken sk in  because th e  p ro te c tiv e  b a r r ie r  o f th e  o u te r
la y e rs  has been removed and only th e  p a r t i t i o n  c o e f f ic ie n t
o f th e  drug between th e  base and th e  wound exudate need be 
2-8
considered . Following th e  a p p lic a tio n  o f  su lphanilam ide
to  wounds in  r a b b its  LegrouS found a maximum blood
co n cen tra tio n  o f 4 -  5 mg./lOO ml* A study  in  th e  system ic
ab so rp tio n  o f minute q u a n ti t ie s  o f  n e u tra l so lu b le  stron tium -89
t h r o u ^  th e  sk in  of th e  r a t  showed th a t  f i f t y  p e r  cent o f th e
amount app lied  reaches th e  body in t e r i o r  when th e  c o n tin u ity
10
o f th e  o u te r sk in  la y e rs  i s  broken. Repeated a p p lic a tio n s  
o f  a f iv e  p e r cent su lp h a th iazo le  ointm ent over h a l f  th e  
body su rface  o f in fa n ts  under trea tm en t fo r  sk in  in fe c tio n s  
were shown to  g ive blood le v e ls  o f  2-4 m g./100 m l.
As e a r ly  as  1809 th e  system ic ab so rp tio n  o f drugs
through th e  sk in  was proved by th e  d e te c tio n  in  th e  u r in e  o f
12
substances which had been p rev io u sly  ap p lied  to  th e  sk in .
In  1871 and I 88O, h is to lo g ic a l  methods in d ic a te d  th a t  th e  
avenues fo r  th e  en trance of mercury ap p lied  to  th e  sk in  in
13,14
an ointm ent were th e  h a ir  f o l l i c l e s  and sebaceous g lan d s .
I t  has been observed th a t  p re trea tm en t o f th e  sk in  w ith  
such substances as chloroform , e th e r  o r a lcoho l enhances 
th e  p e n e tra tio n  o f w ater so lu b le  a lk a lo id a l s a l t s ,  s in ce  
th e  hygroscopic p ro p e r tie s  o f th e  sk in  su rface  and o f th e  
w a lls  of th e  h a i r  f o l l i c l e s  and sebaceous g lands had been 
in c reased  w ith  th e  removal o f th e  n a tu ra l  w ater r e p e l l in g
15
l ip o id  m a te r ia ls . This work was l a t e r  confirmed and
chloroform , e th e r  and a lco h o ls  were shown to  have p e n e tra te d  
16
th e  sk in . An e a r ly  review  ( 19OI) emphasised th a t  many 
m edicinal agen ts ap p lied  to  th e  unbroken sk in  would produce
17th e ra p e u tic  e f f e c t s .  Mention was made o f th e  c o n s t i tu t io n a l  
e f f e c ts  o f  belladonna from p la s te r s  con ta in ing  th e  drug; 
s a l iv a t io n  from mercury in u n c tio n , system ic e f f e c ts  from 
cutaneous a p p lic a tio n s  o f p ilo c a rp in e  mixed w ith  la r d ,  and 
th e  f in d in g  in  th e  u rin e  o f io d in e , s a l i c y l i c  a c id , tu rp e n tin e , 
g u a iac o l, c reo so te  and phenol as a r e s u l t  o f percutaneous 
ab so rp tio n . The u se fu ln ess  of in u n c tio n  w ith  cod l i v e r  o i l
17
in  scro fu lous co n d itio n s was a lso  no ted . In  I 9O8 th e  dyes 
fu sch in  and s c a r le t  red  were added to  a number o f  f a t s  and 
o i l s  in  o rder to  tr a c e  t h e i r  p a th s  in to  th e  sk in  a f t e r  
in u n c tio n . In  no in s tan ce  was dyed f a t  ever observed to  
pass d i r e c t ly  in to  o r through th e  sk in  from which i t  was
18
assumed th a t  th e  sk in  was impermeable to  f a t .  P e n e tra tio n , 
however, occurred in  th e  appendages. An approxim ate 
ev a lu a tio n  o f th e  degree o f p e n e tra tio n  o f th e se  common o i l s  
and f a t s  showed th a t  th e  p e n e tra tio n  of m ineral o i l s  and 
p a ra f f in s  was poor w hile th e  p e n e tra tio n  o f animal f a t s  such
19
as goose g rease was e x c e lle n t. By adop ting  a method o f te n  
re fe r re d  to  as  th e  "a n a ly s is  by d iffe re n ce "  tech n iq u e . Wild 
in  1911 obtained  q u a n ti ta t iv e  r e s u l t s  fo r  a range o f ointm ent 
bases con ta in ing  m ercu ria ls . The experim ents were made by 
rubbing a c a re fu lly  weighed q u a n tity  o f th e  ointm ent in to  a 
d e f in i te  area  o f  sk in  fo r  a f ix e d  tim e. The ointm ent was 
then  scraped o f f  by a d u lle d , ta re d  razo r b lade which was 
weighed* The lo ss  o f weight rep resen ted  th e  amount o f 
ointment absorbed. The co n c en tra tio n  o f mercury o r m ercuria l 
s a l t  in  th e  ointm ent befo re  and a f t e r  a p p lic a tio n  gave th e  
amount o f mercury absorbed. The r e s u l t s  showed that g re a te s t  
abso rp tion  o f mercury took p la c e  from a la rd  base but showed 
a lso  th a t  hydrous wool f a t  was absorbed to  a g re a te r  ex ten t
8th an  la r d  although th e  ab so rp tio n  o f mercury was a c tu a l ly
le s s .  Of th e  d i f fe re n t  m ercu ria ls  te s te d  th e  oxide was
20
th e  most re a d i ly  absorbed. Burgi adapted t h i s  method by
cementing to  th e  sk in  a b e ll-sh ap ed  g la s s  v esse l f i l l e d  w ith
th e  substance to  be s tu d ie d . A liquot p o r tio n s  were removed 
21
and assayed . The weakness o f th e  technique l i e s  in  th e  
assum ption th a t  when a substance d isappears from th e  su rface  
o f  th e  sk in  i t  has passed  t h r o u ^  th e  sk in  and en te red  th e  
organism . Some m a te ria l a lleg e d  to  have "p e n e tra te d ” may 
have been lodged in  th e  sk in  appendages, and must be judged 
o u ts id e  th e  body.
D iscussing  n u tr ie n ts  f o r  ex te rn a l a p p lic a tio n s  to  
th e  body L atze l and S te js k a f  prepared  emulsions from 
substances such as hog f a t ,  b u t te r ,  o liv e  o i l  and v itam ins 
and claimed th a t  i t  was p o ss ib le  to  feed  p a t ie n ts  by d a i ly  
in unc tion  w ith  I 5O -  200 grammes o liv e  o i l .  W in tern itz
23
and Nauman re je c te d  t h i s  claim  and found on th e  b a s is  o f  
io d ised  o i l  in je c t io n s  th a t  approxim ately  one f i f t e e n th -  
hundreth o f th i s  amount p e n e tra te d .
The dangers a s so c ia ted  w ith  th e  ab so rp tio n  o f
24-26
drugs through th e  sk in  has been noted from tim e to  tim e.
A f a t a l i t y  r e s u lte d  from th e  s p i l l i n g  o f an a rse n ic a l l iq u id
27
over th e  le g s  and f e e t .  Death has re s u lte d  from th e  ab so rp tio n
o f  phenol through th e  broken sk in  and ren a l damage has
28
follow ed th e  a p p lic a tio n  of phenol d re ss in g s . F a ta l i t i e s
have been rep o rted  due to  th e  ex te rn a l a p p lic a tio n  o f 
29,30
s a l ic y l ic  ac id  and cases o f po ison ing  have r e s u l te d  from
31th e  use of f iv e  to  te n  p e r cent s a l i c y l i c  a c id  o in tm ents.
The purpose fo r  which a to p ic a l  a p p lic a tio n  i s  
intended must be considered  in  th e  design  o f any t e s t  fo r  
th e  ev a lu a tio n  o f i t s  e f f ic ie n c y . The r a te  o f l ib e ra t io n  
o f a medicament from a base may be conven ien tly  determ ined 
by in  v i t r o  t e s t s  such as d if fu s io n  tech n iq u es. Degree 
o f p e n e tra tio n  may be estim ated  by in  vivo t e s t s  making 
use o f  h is to lo g ic a l  or h istochem ical methods. A bsorption 
in to  th e  bloodstream  can be assessed  by in  vivo o r by 
c l in ic a l  t e s t s  invo lv ing  th e  determ ination  o f  th e  drug in  




Several reviews have d e a lt  f u l ly  w ith  th e  ab so rp tio n  
o f d rugs. A survey and ev a lu a tio n  o f  th e  wide v a r ie ty  o f  
methods which have been devised to  determ ine th e  r a t e  o f  
re le a s e , degree o f p e n e tra tio n  and ab so rp tion  o f  th e  ap p lied  
medicament from th e  v e h ic le  i s  g iven . Chemical, p h y s ic a l, 
pharm acological, to x ic o lo g ic a l , h is to lo g ic a l  and m ic ro b io lo g ica l 
methods have been used . In  t h i s  wide range o f t e s t s  and 
techniques some have concerned them selves w ith  l ib e r a t io n ,  
some w ith  p e n e tra tio n , and some w ith  ab so rp tio n . To 
r a t io n a l i s e  th e  range o f methods th e  fo llow ing  c l a s s i f i c a t io n  
has been adopted .
CLASSIFICATION OF THE METHODS USED FOR THE 
EVALUATION OF DRUG RELEASE FROM TOPICAL 
APPLICATIONS
1. In  v i t r o  Methods (a )  D iffu sion  Methods
( i )  Chemical and P hysica l
E stim ations
( i i )  M icrob io log ica l Assay 
(b) Membrane Methods
( i )  Chemical and P hysica l
E stim ations
( i i )  M icrob io log ical Assay
11






Blood, Urine and Faeces A nalysis 
Organ A nalysis 
C h a ra c te r is t ic  R eactions 
Biopsy Examination 
H is to lo g ic a l Methods 
M iscellaneous Methods
3. C lin ic a l Methods
R ad io -ac tiv e  T racer Methods
12
1 . In  V itro  Methods
The in  v i t r o  methods which have been used a re  of
lim ite d  value but th ey  u su a lly  g ive an in d ic a t io n  o f th e
a b i l i t y  o f th e  v eh ic le  o r base to  l ib e r a te  th e  in co rp o ra ted
medicament under th e  cond itions o f  th e  p a r t ic u la r  t e s t .
(a ) D iffu sion  Methods
The u se fu ln ess  o f th e se  methods l i e  in  th e  f a c t
th a t  a d e f in i te  estim ate  of the  r a te  o f d if fu s io n  o f  a drug
from i t s  v eh ic le  can be made, a va lu ab le  r e s u l t  where th e
su rface  a c t iv i ty  i s  th e  purpose o f th e  a p p l ic a tio n .
( i )  Chemical and P h y sica l E stim ations
The assum ption in  th e  t e s t s  under t h i s  heading i s
th a t  th e  d is t r ib u t io n  o f th e  medicament between th e  v eh ic le
o r base and th e  a rea  o f sk in  under trea tm en t w il l  be s im ila r
to  th e  d is t r ib u t io n  o ccu rring  between th e  v eh ic le  o r base
and th e  medium o f th e  t e s t .  This d is t r ib u t io n  w i l l ,  however,
be c o n tro lle d  by th e  p a r t i t io n  c o e f f ic ie n t ,  which i s
approxim ately equal to  th e  r a t io  o f th e  s o lu b i l i ty  o f th e
medicament in  th e  v eh ic le  o r base to  i t s  s o lu b i l i ty  in  th e
medium o f th e  t e s t .  The amount o f  phenol l ib e ra te d  from a
5 p e r cent so lu tio n  o f phenol in  o i l  was shown to  be almost 
42
n e g lig ib le , and i t  has been po in ted  out th a t  th e  v eh ic le  
must be ab le  to  p a r t  w ith  th e  drug and not "hold" i t ,  t h i s
13
f a c t  being  emphasised by re fe ren ce  to  th e  d if fu s io n  o f
43
s a l i c y l ic  and b o ric  ac id s  from d if fe re n t  b ases . S a lic y lic  
ac id  d iffu sed  ra p id ly  from la rd  and slow ly from p a ra f f in  
in to  a supernatan t aqueous so lu tio n  o f f e r r i c  ch lo rid e  w hile 
th e re  was p r a c t ic a l ly  no d if fu s io n  o f th e  b o r ic  a c id  
inco rpo ra ted  in  a p a ra f f in  ointment* The d if fu s io n  o f 
sulphonamides from v ario u s ointm ent bases in to  bo th  s a lin e
Q 44,45
and serum a t  37 C has been used fo r  t h e i r  e v a lu a tio n . F u lle r ,
46
Hawking and P a r tr id g e  c a rr ie d  out experim ents to  determ ine 
th e  r a te  o f  d if fu s io n  in to  w ater o f sulphonamides incorpora ted  
in  a s o lid  gel o f  agar o r g e la t in  and o i ly  b ases . They 
concluded th a t  only  a sm all p ro p o rtio n  o f th e  t o t a l  sulphonamide 
passed  in to  th e  w ater from an ointm ent base and th e  d if fu s io n  
took p lace  from th e  su rface  la y e r s ,  th e  p re p a ra tio n s  m isc ib le  
w ith w ater l ib e ra te d  th e  drug much more re a d i ly  than  
p rep a ra tio n s  im m iscible w ith w ater and th a t  in c re ase  in  
p a r t i c le  s iz e  o f th e  drug and p r e f e r e n t ia l  w e ttin g  w ith o i l  
re ta rd e d  d if fu s io n . The speed o f  d if fu s io n  o f s a l ic y la te s  
from tw elve bases in to  w ater, g e la t in  b locks and o liv e  o i l  
has a lso  been compared!
( i i )  M icrob io log ical Assay Methods
In  very  many cases to p ic a l  a p p lic a tio n s  a re  in tended 
to  be a n t is e p t ic  in  a c tio n  and a number o f methods and
14
techniques have been devised  which depend upon a form o f
m icrob io log ica l a ssay . The t e s t s  a sse ss  th e  a n t i s e p t ic
value and give fundam entally an in d ic a tio n  o f th e  r a t e  and
degree o f re le a s e  of th e  medicament from th e  v e h ic le .
Robert KoéË s ta te d  th a t  phenol when d isso lv ed  in
o i l  d id  not ex h ib it any a n t is e p t ic  p ro p e r t ie s .  In  h is
experim ents s i l k  f ib re s  were impregnated w ith  th e  spores o f
B a c illu s  a n th ra c is  and immersed in  phenol s o lu tio n  and he
was ab le  to  dem onstrate th a t  th e  spores were no t k i l l e d
a f t e r  immersion in  a 5 p e r  cent phenol in  o i l  s o lu t io n  fo r
110 days. T his p a r t i t io n  o f phenol in  an o i ly  so lu tio n  has
42
a lread y  been no ted . I t  has been shown th a t  a phenol 
ointm ent f a i le d  to  in h ib i t  growth when samples were 
in o cu la ted  w ith  S e r râ tia  m arcescens and Pseudomonas
49flu o réscen s and t r a n s f e r s  made to  n u tr ie n t  g e la t in .  Under 
th e  same co n d itio n s an ointment o f m ercuric ch lo rid e  
in h ib ite d  growth. A method was devised  in  1895 whereby 
p la t e l e t s  o f g la s s  were in o cu la ted  w ith  a b ro th  o f  S e rrâ t ia  
marcescens and d r ie d . The p l a t e l e t s  were then  in troduced  
in to  th e  ointm ent under t e s t  fo r  a d e f in i te  tim e, washed w ith 
e th e r  to  remove th e  ointm ent, t r a n s fe r r e d  to  s t e r i l e  b ro th  
and observed fo r  growth. The conclusions a r r iv e d  a t  in  th e
15
s e r ie s  o f t e s t s  were th a t  cold  cream and la n o lin  were th e  b es t
50
bases fo r  a n t is e p t ic s .  A v a r ia t io n  o f t h i s  method was used 
where a n t is e p t ic  ointm ents were spread on cover s l i p s  which 
were then  la id  under agar in  a p e t r i  d ish . The su rfa ce  o f 
th e  agar was now in o cu la ted  w ith  M. pyogenes v a r aureus and 
incubated . Growth was observed and of th e  v e h ic le s  used 
la n o lin  gave th e  b e s t r e s u l t s  w hile hydrocarbons gave the
51p o o re s t•
52
Reddish devised th e  most w idely used t e s t  f o r
a s se ss in g  th e  e f fe c tiv e n e ss  of a n t is e p t ic s  inc luded  in
ointment bases and th i s  t e s t  w ith  c e r ta in  m o d ifica tio n s was
ev en tu a lly  adopted by th e  U nited S ta te s  Food and Drugs 
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A dm in is tra tion . I t  i s  th e  only  o f f i c i a l l y  recognised  t e s t  
fo r  ointm ent e f f ic ie n c y . In  th e  o r ig in a l t e s t  p la te s  were 
in o cu la ted  w ith  a c u ltu re  o f M. pyogenes v a r . aureus and 
spread w ith  th e  ointm ent under t e s t  m elted a t  37°C. C ontrols
u sin g  th e  base w ithout medicament were a ls o  s e t  up. A fte r
incubation  th e  w idth o f th e  zone o f in h ib i t io n  was taken  by 
Reddish to  be an in d ic a tio n  o f a n t i s e p t ic  v a lu e . He 
suggested th a t  th e  n u tr ie n t agar o f th e  p e t r i  d ish  sim ulated 
th e  cond itions met w ith  in  wounds and sk in  and s ta te d ,  " i t  
i s  perm eable, sem iso lid , and is o to n ic  and c o n s t i tu te s  a
16
v aluab le  la b o ra to ry  means o f approxim ating th e  co n d itio n s  
found in  human and animal t i s s u e " .  This medium, however, 
i s  h y d ro p h ilic  and uniform ly permeable whereas anim al sk in
i s  hydrophobic and permeable only by way o f i t s  appendages.
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Reddish and Wales and o th e r workers u s in g  t h i s
and s im ila r  t e s t s  have shown th e  much g re a te r  e f f ic ie n c y  o f
em ulsified  bases over f a t ,  o i l  and wax bases as c a r r i e r s  o f
a n t i s e p t ic s .  Reddish* s  t e s t  was m odified by th e  use o f
weighed q u a n t i t ie s  o f ointm ent spread over a  d e f in i t e  a rea
and i t  was shown th a t  a n t i s e p t ic  e f f ic ie n c y  was dim inished
o r e n t i r e ly  absent w ith  f a t ,  o i l  o r wax b ases , w hile
o il- in -w a te r  emulsion bases gave a g re a t ly  enhanced germ icidal
62 63
v a lu e . G ershenfeld and B r i l lh a r t  found th a t  th e  more w ater
a base contained  th e  g re a te r  was i t s  zone o f in h ib i t io n .  In
m easuring th e  hydrogen ion  co n cen tra tio n  in  h y d ro p h ilic
ointm ents and lo t io n s  agar cup p la te  t e s t s  in d ic a te d  th a t
in  genera l th e  g re a te r  th e  hydrogen ion  co n c en tra tio n  th e
g re a te r  th e  germ icidal o r b a c te r io s ta t ic  p ro p e r t ie s  o f  th e
64p re p a ra tio n s . S traksoch and Olsen dem onstrated th a t  th e  
maximum b a c te r io s ta t i c  e f fe c t  o f sodium su lp h a th ia zo le  was 
obtained  by a f iv e  p e r  cent ointm ent and n o th in g  could be
17
gained by a h ig h e r concentration* S im ilar methods have
65-73been used by o th e r workers* S i l ic a  g e ls  have been
74
in v e s tig a te d  in  t h i s  way as c a r r ie r s  fo r  a n t i s e p t ic s  and 
i t  has been found th a t  th e  a n t is e p t ic  value o f c e r ta in  
ointm ents i s  improved when th e  w ater content i s  in c reased
75
in  th e  presence o f ozy-chole s te r o l . Increased  e f fe c tiv e n e ss  
was a lso  noted when su lphated  hydrogenated c a s to r  o i l  was
76
used as a base w ith 40 p e r  cent w ater a l th o u ^  c e r ta in  
claim s fo r  w ater co n ta in in g  bases were not f u l ly  supported . 
The p la te  method has a lso  been used to  in v e s tig a te  th e  
e f fe c t  o f p a r t i c l e  s iz e  and th e  ad d itio n  of a w ettin g  agent
77
on a n t is e p t ic  a c t iv i ty .  A unique method o f  m easuring th e  
a n t is e p t ic  a c t i v i t y  o f ointm ents involved scrubbing th e  
hands according  to  a standard  technique fo r  a g iven p eriod  
o f tim e. The number o f b a c te r ia  removed was determ ined 
by p la t in g  a sample of th e  f in a l  r in s in g s . Ointment was 
then app lied  fo r  a s ta te d  tim e and a f t e r  removal and washing 
th e  number o f b a c te r ia  was again  determ ined, comparison o f
78
dim inution in  count being  th e  c r i te r io n  o f e f f ic ie n c y .
(b) Membrane Methods
Membrane methods a re  used in  an attem pt to  sim ulate 
in  v i t r o  th e  b a r r ie r  which i s  p resen ted  by th e  sk in  to  a 
to p ic a l  a p p lic a tio n . Both a r t i f i c i a l  and n a tu ra l membranes
18
bave been used and i t  i s  assumed th a t  th e  p rocess o f  
p e n e tra tio n  ta k in g  p la ce  in  th e  sk in  i s  s im ila r  to  th e  
q u a n ti ta t iv e  d if fu s io n  o f a drug from th e  v eh ic le  t h r o u ^  
th e  permeable membrane.
( i )  Chemical and P h y sica l E stim ations
Two methods may be no ted . F i r s t  th e  e s tim a tio n  
of th e  sodium ch lo rid e  re le a se d  from v ario u s ointm ent bases 
a f t e r  d if fu s io n  through a cellophane membrane in to  d i s t i l l e d
79
w ater, and second, th e  comparison o f th e  ezosmosis o f 
potassium  io d id e , phenol and re so rc in o l from p a r a f f in ,  la rd ,  
and la n o lin  bases a l l  of which had been suspended in  sheeps*
So
b ladders immersed in  w ater a t  37^0.
( i i )  M icrob io log ical Assay Methods
The d if fu s io n  o f p e n ic i l l in  and sulphonamides from
v arious bases has been determ ined by p la c in g  th e  ointm ents
to  be examined in  cellophane bags and immersing them in
s a lin e  a t  37°C fo r  a f ix ed  tim e, th e  amount of p e n ic i l l i n
o r sulphonamide d if fu s in g  in to  th e  s a lin e  being  es tim ated
81.82
by th e  cup p la te  method. Samples o f d if f e re n t  ointm ents 
co n ta in in g  a n t is e p t ic s  have been ap p lied  to  cellophane squares 
which were then  p laced  on th e  su rface  o f in o cu la ted  media. 
A fte r  incubation  th e  tim e req u ired  to  produce in h ib i t io n  o f 
growth was taken  as a measure of drug r e le a s e .  No d if fu s io n
19
o f a c tiv e  agent could be d e tec ted  from s c a r le t  re d , icthammol, 
coal t a r  and s a l i c y l ic  ac id  ointm ents when te s te d  by t h i s  
method* Other workers have examined th e  d i f f u s i b i l i t y  o f
a n t ib io t ic s  from v arious ointm ents and creams by p la c in g  them
84
in  d ia ly s e rs  and ta k in g  frequen t sang les fo r  a ssay .
2. In  Vivo Methods
Numerous methods u sin g  t e s t  anim als have been 
devised  to  determ ine both  p e n e tra tio n  and ab so rp tio n  o f th e  
medicament inco rpo ra ted  in  a v eh ic le  o r base and i t  has been 
found th a t  a lthough d if fe re n c e s  in  p erm eab ility  between 
human and animal sk in  e x is t  th e  r e s u l t s  of animal experim ents 
may ju s t i f i a b ly  be extended to  problems concerning human beings,
(a ) Blood, Urine and Faeces A nalysis
Following i t s  cutaneous a p p lic a tio n  th e  d e te c tio n  
o f a substance in  th e  bloodstream , u r in e  o r faeces  o f fe r s  th e  
most conclusive p roof o f  i t s  ab so rp tio n . Blood le v e ls  have
been taken as a measure o f th e  ab so rp tio n  o f to p ic a l ly  ap p lied
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sulphonamides. Woodward and o th e rs  determ ined su lp h a th ia zo le
le v e ls  in  blood samples from r a b b i ts  a f t e r  th e  a p p lic a tio n  of
an ointm ent to  a d e f in i te  area  o f c lipped  sk in . V arious
ointm ents were te s te d  com paratively u sing  s u ita b ly  designed
experim ents and s u f f ic ie n t  anim als to  ensure th a t  th e
20
d iffe re n c e s  rep o rted  were s t a t i s t i c a l l y  s ig n i f ic a n t .  Bases 
co n ta in ing  propylene g lyco l were su p e rio r  to  f a t  o r  o i l  bases 
as regards th e  p e n e tra tio n  o f su lp h a th ia zo le . The a d d itio n  
of c e r ta in  su rface  a c tiv e  a g en ts , no tab ly  sodium la u ry l  
su lpha te  o r an a ry l a lk y l p o ly -e th e r  a lco h o l, improved 
p e n e tra tio n  w hile o th e rs  d id  n o t. These substances 
increased  th e  i r r i t a n t  p ro p e r tie s  of th e  b ases . The au tho rs 
s ta te d  th a t  ab so rp tio n  from a 5 p er cent su lp h a th iazo le  
ointm ent equalled  th a t  from a 20 p e r cent ointm ent and 
confirmed in  vivo th e  r e s u l t s  o f c e r ta in  in  v i t r o  t e s t s .
T ests have been c a rr ie d  out to  compare ointm ent bases u sing  
pheno lsu lpho tha le in  and potassium  io d id e . The ointm ents 
were ap p lied  to  r a t e .  The tim e taken  fo r  th e  f i r s t  
c o lo ra tio n  of th e  u r in e  w ith  phenol su lp h o th a le in  was noted 
and a chemical an a ly s is  was made fo r  potassium  io d id e . The 
r e s u l t s  were c o r re la te d  w ith  th e  f in d in g s  ob ta ined  from th e  
agar p la te  method and i t  was found th a t  th e  a d d itio n  o f a 
w ettin g  agent d id  l i t t l e  to  in c re ase  ab so rp tio n , w hile th e  
ad d itio n  o f 2 p e r  cent s i l i c a  o r 5 cent c e ty l a lcohol
88 46
markedly reduced ab so rp tio n . F u l le r ,  Hawking and P a r tr id g e  
estim ated  th e  ex c re tio n  in  th e  u r in e  o f v arious sulphonamides 
a f t e r  a p p lic a tio n  to  su rface  wounds in  r a b b i ts  and observed 
th e  r a te s  o f ab so rp tio n  o f su lphanilam ide, sulphapyridene
89
and su lp h a th ia zo le . Lund s tu d ied  th e  ab so rp tio n  o f calcium
21
and sodium p e n ic i l l in s  from v ario u s ointment bases by 
assay in g  th e  drug in  u r in e  sam ples. Mercury, ap p lied  
percu taneously , has been estim ated  in  th e  body f lu id s ,
90,91
t i s s u e s  and ex cre ta  by ro u tin e  chemical a n a ly s is .
(b) Organ A nalysis
There i s  a tendency fo r  th e  animal body to  s to re  
in  p a r t ic u la r  organs th e  drug being ap p lied  and in  th e se  
cases th e  determ ination  o f th e  drug in  th e  blood, u rin e  o r 
faeces may not g ive a  t ru e  p ic tu re  o f  the  r a t e  o f  ab so rp tio n . 
In  confirm ation  o f t h i s  i t  has been shown th a t  a f t e r  
in u n c tio n  w ith  a m ercuria l o intm ent, one hundred tim es as 
much mercury was found in  th e  kidney as was found in  th e
92
r e s t  o f th e  body and u r in e . The ab so rp tio n  o f lead  from
d if fe re n t  v eh ic le s  ap p lied  to  r a t s  has been determ ined in
93
th e  kidney, l i v e r ,  muscle and lung.
( 0 ) C h a ra c te r is t ic  R eactions
Many workers have adopted pharm acological or 
p h y sio lo g ica l end-po in ts to  determ ine th e  tim e taken  fo r  th e  
passage o f a drug through th e  sk in  and to  produce a system ic 
e f f e c t .  The a c tio n s  o f various ointm ent bases on th e  
p e n e tra tio n  o f  a lk a lo id s  has been s tu d ied  u sin g  s try ch n in e . 
Tonic spasm was taken  as the  end-point in  t e s t s  on r a t s  and
22
mice and th e  r e s u l t s  seemed to  in d ic a te  th a t  th e  use of 
v e h ic le s  d id  l i t t l e  to  improve and may even have h indered
94p e n e tra tio n . A number o f v o la t i le  o i l s  were su c c e ss fu lly  
used as v eh ic le s  to  in troduce in to  th e  body vario u s po ten t 
a lk a lo id s  and o th e r d rugs, A d ire c t  technique has been 
used to  dem onstrate th e  percutaneous ab so rp tio n  o f an tig en  
by f i r s t  s e n s i t iz in g  p a ss iv e ly  a sk in  s i t e  to  th e  an tig en  
and then  proving  ab so rp tion  by th e  p roduction  o f an
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u r t i c a r i a l  re a c tio n  a t  ano ther s i t e  24-48 hours l a t e r .
The e f fe c t  o f th e  passage o f hormones th r o u ^  th e
sk in  has been th e  su b jec t of wide re se a rc h . In  1929 Zondek
dem onstrated th e  p h y sio lo g ica l e f f e c ts  r e s u l t in g  from th e
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passage of sex hormones through th e  sk in  and o th e r workers
97-101
confirmed Zondek’s f in d in g s . I t  i s  worth n o tin g  th a t  
102
Moore re p o r tin g  on th e  e f f e c ts  androgens and oestrogens had on 
th e  sk in  of guinea p ig s  s ta te d  th a t  " th e re  i s  yet a lack  
o f ap p rec ia tio n  o f th e  read in ess  w ith  which substances a re
103
taken  up by th e  sk in  and a re  e f fe c t iv e  in  th e  body". Zondek 
making use o f a lco h o l, e th e r  and benzene as v eh ic le s  fo r  th e  
a p p lic a tio n  o f oestrogen  was ab le  to  d e te c t only l i t t l e  
d if fe re n c e  between th e  cutaneous and subcutaneous 
a d m in is tra tio n  o f th e  drug. Using th e  weight in c rease  in
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th e  p ro s ta te  and seminal v e s ic le s  o f th e  r a t  as  th e
104c r i te r io n  o f measurement Nelson and o th e rs  found te s to s te ro n e  
more e f fe c t iv e  in  a lcoho l than  in  o i l ,  la n o lin  o r ointm ent, 
and more e f f ic ie n t  percu taneously  in  alcoho l than  subcutaneously  
in  o i l .  I t  was, however, le s s  e f f i c ie n t  percu taneously  in  
o i l ,  la n o lin  o r ointm ent than  subcutaneously  in  o i l ,  a 
f in d in g  which emphasises th e  su p e rio r  p en e tran t p ro p e r tie s  
o f a lc o h o l. T his f in d in g  i s  in  agreement w ith th a t  o f
105
Emmens who showed th a t  th e  v o la t i l e  organic so lv en ts  e th e r , 
benzene and 96 p e r  cent a lcoho l a re  more e f fe c t iv e  as c a r r ie r s  
o f  androgens, oestrogens and p rogeste rone  from, th e  sk in  
su rface  than  i s  o i l  o r la n o lin . In  t e s t s  w ith  r a b b i ts ,  
inu n c tio n  w ith  benzene but not w ith  e th e r  was su p e rio r  to  
t h e i r  in je c t io n  in  o i l .  A s l ig h t  but c o n s is te n t s u p e r io r i ty  
when d ea lin g  w ith  oestrogens was found w ith  e th e r  as a medium 
and when d ea lin g  w ith androgens and p rogesterone w ith  benzene 
as a medium. The e f f e c ts  o f th e  sex hormones fo llow ing  t h e i r  
percutaneous a p p lic a tio n  may be exp lained  by th e  extrem ely 
sm all amounts req u ired  in  th e  bloodstream  to  produce th e i r  
c h a ra c te r i s t ic  e f f e c ts  and th e se  amounts a re  u su a lly  w ith in  
th e  co n cen tra tio n s a t ta in e d  by substances ap p lied  percu taneously .
24
Several au tho rs have claimed th a t  in s u l in  w ill  p e n e tra te  th e  
106-110
sk in  w hile o th e rs  have rep o rted  th a t  ab so rp tio n  can be
111,112
in c reased  by p re trea tm en t o f th e  sk in  w ith  saponins and
113organ ic so lv en ts  which p a th o lo g ic a lly  in c re ase  i t s
p e rm e ab ility . The a c tio n  o f a h ep a rin  cream was stu d ied
on r a b b its  and humans and caused a s ig n if ic a n t  in c re a se  in
114th e  coagu lation  tim e o f th e  blood of anim als and humans.
The passage o f v itam ins through th e  sk in  has been
shown to  occur and as e a r ly  as 1927 experim ents i l l u s t r a t e d
th a t  th e  a p p lic a tio n  of i r r a d ia te d  c h o le s te ro l to  th e
115
undamaged sk in  prevented  r ic k e ts  but vary ing  th e  v eh ic le
116
had l i t t l e  or no in flu en ce  on th e  ab so rp tio n  of v itam in  D. 
The p e n e tra tio n  and lo c a l e f f e c ts  have been noted  when
117vitam in  A was ap p lied  to  th e  sk in  o f guinea p ig s .
A com parative a n a ly s is  o f ointm ents has been
c a rr ie d  out by study ing  a pharm acological re a c tio n  fo llow ing
th e  re le a s e  o f lo c a l  a n a e s th e tic s . A p a in  th re sh o ld  method
was adopted and ointm ents co n ta in in g  lo c a l a n a e s th e tic s
were ap p lied  to  th e  blackened t a i l s  o f r a t s .  A t e s t
stim ulus was given by means o f ra d ia n t hea t and co n tro l
118
ointm ents co n ta in in g  no a n a e s th e tic s  served as a check.
A s im ila r  technique was used by means o f th e
25
Harding-W olff-Goodal? p a in  th re sh o ld  a p p a ra tu s . The t a i l  
o f an a lb in o  r a t  was coated  w ith  In d ian  ink  and su b jec ted  
to  400 m i l l i c a lo r ie s  of h ea t u n t i l  a  p o s i t iv e  r e a c tio n  was 
no ted . Ointment bases co n ta in in g  lo c a l  a n a e s th e tic s  
were th en  ap p lied  and th e  re a c tio n  tim e n o ted .
The p ro te c t iv e  e f fe c t  o f to p ic a l ly  a p p lied  
chem otherapeutic ag en ts  has been used to  dem onstrate
ab so rp tio n  and could be used to  ev a lu a te  v e h ic le s .
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Zondek has s tu d ied  th e  use o f halogenated  pheno ls, 
p a r t i c u la r ly  p -ch lo ro x y len o l, as e x te rn a l d is in fe c ta n ts  in  
p ro te c t in g  r a t s  in fe c te d  w ith  s tre p to c o c c i and pneumococci, 
a p ro te c t iv e  e f f e c t  which has been u t i l i s e d  in  c l in i c a l  
t r i a l s  (v id e  i n f r a ) .  The q u a n tity  o f ch lo roxy leno l 
ex cre ted  a f t e r  rubb ing  in  th e  form o f an ointm ent on th e  
shaved back o f a r a b b it  was found to  be approxim ately  
15 p e r  c e n t. P ercu taneously  ap p lied  in  man in  th e  form 
o f a 30 p e r  cent o in tm ent, a chem otherapeutic e f f e c t  was 
no ted . The u r in e  ex c re ted  remained s t e r i l e  and w hile 
organism s in o cu la ted  in to  th e  co n ten ts  o f can th a rid e  
b l i s t e r s  in  human su b je c ts  m u ltip ly  ra p id ly , s tro n g  
a n t ib a c te r ia l  e f f e c ts  a re  possessed  by th e  same co n ten ts
26
in  p a t ie n ts  t r e a te d  with, p -ch lo ro x y len o l o in tm en ts . The
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r e s u l t s  o b ta in ed  encouraged Zondek and o th e rs  to  con tinue 
t h i s  work u s in g  sulphonamides and th ey  showed th a t  th e se  
compounds were absorbed by th e  sk in  and were p re se n t in  
th e  blood a f t e r  cutaneous a p p l ic a t io n . Using r a b b i ts  i t  
was found th a t  th e  a p p l ic a tio n  o f o in tm ents gave le s s  
s a t i s f a c to r y  r e s u l t s  th an  th e  use o f  o rgan ic  so lv e n ts  in  
th e  a d m in is tra tio n  o f a sulphonamide when ap p lie d  to  th e  
shaved sk in  o f th e  backs o f th e  an im als. The e s tim a tio n s  
were c a r r ie d  out on blood and i t  was no ted  th a t  percu taneous 
ab so rp tio n  was augmented by th e  a d d i t io n  o f soap and 
g ly c e r in . They s ta te d  th a t  th e  co n c en tra tio n  o f 
su lphanilam ide in  r a b b i t  blood fo llo w in g  i t s  percu taneous 
a d m in is tra tio n  was as  h igh  as  th a t  ob ta in ed  a f t e r  i t s  o ra l 
a d m in is tra tio n  but i n f e r io r  to  th a t  fo llo w in g  subcutaneous 
o r in tram u scu la r in je c t io n s .  Although th e  blood 
co n cen tra tio n  o f  su lphanilam ide fo llo w in g  i t s  percu taneous 
ad m in is tra tio n  in  men i s  low er th an  th a t  a f t e r  o ra l  a d m in is tra tio n  
th e  au th o rs s t a t e  th a t  th e  percu taneous use o f  su lphanilam ide 
may serve as an a u x i l ia ry  method o f  chem otherapeutic 
trea tm en t in  c e r ta in  c a se s . In v e s t ig a t io n  o f th e  a c t i v i t y  
o f  v a rio u s  su lphanilam ide creams has been c a r r ie d  out by
27
in o c u la tin g  a group of mice in tram u scu la rly  w ith
Staphlycoccus pyogenes. The creams were then  in je c te d
subcutaneously and th e  su rv iv a l tim es o f th e  mice compared
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w ith th e  su rv iv a l tim es o f u n trea te d  in fec ted  c o n tro ls .
I r r i t a t i o n  s tu d ie s  have been conducted on
ointm ent bases and th e  r e s u l t s  o f  pa tch  t e s t s  on in ta c t
and abraded sk in  o f  anim als have been c o rre la te d  w ith  
122
p atch  t e s t s  on man. I t  was shown th a t  th e  a d d itio n  o f
su rface  a c tiv e  agen ts increased  th e  i r r i t a t i o n  o f th e  
123
oin tm ents.
The k e r a to ly t ic  a c tio n  of d if fe re n t  ointm ents
may in flu en ce  th e  ab so rp tio n  o f medicaments and th e  e f f e c ts
o f su lphu r, s a l ic y l ic  ac id  and re so ro in o l in  d i f f e r e n t  bases 
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have been no ted . B iopsies were performed a t  in te rv a ls  and
th e  tim e to  produce k e ra to ly s is  was taken  as a measure o f 
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e ff ic ie n c y .
(d) B iopsies
The use o f b io p s ies  e n ta i l s  th e  removal o f t i s s u e
from th e  animal under t e s t  and e x tra c tin g  and e s tim a tin g  th e
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drug in  th e  t i s s u e  by s u ita b le  means. E l le r  and W olff 
ap p lied  m a te r ia ls  to  the  shaved sk in  of a lb ino  r a t s ,  
b io p s ie s  were tak en , and exam ination showed th a t  animal f a t s
28
were th e  most e f f ic ie n t  and m ineral f a t s  th e  le a s t  e f f i c i e n t .
V o la t i le  substances such as  a lco h o l, e th e r  and benzene were
v e h ic le s  w ith  a much h ig h er ab so rp tio n  r a te  th an  f a t s .
Optimum p e n e tra tio n  was observed a f t e r  fo u r to  s ix  hours and
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w ettin g  agen ts were shown to  a s s i s t  t h i s  p ro cess . The
p e n e tra tio n  o f sulphonamides through th e  in ta c t  sk in  o f  r a t s ,
r a b b i ts  and humans was measured by means of t i s s u e  a n a ly s is
and th e  r e s u l t s  ob tained from th e  a p p lic a tio n  o f wet d re ss in g s ,
io n to p h o res is  and ointm ents have been compared. A lth o u ^
in d iv id u a l v a r ia tio n s  were la rg e , t i s s u e  co n cen tra tio n s
tended to  p la te a u  a f t e r  two to  th re e  hours. P e n e tra tio n
from an ointm ent was in f e r io r  to  th a t  from wet d re ss in g s  
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or io n to p h o re s is . The r a te  o f  p e n e tra tio n  o f sulphanilam ide 
in to  th e  in ta c t  sk in  of guinea p ig s  from w a te r - in -o il  and 
o i l- in -w a te r  em ulsions has been determ ined by d ir e c t  chemical 
a n a ly s is ,  but no d if fe re n c e  in  e f f ic ie n c y  between th e  
em ulsions was found. In c reas in g  th e  co n cen tra tio n  o f 
su lphanilam ide in  th e  bases above one p e r cent had l i t t l e  
e f f e c t  on th e  t i s s u e  le v e ls  reached whereas in c re a s in g  th e  
tim e o f  a p p lic a tio n  c o n s is te n tly  inc reased  th e se  le v e ls .
The a d d itio n  o f a su rface  a c tiv e  agent d id  not g ive improved 
r e s u l t s  but in ju red  sk in  took up g re a te r  amounts o f  
su lphanilam ide than  in ta c t  sk in . Sulphanilam ide, su lp h a th iazo le  
and su lphad iaz ine  gave comparable t i s s u e  le v e ls  but a f t e r  a
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3 day a p p lic a tio n  tim e sodium sulphac e tamide gave g re a te r
i:
p e n e tra tio n  than  th e se  th re e  compounc132,133ids.
As a r e s u l t  o f t i s s u e  a n a ly s is , th e  use o f  po lyethy lene
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g ly c o ls  has been recommended fo r  th e  sulphonamides.
(e )  H is to lo g ic a l Methods
The h is to lo g ic a l  methods adopted fo r  th e  
e v a lu a tio n  o f drug  re le a s e  a re  concerned w ith  th e  degree 
o r depth o f p e n e tra tio n  o f th e  v eh ic le  and th e  in co rp o ra ted
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drug in to  th e  sk in . F luorescen t microscopy has been used
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to  d e te c t chem otherapeutic substances in  se c tio n s  o f t i s s u e .  
The flu o rescen ce  o f many common drugs in  u l t r a - v io l e t  
l i ^ t  can be dem onstrated in  very  low co n c en tra tio n s .
The organs and p ie c e s  o f t i s s u e  to  be s tu d ied  a re  removed 
and im m ediately frozen  in  l iq u id  a i r .  They a re  d ried  
over phosphorus pen t oxide in  vacuo a t  about - 40^0 . and 
sec tio n ed . Drugs o f which th e  flu o rescen ce  co lour i s  
o th e r than  b lu e , fo r  example P ro n to s il  rubrum,can be 
dem onstrated d i r e c t ly  in  th e  t i s s u e .  Drugs w ith  a b lue 
f lu o rescen ce  ( th e  n a tu ra l fluo rescence  o f  th e  t i s s u e s )  
can be made to  change t h e i r  f luo rescence  co lour by 
h e a tin g  to  $a d i f f e re n t  tem perature fo r  d if f e re n t  p erio d s 
o f  tim e . By t h i s  method i t  i s  p o ss ib le  to  dem onstrate
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su lp h a th ia zo le , su lphanilam ide, su lphapyridene, papaverine, 
in u lin  and p e n ic i l l in  in  t i s s u t ^ .  Other h is to lo g ic a l  
methods use a s p e c if ic  dye fo r  th e  o i l  o r drug ap p lied  to  
th e  t i s s u e s .
( f )  M iscellaneous Methods
An unusual method o f es tim atio n  measured th e  
re le a s e  and p e n e tra tio n  of drugs by th e  use o f ch ick  
embryos. The c h o r io -a lla n to ic  membrane served as th e  
medium fo r  p e n e tra tio n , th e  ointm ent being  in je c te d  in to  
th e  n a tu ra l a i r  sa c . T o x ic ity  was determ ined by th e  
number o f embryos rem aining a l iv e  a f t e r  vary ing  tim es . 
P erm eab ility  was determ ined by th e  in co rp o ra tio n  o f 
a n t ib io t ic s  in  th e  ointm ents and assay ing  a liq u o t p o rtio n s
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of th e  a l la n to ic  f lu id  gave an assessm ent of r e le a s e .
3 . C lin ic a l Methods
C lin ic a l methods have amply dem onstrated th e
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system ic ab so rp tio n  o f medicaments. D aily  in u n c tio n  w ith 
an a rse n ic  ointm ent le d  to  an ex c re tio n  o f th e  element as
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h i ^  as 10 mg. d a i ly , and a rse n ic  has been d e tec ted  in  th e  
u r in e  a f t e r  exposure o f th e  f e e t  to  a hot b a th  o f d i lu te
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a rse n ic a l s o lu t io n . Work has been c a rr ie d  out on th e  
p e rm eab ility  o f  th e  human sk in  to  lead  o le a te  and
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p ro g ress iv e  perm eation o f t h i s  compound has been shown on
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prolonged c o n ta c t. The p e n e tra tio n  o f copper o le a te  from 
a la n o l in -p a ra f f in  base has been examined and i t  was noted 
th a t  th e  amount o f  copper excreted  in c reased  i f  th e  sk in  was
152
damaged. The "a n a ly s is  by d iffe re n ce "  p rev io u s ly  re fe r re d
21,153 154
to  was continued by Wild and Roberts who te s te d  v arious 
bases and found th a t  th e  g re a te s t  ab so rp tio n  took  p lace  
from la r d .  They s ta te d  th a t  in u n c tio n  w ith fo u r grammes 
o f a m ercu ria l ointm ent fo r  two minutes gave an ab so rp tio n  
in to  th e  body not exceeding 0.12  grammes o f mercury, and 
a f t e r  10 m inutes an abso rp tion  not exceeding O .I7 grammes.
155-166
Evidence has been supp lied  by many workers fo r  
th e  l ip o id  th eo ry  o f ab so rp tion  which holds th a t  l ip o id  
so lu b le  drugs w il l  be absorbed more re a d i ly  than  l ip o id  
in so lu b le  d ru g s. The presence of b o r ic  ac id  was 
dem onstrated in  th e  u rin e  a f t e r  immersion o f th e  fe e t  in  
a lco h o lic  b o r ic  a c id  so lu tio n  but no boron could be
167,168
d e tec ted  when th e  sodium s a l t  was used. I t  has been 
claim ed th a t  th e  sugar content o f th e  blood and u r in e  of 
both d ia b e tic s  and normal persons has been increased  a f t e r
169
th e  a p p lic a tio n  o f o i l s  con ta in ing  su g ars .
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Moncorps c a rr ie d  out th e  f i r s t  c l in ic a l  t r i a l s  
which could he considered  com parative when he measured th e  
amount o f s a l i c y l i c  ac id  e lim inated  a f t e r  i t s  cutaneous 
a p p lic a tio n  in  v a rio u s  h a se s . Much has been pub lished  on
171-177 178-189
th e  ab so rp tio n  o f s a l ic y la te s  and io d id e s . Brown and
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S co tt s tu d ied  th e  ab so rp tio n  o f s a l ic y la te s  from aqueous
so lu tio n s  and considered  th e  in flu en ce  which d i f f e r e n t  o i l s
and ointm ent bases had on ab so rp tio n . In  t h e i r  experim ents,
th e  hands served  as th e  a rea  o f a p p lic a tio n  and th e  ex c re tio n
o f  s a l ic y la te  in  th e  u rin e  was determ ined. No e s s e n t ia l
d if fe re n c e  between o liv e  o i l  and la rd  was noted  but th e
ab so rp tio n  from l iq u id  p a ra f f in  and anhydrous la n o lin e  was
h i ^ e r .  Temperature proved to  be an im portant f a c to r ;  a
r i s e  from 26-28^C to  43-44^0 re s u lte d  in  a tw o-fo ld  in c re ase
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in  th e  ab so rp tio n  o f s a l ic y la te .  Zondek in  h is  work on 
p -ch lo roxy leno l showed th a t  the blood o f p a t ie n ts  who had 
rece iv ed  percu taneous trea tm ent w ith  th e  d is in fe c ta n t  was 
ab le  to  in h ib i t  th e  growth o f s tap h y lo co cc i. Treatment 
w ith  p -ch l oroxyl enol was f a r  more e f fe c t iv e  than  th a t  w ith 
su lphanilam ide, sulphapyridene o r su lp h a th ia z o le . N adkam i
191
and o th e rs  ap p lied  pheno lsu lpho tha le in  to  a group o f p a t ie n ts
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and e a t i mated c o lo r im e tr ic a lly  th e  co n cen tra tio n  o f dye 
excre ted  in  th e  urine*  On normal human sk in  they  concluded 
th a t  th e  use o f a w ater so lu b le  v eh ic le  promoted g re a te r  
ab so rp tio n  o f th e  dye th an  d id  an o leagineous base and found 
po lye thy lene g ly c o ls  more e f f ic ie n t  as v eh ic le s  fo r  inflam ed
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sk in  than  p a ra f f in  b a se s . S h e lley  and Melton confirm ed th a t  
v e h ic le s  co n ta in in g  propylene g lyco l and su rface  a c t iv e  agen ts 
f a c i l i t a t e d  the  passage o f a c e ty lc h o lin e  ch lo rid e , p ilo c a rp in e  
n i t r a t e ,  a tro p in e  su lp h a te , hyoscine, ephedrine and 
h istam ine phosphate t h r o u ^  human sk in . Inunction  w ith  
h istam ine  r e s u lte d  in  p e r i f o l l i c u la r  wheals and d if fu s e  
erythema which in d ic a te d  th a t  th e  s ig n if ic a n t  ro u te  o f 
p e n e tra tio n  was th a t  by way o f th e  h a ir  f o l l i c l e s  and 
sebaceous g lan d s. I t  was a ls o  shown by th e se  experim ents 
th a t  g re a te s t  ab so rp tio n  occurred  in  th e  most h i r s u te  a rea s  
o f  th e  body w hile no evidence o f ab so rp tio n  was noted  when 
th e  drugs in co rp o ra ted  in  p e n e tra tin g  types o f v e h ic le s  
were ap p lied  to  th e  palms of th e  hands and th e  so le s  o f  th e  
f e e t ,  a rea s  where h a i r  f o l l i c l e s  a re  norm ally a b se n t. The 
fo rm ulation  and exam ination of new p en e tran t v eh ic le s  
co n ta in in g  propylene g lyco l has been c a rr ie d  out by Hermann
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and o thers*  M etals and sulphanilam ide were shown to  have 
p e n e tra te d  by e s tim a tio n s  on blood and u rin e  and maximum 
p e n e tra tio n  was rep o rted  w ith in  o n e -h a lf  to  th re e  hours 
a f t e r  a p p lic a tio n .
An unusual method fo r  th e  determ ination  o f 
ab so rp tio n  from ointm ents and creams involved th e  mixing 
o f Sudan Red w ith  th e  p rep a ra tio n s  te s te d .  F i l t e r  paper 
i s  la id  upon th e  c i r c le  o f sk in  t r e a te d  w ith  ointm ent and 
p re ssu re  a p p lie d . The procedure i s  rep ea ted  w ith  f re s h  
paper u n t i l  no co lour comes o f f  th e  sk in . A photom etric 
va lue  o f th e  sk in  i s  then  taken and compared w ith  th a t  f o r  
u n tre a te d  sk in . T his v a lu e , taken  to  be a measure o f 
p e n e tra tio n , was obtained fo r  each o f th e  p re p a ra tio n s
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te s te d .
4 . R ad io -ac tiv e  T racer Methods
R ad io -ac tiv e  t r a c e r  techn iques have been 
in c re a s in g ly  used in  ev a lu a tin g  drug re le a s e  from to p ic a l  
ap p lica tio n s*  Completely n eg a tiv e  p en e tran t values have 
been ob ta ined  fo r  c h o le s te ro l , v a se lin e  and th e  sa p o n ifia b le  
components o f o in tm en ts. L abelled  sodium ch lo rid e  has been 
in co rp o ra ted  in  la n o lin e , p a ra f f in  and la rd  ap p lied  to
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human sk in . The u r in e  o f a l l  th e  p a t ie n ts  was found to  he 
ra d io -a c t iv e  and th e  g re a te s t  ab so rp tio n  was observed from 
la r 2 .  Radon has been ap p lied  to  sk in  in  a la n o lin e  base 
and i t s  ex h a la tio n  through th e  lungs no ted . S ig n if ic a n tly  
g re a te r  ab so rp tio n  was found when th e  ointm ent was ap p lied
196
to  wounds. The ab so rp tio n  o f ra d io -a c tiv e  sodium io d id e  
from d if f e re n t  bases has been measured and i t  was found 
th a t  no ap p rec iab le  d if fe re n c e  in  ab so rp tio n  took p la ce  when 
th e  v e h ic le  was an o il- in -w a te r  o r a w a te r - in -o il  em ulsion. 
By a s im ila r  method, la rd , wool f a t  and p a ra f f in  have been 
compared as b ases , th e  e n t ire  th y ro id  gland being  used to  
determ ine th e  amount o f sodium iod ide  absorbed. The 
amount o f ra d io -a c t iv e  iod ine  absorbed by th e  gland was 
sm all but th e  ab so rp tio n  from p a ra f f in  was g re a te r  th an
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th a t  from wool f a t  o r la rd .  The e f f ic ie n c y  o f l iq u id  
p re p a ra tio n s  and creams have been examined by comparing th e  
r a t e  o f d if fu s io n  o f t h e i r  la b e lle d  in g re d ie n ts  ac ro ss
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is o la te d  fro g  membranes. By m easuring th e  r a d io - a c t iv i ty
o f th e  u r in e , ab so rp tio n  from w ater m isc ib le  bases
co n ta in in g  z inc  su lp h a te  was h ig h e r than  th a t  from greasy
bases although th e  e f f ic ie n c y  o f th e  l a t t e r  was in c reased
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by th e  ad d itio n  o f soap. A utoradiographic f in d in g s  have
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shown th a t  rad io thorium  which sc a rc e ly  p e n e tra te s  in to  th e
hom y la y e r  p re fe ra b ly  perm eates in to  c e r ta in  s tru c tu re s
such as th e  h a ir  f o l l i c l e s  and th e  ex c re to ry  ducts  o f th e
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sweat glands in  human sk in  and th i s  has been confirmed by 
th e  exam ination o f b io p s ie s  o f t i s s u e  t r e a te d  w ith  Thorium X
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in  v arious v e h ic le s . With an is o to p ic  technique no 
deuterium  oxide could be dem onstrated in  th e  p roducts o f 
combustion o f th e  body f a t s  a f t e r  a p p lic a tio n  o f a sa lve
205,206
made of hydrated o i l  co n ta in in g  deuterium  oxide.
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EXPERIMENTAL
As has been shown in  the review  se c tio n  a la rg e  number 
o f in  v i t r o  methods has been used to  in v e s tig a te  the d if fu s io n  
o f drugs from vario u s v e h ic le s  and bases and an eq u a lly  la rg e  
number o f in  v ivo t e s t s  has been used to  determ ine th e  degree 
of percutaneous p e n e tra tio n  and ab so rp tion  of drugs from 
to p ic a l  a p p lic a tio n s . I t  i s  c le a r  th a t  p e n e tra tio n  and 
ab so rp tion  i s  b es t in v e s tig a te d  by means of in  vivo techn iques 
s in ce  these  give r e s u l t s  o f p r a c t ic a l  importance and throw 
some l ig h t  on the fa c to rs  in flu en c in g  percutaneous ab so rp tio n .
In  the  f i r s t  s tag es o f the experim ental work i t  was 
decided to  in v e s tig a te  the p ro p e r tie s  o f is o la te d  r a t  sk in  as 
a b a r r ie r  to  the passage of drugs. This in v e s tig a tio n  proved of 
l i t t l e  value and the rem ainder of th e  work involved es tim a tin g  
the  concen tra tion  o f drug, fo llow ing  i t s  to p ic a l  a p p lic a tio n , 
in  the  blood o f r a b b i ts .  Two asp ec ts  o f percutaneous ab so rp tio n  
were s tu d ied . In  the f i r s t  in stance  the  ab so rp tio n  of a s in g le  
drug, namely su lphanilam ide, from a range o f v e h ic le s  and bases 
was s tu d ied , and in  the  second, a range o f drugs from a lim ite d  
number o f v e h ic le s  and bases was examined.
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1• The Passage o f Sulphanilam ide through I s o la te d
In ta c t  Rat Skin
The fa c to rs  which exert th e  g re a te s t  in flu en ce  on 
abso rp tion  are  the  p ro p e r tie s  o f in ta c t  sk in  and th e  e f f e c ts  
th ese  have on the  passage o f bases and drugs. An attem pt to 
examine th ese  p ro p e r tie s  was made by suspending se c tio n s  of 
l iv in g  sk in  in  oxygenated mammalian Ringer so lu t io n . The 
passage of a drug ap p lied  to  t h i s  could then  be follow ed 
sim ply by es tim a tin g  the  co n cen tra tio n  of drug in  th e  
Ringer so lu tio n .
Experim ental D e ta i ls .
The backs and s id es  o f s ix ,  h ea lth y , m ature male 
a lb ino  r a t s  were c lo se ly  shaved by means of an e l e c t r i c  shaver 
on the  day p r io r  to  th e  experim ent. The r a t s  were then  
s a c r i f ic le d  and th e  sk in  o f the d o rsa l- th o ra c ic o  lum b ^  
reg ion  quickly removed. The is o la te d  sk in  was la id  on a 
wad of f i l t e r  paper moistened w ith  mammalian R inger warmed 
to  37°C, th e  in te r io r  su rface  of th e  sk in  being in  con tact 
w ith  th e  R inger. On an area  o f sk in  one inch in  d iam eter, 
approxim ately two grammes of an ointm ent co n ta in in g  te n  p e r 
cent sulphanilam ide were g en tly  a p p lie d , and th e  sk in  p laced  
around one end of a p iece  of g la s s  tu b in g , f iv e  inches long, 
one m illim e tre  th ic k  and one inch in  d iam eter, in  a manner
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such th a t  th e  e x te r io r  su rface  of the  sk in  was in  co n tac t 
w ith  th e  g la s s . The t i s s u e  was suspended in  100 ml. 
oxygenated mammalian Ringer so lu tio n  a t  a tem perature o f 
3 7 t hi s  tem perature being reg u la ted  to  w ith in  O.l^C by 
means o f a c o n tro lle d  tem perature w ater b a th . At in te rv a ls  
o f t h i r t y  m inutes, samples of Ringer so lu tio n  were withdrawn 
by p ip e t te  and assayed fo r  sulphanilam ide co n ten t. The 
t is s u e  was suspended u su a lly  fo r  e ig h t hours but on no 
occasion was any sulphanilam ide d e tec ted  in  the  Ringer 
so lu tio n  even when the t i s s u e  was suspended fo r  tw en ty-four 
hou rs. L iquid p rep a ra tio n s  con ta in ing  th e  drug were p laced  
on th e  area  of sk in  a f t e r  i t  had been strapped  around th e  
g la ss  tub ing  and suspended in  the  Ringer so lu tio n .
In  a l l  cases neg a tiv e  r e s u l t s  fo r  th e  d e te c tio n  
o f sulphanilam ide were ob ta ined . The p rep a ra tio n s  te s te d  
were la rd , woolfat and so f t p a ra f f in ;  th e  liq u id  
p rep a ra tio n s , s a tu ra te d  w ith sulphanilam ide,w ere l iq u id  
p a ra f f in ,  g ly c e r in , propylene g lyco l and w ater.
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2. The A bsorption o f Sulphanilam ide through th e
In ta c t  Skin of th e  Rabbit from v ario u s v eh ic le s
and bases
In  the  l ig h t  o f the foregoing experim ents i t  was 
decided to  conduct experim ents u t i l i s i n g  s u ita b le  in  v ivo 
techniques since  no a r t i f i c i a l  or n a tu ra l membrane e x is ts  
which sim ula tes th e  p ro p e r tie s  o f in ta c t  h ea lth y  sk in .
The most prom ising method fo r  t h i s  work was 
considered to  be a technique whereby su lphanilam ide, 
fo llow ing i t s  cutaneous a p p lic a tio n , was d e tec ted  in  th e  
bloodstream  o f an im als. This method provided conclusive 
p roof o f i t s  abso rp tion  s in ce  sulphanilam ide ap p lied  in  a 
s u ita b le  v eh ic le  must n e c e s s a r ily  p e n e tra te  the sk in  and 
en te r  the  bloodstream  in  order to  be d e tec ted  and sim ple 
p e n e tra tio n  or lodgement w ith in  th e  appendages may be 
d iscounted . The blood le v e ls  o f sulphanilam ide 
estim ated  a t  su ita b le  tim e in te rv a ls  would allow  a 
comparison o f the  e f f ic ie n c y  of v ario u s v e h ic le s  and 
ointm ent bases as " c a r r ie r s "  fo r  the drug. Since the  
study o f blood co n cen tra tio n s has been a fe a tu re  of 
sulphonamide therapy  and the  sulphonamide drugs a re  
uniform ly d is t r ib u te d  in  the  animal body, th i s  seemed the
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lo g ic a l approach. Furtherm ore, th e  passage o f a drug 
th r o u ^  th e  sk in  i s  not d is s im ila r  to  a form o f continuous 
d rip -fe e d  and i t  i s  th e re fo re  im portant to  have an o v e ra ll 
es tim ate  o f the  system ic co n cen tra tio n  a t ta in e d  over a 
p erio d  of tim e from a to p ic a l ly  ap p lied  drug. The es tim a tio n  
o f drug content in  th e  u rin e  was re je c te d  on th e  grounds th a t  
i t  cannot he assumed th a t  th e  r a te  o f  ex c re tio n  of a drug i s  
d i r e c t ly  p ro p o rtio n a l to  i t s  r a te  o f  en try  in to  th e  animal 
body. This method a lso  excludes th e  p o s s ib i l i ty  o f 
p re fe re n t ia l  ab so rp tio n , such as io d in e  by th e  th y ro id , o r 
th e  d e s tru c tio n  o r sto rage  o f th e  drug in  th e  l iv e r  or kidney, 
While the  t o t a l  blood volume o f th e  anim als cannot be known 
a c cu ra te ly , th e  r e la t iv e  changes in  ab so rp tio n  which can be 
obtained from blood estim a tio n s a re  o f value in  th a t  they  
y ie ld  r e s u l t s  l ik e ly  to  be met w ith  in  p ra c t ic e .
Design of Test
In  th i s  f i e ld  previous w orkers, w ith  th e  exception 
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o f Woodward, have g en e ra lly  provided in s u f f ic ie n t  r e s u l t s  
fo r  complete s t a t i s t i c a l  exam ination. The s e r ie s  o f 
experim ents undertaken were designed w ith a view to  o b ta in in g  
s u f f ic ie n t  r e s u l t s  to  make such an a n a ly s is .
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A ll t e s t s  were made on s ix  ra b b its  from th e  same 
l i t t e r ,  s in ce  l i t t e r - m a tes u su a lly  y ie ld  r e s u l t s  le s s  v a r ia b le  
than  th o se  ob ta ined  from anim als s e le c te d  a t  random from an 
animal p o p u la tio n . L i t t e r s  from th ree  sep a ra te  breeds of 
ra b b it  were used , th e se  breeds being  Copenhagen W hite, Dutch 
and an in b red  l i t t e r  o f Beveren r a b b i ts .  With experience i t  
was found th a t  the  Copenhagen Whites gave r e s u l t s  uniform  
w ith in  th e  l im i ts  o f  the t e s t  and th is  breed o f r a b b i t  was 
used in  a l l  subsequent t e s t s .  The v a r ia t io n  between 
l i t t e r - m a t  es and non li t te r -^ n a te s  in  th i s  breed could be 
compared in  th e  l a t e r  s tag es of the  work by u sin g  s ix  
l i t te rn m a te s  and s ix  r a b b its  drawn a t  random from the  normal 
p o p u la tio n . R abbits used in  th e  t e s t s  co n s is ted  o f males 
and fem ales between 2 .5  and 3.5  Kg. in  w eight. The design 
o f the t e s t s  involved the  a p p lic a tio n  of th e  th re e  v e h ic le s  
o r bases under exam ination. A, B, and C, to  s ix  r a b b i ts  in  
random o rd e r, thus avoiding any cum ulative e f f e c t  which 
might have occurred . By ^Pplying a base tw ice an es tim a te  
was ob ta ined  o f the  e r ro r  in c u rred  in  d u p lic a tin g  an 
experim ent. The design o f the  d u p lic a ted  t e s t s  on the  th re e  
basés may be rep resen ted  d iagram m atically .
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Experim ental D e ta ils
S ix  r a b b i ts ,  l i t t e r - m a tes , weighed and sexed, were 
used in  each t e s t .  Food, but not w ater, was w ithheld  fo r  
e igh teen  hours before the  t e s t  s in ce  i t  was found th a t  by 
t h i s  procedure the  anim als seldom i f  ever u r in a te d  o r 
defaeca ted  w hile th e  t e s t  was in  p ro g re ss . On th e  day before 
th e  t e s t  the  fu r  was removed from th e  sk in  o f the  back and 
s id e s  of each animal w ith e le c t r ic  c l ip p e r s , ta k in g  care  not 
to  damage th e  sk in . The area  under t e s t  was marked by a 
dermograph p en c il u sing  a 6 x 4 inch tem plate p laced  on th e  
d o rsa l thoacico-lum bar reg ion  o f the  r a b b i t .  The ra b b i ts  were 
then  p laced  in  r e s tr a in in g  boxes which co n s is ted  m erely of 
two s id e s  and a f lo o r  and were f i t t e d  only  w ith  n eck -s to ck s.
The d is tan ce  between th e  f lo o r  and th e  ho le  in  th e  neck-stock  
could be ad ju sted  to  s u i t  the  s iz e  o f th e  ra b b it  req u ired  in
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th e  experim ent. D e ta ils  of th e  boxes have been describ ed  by Wylie. 
The anim als were thus rendered immobile but com fortable and ,being  
held  g en tly  but firm ly  in  the  n eck -s to ck , were p revented  from
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absorb ing  o r a l ly  the  ap p lied  p re p a ra tio n . A p iece  o f cardboard 
was f ix e d  to  th e  c ro ss-b a rs  o f th e  boxes to  p reven t the  ra b b it  
f l ic k in g  i t s  ea rs  behind the  c ro ss -b a r  on to  th e  ap p lied  
o in tm ent. This ensured th a t  a l l  ab so rp tion  tak in g  p la ce  was 
percu taneous and e lim inated  the p o s s ib i l i t y  o f a c c id e n ta l 
contam ination . F igure I  shows a r e s t r a in in g  box co n ta in in g  a 
r a b b i t  whose a rea  of a p p lic a tio n  i s  covered w ith  ointm ent.
A blood sample was withdrawn from the  m arginal ea r 
v e in  o f each animal as  a blank fo r  assay  purposes. About 30 
grammes o f v eh ic le  o r b ase , con ta in ing  th e  drug, were ap p lied  
to  th e  marked a rea  and rubbed in  fo r  a p e rio d  of th re e  m inutes. 
L iquid p re p a ra tio n s  were ap p lied  w ith  a s o f t  h a i r  b rush . 
R e ap p lica tio n s , in  both  in s ta n c e s , were a t  f i f t e e n  minute 
in te r v a ls .  At in te rv a ls  of t h i r t y  m inutes a f t e r  the  i n i t i a l  
a p p lic a tio n , blood samples were withdrawn over a p e rio d  o f 
e ig h t hours.
In  th e  e a r ly  s tag es  o f the  work a s ix  hour p erio d  
was considered  adequate bu t th i s  was extended to  e ig h t hours 
to  ensure th a t  the  perio d  of maximal ab so rp tio n  had been 
passed  and a lso  to  determ ine whether th e  f lu c tu a t io n s  in  th e  
system ic co n cen tra tio n s tended to  d isap p ea r.
Thus each completed t e s t  involved the  w ithdraw al o f 
s ix te e n  blood samples from th e  ea r o f  each of th e  s ix  r a b b i ts
Figure I  
T est Animal in  R estra in in g  Box
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g iv ing  a t o t a l  o f n in e ty -s ix  samples fo r  one base , and fo r  
the complete experiment on th re e  b ases , each ap p lied  tw ice , 
a t o t a l  of f iv e  hundred and se v en ty -s ix  blood samples* On 
com pletion of a s in g le  t e s t ,  th e  r a b b i ts  had th e  a p p lic a tio n  
removed and the ano in ted  a rea  thoroughly  washed w ith  warm, 
soapy water* A fte r se v e ra l washings, t h e i r  backs were r in se d  
and dried* In  o rder to  f a c i l i t a t e  th e  w ithdrawal o f b lood , 
the  ea rs  of the  r a b b i ts  were v igo ro u sly  massaged o r , in  the 
case of s lugg ish  c i r c u la t io n ,  t r e a te d  w ith  x y lo l which was 
washed o f f  w ith a lcoho l im m ediately i t  had exerted  i t s  e f f e c t .
On the com pletion of th e  t e s t ,  the ea rs  of the  ra b b its  were 
smeared w ith w hite s o f t  p a r a f f in  which prevented  any 
u n d esirab le  e f f e c ts  such as hardening or desquamation.
Before a fu r th e r  t e s t ,  th e  r a b b its  were allowed a t  l e a s t  one 
week’s r e s t  and th e i r  blood was then te s te d  fo r  absence o f drug.
Choice of Drug.
A drug was se le c te d  to  dem onstrate a wide range o f 
pharm acological and chem ical p ro p e r tie s  bu t the  choice was 
lim ited  to  one r e a d i ly  and a c c u ra te ly  determ ined in  sm all 
q u a n ti t ie s  in  b lood. The drug chosen was su lphanilam ide, 
one of the more ra p id ly  absorbed sulphonam ides.
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Sulphanilam ide, p-aminobenzenesulphonamide, has a 
s o lu b i l i ty  in  w ater o f 4OO mg./lOO ml. a t  15^ , and 1,500  
mg./lOO ml* a t  37^, and a s o lu b i l i ty  in  serum o f 1,970 
mg*/lOO ml* I t  i s  so lu b le  in  e th an o l, ace tone , g ly c e ro l, 
h y d roch lo ric  a c id  and sodium and potassium  hydroxide* I t  
i s  in so lu b le  in  e th e r  and benzene and so lu b le  in  chloroform  
to  the  ex ten t o f 25 mg*/lOO ml* and in  propylene g ly co l to  
the  ex ten t o f 10,000 mg*/lOO ml* The ac id  d is s o c ia tio n  
constan t (pKa) i s  10*43#
Choice o f V ehicles
The v e h ic le s  and bases in  which sulphanilam ide was 
in co rp o ra ted  inc luded  those in  wide use* Seven common 
c o n s titu e n ts  o f ointm ent bases were te s te d  fo r  th e i r  a b i l i t y  
to  promote the  ab so rp tio n  of sulphanilam ide and th e i r  
re sp e c tiv e  e f f ic ie n c ie s  were compared* The v eh ic le s  chosen were 
l iq u id  p a r a f f in ,  w hite s o f t  p a r a f f in ,  la rd , w oo lfa t, propylene 
g ly c o l, e th y l o le a te  and w ater in  the  form o f a f iv e  p e r cent 
carboxymethyl c e llu lo s e  g e l .
Four bases were te sted *  They were Hydrous Ointment 
B*P*, a w a te r - in -o il  em ulsion, Em ulsifying Ointment H*P*, and two 
o i1 -in -w a te r  em ulsions. Hydrous Em ulsifying Ointment B*P* and 
a cetomacrogol em ulsify ing  wax base*
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To ensure s tan d ard  p rep a ra tio n s  the drug was 
in co rp o ra ted  in to  th e  v e h ic le s  and bases by hand and 
subsequently  passed  through an ointm ent m il l .  The 
carboxymethyl c e llu lo s e  g e l was prepared  by adding 10 
grammes of carboxymethyl c e llu lo se  to  I 90 ml. d i s t i l l e d  
w ater in  a bowl In to  which were immersed e l e c t r i c a l ly  
d riven  s t i r r e r s .  By s u ita b ly  a d ju s tin g  the speed of 
r o ta t io n  a smooth g e l was ob ta ined . The r e q u is i te  
co n cen tra tio n  of drug was then  added and thoroughly 
s t i r r e d  in .
C oncentration  of In co rp o ra ted  Drug
The co n cen tra tio n  of sulphanilam ide used in  the  
v e h ic le s  and bases was te n  p e r cent w eig h t-in -w eig h t, one
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which had been recommended as a maximum u se fu l co n cen tra tio n .
E stim ation  of Sulphanilam ide
Before being  excre ted  by the  body, sulphanilam ide i s
conjugated w ith  a c e t ic  ac id  to  fo rm /ace ty l-su lphan ilam ideK
and since  the  chemical assay  depends on the  presence of a 
f re e  amino group in  the sulphanilam ide m olecule, the conjugated 
complex must be broken down in to  f re e  sulphanilam ide and 
a c e tic  ac id  by one h o u r 's  h y d ro ly sis  w ith  IN’ hyd roch lo ric  ac id .
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The to ta l  amount of c i r c u la t in g  su lphanilam ide, both f re e
and conjugated , was thus determ ined in  the assay  s in ce  i t
cannot be assumed th a t the degree o f a c é ty la tio n  in  the
ra b b its  was uniform  and co n stan t.
The assay  adopted was K ing 's  m icro-m odification  o f
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the  method of B ra tto n  and M arshall.
To 3.2 ml. w ater was added 0 .2  ml. blood follow ed
by 0 .6  ml. o f 25 p e r cent t r ic h lo r a c e t ic  a c id . The
p re c ip i ta te d  p ro te in s  were f i l t e r e d  o f f .  To 2 ml. o f the
f i l t r a t e  in  a 5 lûl. volum etric f la s k  were added 0 .5  ml.
IK hyd roch lo ric  a c id  and th i s  so lu tio n  was hea ted  a t  98-100°C
fo r  one hour. On coo ling , one drop of a f re s h ly  prepared
so lu tio n  o f 0 .5  p er cen t sodium n i t r i t e  was added and the
so lu tio n  allow ed to  stand fo r  th ree  m inutes; th i s  was
follow ed by 1 ml. o f a 0 .5  p er cent so lu tio n  of ammonium
sulphamate to  remove excess n i t r i t e  and the so lu tio n  allowed
to  stand  fo r two m inutes, 1 ml. o f a 0 .1  p er cent so lu tio n
of N -(l-n ap h th y l) ethylenediam ine d ihydroch loride in  w ater
was added and the  so lu tio n  f in a l ly  d ilu te d  to  5 ml. w ith
w ater. The in te n s i t i e s  of the co lours formed in  the d if fe re n t
samples were measured a t  540 mu, the  wavelength of maximal
. 209ab so rp tio n  fo r  sulphanilam ide so lu tio n s . Reagent blanks 
were prepared  w ith d i s t i l l e d  w ater.
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The Standard S o lu tio n  was made by d isso lv in g  100 mg. 
sulphanilam ide in  10 ml. O.O5K sodium hydroxide and d i lu t in g  
to  one l i t r e  w ith  d i s t i l l e d  w ater. To 5 ml. o f th i s  so lu tio n  
was added 20 ml. o f  I 5 p e r cen t t r ic h lo r a c e t ic  a c id  and 
75 ml. w ater. The e x tin c t io n  o f th i s  d i lu t io n  which contained  
the  eq u iv a len t o f O.OO5 mg. sulphanilam ide p er ml, was 
measured a t  540 mu.
Comparison o f Four Modes of A dm in istra tion  o f Sulphanilam ide 
The e f f ic ie n c y  o f percutaneous a p p lic a tio n s  w ith o th e r  
modes of ad m in is tra tio n  was compared by ad m in is te rin g  
sulphanilam ide to  the ra b b its  o ra l ly  and by subcutaneous and 
in travenous in je c t io n s .  The experim ents were then c a rr ie d  
out as b e fo re , th e  blood samples being  withdrawn a t  h a l f -  
hou rly  in te rv a ls  a f t e r  a d m in is tra tio n .
3# The A bsorption of v a rio u s  drugs through th e  In ta c t  
Skin o f the Rabbit from th ree  v e h ic le s  and b a se s .
The r e s u l t s  ob tained from th ese  experim ents showed th a t  
d if fe re n c e s  in  e f f ic ie n c y  e x is te d  between bases as " c a r r ie r s "  
o f su lphanilam ide. I t  was then  decided to  in v e s tig a te  whether 
the  e f f ic ie n c ie s  o f v eh ic le s  and bases occurred  in  the same 
o rder fo r  drugs o th e r  than su lphanilam ide. B esides allow ing 
a study o f th e  d if fe re n c e s  in  e f f ic ie n c y  between the v e h ic le s
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and bases chosen, the  r e s u l t s  would a lso  y ie ld  com parative 
v a lu es showing the  e f fe c ts  o f d i f f e re n t  drugs on ab so rp tio n .
D esign o f  T est and Experim ental D e ta ils
The design  o f t e s t  and the experim ental d e ta i l s  were 
s im ila r  to  those fo r  sulphanilam ide.
Choice o f  Drugs
The drugs fo r  fu r th e r  exam ination were chosen because 
they  ex h ib ited  a wide range o f p ro p e r tie s  and could be 
a c c u ra te ly  assayed in  blood w ith r e la t iv e  s im p lic ity . The 
drugs chosen were s a l ic y l ic  a c id , copper a c e ty l-a c e to n a te  
and copper su lp h a te .
S a l ic y l ic  a c id , o-hydroxybenzoic a c id , an organic compound 
has a s o lu b i l i ty  in  w ater of l80 mg/lOO ml. a t  20^C and 
6,670  mg./lOO ml. a t  lOO^C. I t  i s  so lu b le  to  the  ex ten t of
3.330  mg./lOO ml. in  a lco h o l, 2,220 mg./lOO ml. in  chloroform ,
3.330  mg./lOO ml. in  e th e r and 740 mg./lOO ml. in  benzene.
The s o lu b i l i ty  o f s a l ic y l ic  a c id  in  f ix e d  o i l s  i s  about 1 in
40 .
Copper a c e ty l-a c e to n a te  i s  a non-ion ic compound of copper 
ch e la ted  w ith  a c e ty l acetone. This complex i s  in so lu b le  in  
w ater and e th e r  bu t so lu b le  in  a lcoho l and chloroform .
Copper a c e ty l-a c e to n a te  i s  s ta b le  in  so lu tio n s  of su lp h u ric ,
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n i t r i c  and h y d ro ch lo ric  ac id s  but i s  u n stab le  in  so lu tio n s  
o f a l k a l i ,  p re c ip a tin g  copper s a l t s .
Copper su lpha te  i s  an io n ic  compound o f copper. The su lp h a te  
of copper has a s o lu b i l i ty  in  w ater o f 3,330 mg./lOO ml. a t  
15°C w hile 200 grammes w il l  d isso lv e  in  100 ml. w ater a t  
100°C. I t  i s  so lu b le  in  a lcoho l to  th e  ex ten t o f 200 m g./
100 ml. and i s  very  slow ly so lub le  in  g ly c e r in  to  th e  ex ten t 
o f 3,330 mg./lOO ml. Copper su lphate  i s  in so lu b le  in  f ix ed  
o i l s .
Choice o f V ehicles
Three v e h ic le s  and bases were chosen on the b a s is  of 
the  r e s u l t s  ob ta ined  w ith sulphanilam ide. They were la rd ,  
which was shown to have the  h ig h est e f f ic ie n c y  v a lu e , and 
w ate r, as  a f iv e  p e r cen t carboxymethyl c e llu lo se  g e l ,  which 
was shown to  have the  low est e f f ic ie n c y  v a lu e . Em ulsifying 
ointm ent was inc luded  since  i t  had an e f f ic ie n c y  value 
in te rm ed ia te  between those fo r  la rd  and w ater, as a f iv e  p er 
cen t carboxymethyl c e llu lo s e  g e l; i t  had a fu r th e r  in te r e s t  
o f being  an ointm ent commonly used in  pharm aceutical 
p re p a ra tio n s .
C oncentration  o f Inco rpo ra ted  Drugs
The co n cen tra tio n s  of drugs used in  the  v eh ic le s  and 
bases was te n  p er cent w eig h t-in -w eig h t, which had been
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133recommended as a u se fu l co n cen tra tio n . In  the case o f
s a l ic y l ic  a c id , however, the co n cen tra tio n  was lowered to
f iv e  p er cent in  o rd er to  reduce the lo c a l i r r i t a n t  and
k e ra to ly t ic  e f f e c t .  I t  was f e l t  th a t  th i s  decrease in
co n cen tra tio n  would no t in v a lid a te  comparative blood le v e l
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s tu d ie s  s ince  i t  had been rep o rted  th a t  an in c rease  of over 
f iv e  p e r cent in  th e  co n cen tra tio n  of the in co rp o ra ted  drug 
d id  not le ad  to  an in c re a se  in  ab so rp tio n .
E stim ation  of In co rp o ra ted  Drugs
The fo llow ing  assays were adopted.
S a lic y lic  ac id
A m o d ifica tio n  o f Smith and T a lb o t 's  c o lo rim e tric  
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method was used.
0 .2  ml. blood was added to  3.2  ml. d i s t i l l e d  w ater 
follow ed by 0 .6  ml. o f a 25 p e r cen t so lu tio n  o f t r ic h lo r a c e t ic  
a c id . To 2 ml. o f  the  f i l t r a t e ,  1 ml. 1. 5K sodium hydroxide 
was added. 0.5  ml. F o lin -C io c a lte u 's  re ag en t, d ilu te d  one to  
fo u r w ith d i s t i l l e d  w ater, was then  added and the volume 
ad ju s ted  to  5 ml. w ith  I.5K sodium hydroxide. A fte r standing  
the  so lu tio n s  were f i l t e r e d  to  remove any phospho-molybdate 
complex formed and the  e x tin c tio n s  measured ag a in s t a reagent 
b lank a t  a wavelength of 69O mu.
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To c o rre c t fo r  n o n -sp e c ific  plasma phenols which 
a re  included  in  th i s  e s tim a tio n , th e  average read ing  of 
t h i r t y - s i z  normal blood samples tre a te d  as above 7/as 
su b trac ted  from th e  observed values before r e f e r r in g  to  a 
c a l ib ra t io n  curve co n s tru c ted  by s im ila r ly  t r e a t in g  knoura 
d i lu t io n s  o f sodium s a l ic y la te  in  d i s t i l l e d  water* The 
co n cen tra tio n  of red u c tab le  m a te r ia l in  blood estim ated  by 
th i s  method gave a value o f 10*41 mg./lOO ml.
Copper a c e ty l-a c e to n a te  and copper su lpha te
Both copper a c e ty l-a c e to n a te  and copper su lp h a te  could 
be estim ated  in  blood by the  same method.
Copper, in  ammoniacal s o lu t io n , was estim ated  
c o lo r im e tr ic a lly  w ith sodium d ie th y l d ith iocarbam ate  which 
i s  capable of d e te c tin g  one p a r t  o f copper in  f i f t y  m illio n
p a r ts  o f so lu tio n . The co lour produced i s  s ta b le  fo r  se v e ra l
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hours.
0 .2  ml. blood was added to  3 .2  ml. d i s t i l l e d  w ater 
follow ed by 0 .6  ml. of a 25 p e r cen t aqueous so lu tio n  of 
t r ic h lo r a c e t ic  a c id . To 2 ml. of the  f i l t r a t e  was added 
0*5 ml. o f a 10 p e r cent so lu tio n  of ammonia. Three drops 
o f a 0.1  p e r  cent so lu tio n  o f sodium d ie th y l d ith iocarbam ate 
were then  added and the  f in a l  volume ad ju s ted  to  5 ml. w ith
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d i s t i l l e d  w ater. The e x tin c tio n s  of the  so lu tio n s  were 
measured ag a in s t reag en t b lanks a t  a wavelength o f 455 mu. 
Estim ated by th is  method, the  co n cen tra tio n  o f copper p resen t 
in  normal c i r c u la t in g  r a b b it  b lood, ta k in g  the  average of 
tw enty-four blood sam ples, was 0.18  mg./lOO ml.
The Standard S o lu tio n s were p repared  by adding known 
co n cen tra tio n s of copper to  f re s h ly  drawn ra b b it  blood and 
the procedure c a rr ie d  out as d escrib ed . The es tim a tio n  of 
copper was ac cu ra te  to  w ith in  one p er cen t so th a t  under the 
co n d itio n s of the  assay  any complexes formed by the  m etal 
and the  blood p ro te in s  appear to  have broken down, th e  copper 
rem aining in  so lu tio n  as the  s ta b le  t r ic h lo r a c e ta te .
The e f f e c t  o f an i r r i t a n t  and an a s tr in g e n t on the  percutaneous
ab so rp tio n  o f su lphanilam ide
125,126
The i r r i t a n t  k e r a to ly t ic  e f f e c t  o f s a l ic y l ic  ac id  on 
the  ab so rp tion  of sulphanilam ide was s tu d ied  by in c o rp o ra tin g  
f iv e  p er cent s a l i c y l ic  a c id  in  la rd  co n ta in in g  ten  p e r cent 
sulphanilam ide. The a s tr in g e n t a c tio n  o f copper su lpha te  was 
observed by in co rp o ra tin g  ten  p e r cent copper su lpha te  in  la rd  
co n ta in in g  ten  p er cent su lphanilam ide. The v e h ic le s  were 
ap p lied  to  r a b b its  and the  blood le v e ls  o f  sulphanilam ide 
a t ta in e d  were determ ined as b efo re .
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RESULTS
The r e s u l t s  a re  recorded  in  th re e  se c tio n s . The 
negative  r e s u l t s  ob ta ined  fo r  th e  experim ent te s t in g  
percutaneous ab so rp tio n  through is o la te d  r a t  sk in , the 
r e s u l t s  ob tained  fo r  the bases te s te d  w ith sulphanilam ide 
and the r e s u l t s  ob ta ined  w ith s a l i c y l ic  a c id , 
su lphanilam ide, copper a c e ty l-a c e to n a te  and copper 
su lpha te  in  s e le c te d  v e h ic le s  and b ases .
Also inc luded  a re  the  r e s u l t s  o f ana lysés of 
variance c a rr ie d  out on the d a ta  from th ree  breeds of 
r a b b i ts ,  each te s te d  w ith the same ointm ent bases.
The r e s u l t s  of the  e n t i r e  s e r ie s  o f experim ents 
are  f u l ly  recorded  in  Appendix One.
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1 . The Passage o f Sulphanilam ide through I s o la te d
I n ta c t  Rat Skin .
Ko sulphanilam ide was ever d e tec ted  in  the  mammalian 
R inger so lu tio n  except in  the  case o f a c c id e n ta l 
contam inati on.
From th ese  experim ents i t  may be concluded th a t  in ta c t  
r a t  sk in , is o la te d  in  oxygenated s a lin e  a t  37^C, i s  impermeable 
to  sulphanilam ide contained in  s o l id  and l iq u id  p re p a ra tio n s ; 
i t  th e re fo re  p re se n ts  an im penetrab le b a r r ie r  to  p rep a ra tio n s  
te s te d  in  th i s  way.
The f a i lu r e  of the  drug to  p e n e tra te  the sk in  may be 
explained  on the grounds th a t  the  blood supply to  th e  dermal 
t is s u e s  had been severed by i s o la t in g  the  t i s s u e s .  Having 
p en e tra ted  to  the  base of a f o l l i c l e ,  no means th e re fo re  
ex is te d  to  tra n sp o r t the drug through the rem aining lay e rs  
o f the  sk in  to  the  Ringer so lu tio n . The p e n e tra tio n  o f 
sulphanilam ide through is o la te d  in ta c t  sk in  would have 
n e c e s s ita te d  the p h y s ic a l perm eation of the  drug through the 
epiderm is, the derm is and the deeper subcutaneous f a t ty  
t i s s u e ,  co n d itio n s which were not to  be expected from 
h is to lo g ic a l  f in d in g s .
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2 . The A bsorption of Sulphanilam ide through the  I n ta c t
Skin of the Rabbit from v ario u s  v e h ic le s  and b a se s .
The r e s u l t s  o f a l l  experim ents a re  shown in  ta b le s .
The w eight, sex and number o f each animal and the  blood 
le v e l o f the  drug in  mg./lOO ml. a t  h a lf-h o u rly  in te rv a ls  
fo llow ing  the  a p p lic a tio n  o f the to p ic a l p re p a ra tio n  a re  
no ted . These v a lu es , added to g e th e r , g ive an es tim a te  of 
the response o f the  s ix  ra b b its  to  the  base under exam ination 
fo r  the  d u ra tio n  o f the  experim ent. The average response of 
the anim als to  th e  v eh ic le  o r base i s  determ ined by d iv id in g  
the  sum to ta l  observed by the  number of blood samples 
withdrawn.
The r e s u l t s  o f a l l  t e s t s  are  summarised in  Table I .
The base ap p lied , the drug and ra b b it  l i t t e r  used, and th e  
sum to t a l s  a re  g iven. The experim ents were not d u p lica ted  
in  every case but only where necessary  fo r  s t a t i s t i c a l  
purposes. Where experim ents were d u p lica ted  the  average of 
the  two r e s u l t s  obtained  a re  en tered .
A summary o f the r e s u l t s  i s  g iven in  Tables I I  -  IV. 
The response of in d iv id u a l ra b b its  to  the  same base v a r ie s  
co n sid erab ly , th i s  being rep resen ted  d iagram m atically  in  
in  F igure I I .  The " s c a t te r "  o f r e s u l t s  w ith in  one r a b b i t ,  
seen in  the ta b le s  of experim ental r e s u l t s ,  in  Appendix One
Figure II
The resp on se  o f  in d iv id u a l r a b b its  to  
s e le c t e d  v e h ic le s  and b ases c o n ta in in g  
su lphanilam ide
A Liquid paraffin.





G 5 Per cent methyl cellulose gel 
in water.
H H ydrous  O in tm en t B.P.
1 Emulsifying O in tm en t B.P.
J H ydrous Emulsifying O in tm ent 
B.P.
K Cetomacrogol emulsifying wax 
base.
The blood level of sulphanilamide observed in individual rabbits following 
the application of the selected vehicles and bases. Six animals were used with each 
base.
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i s  wide. D uplicated t e s t s  a lso  show d iffe re n c e s  in  
r e s u l t s .
The summarised r e s u l t s  ob ta ined  fo r  sulphanilam ide 
are  shown in  Table I I .  These a re  given fo r  s ix  in d iv id u a l 
r a b b i ts ;  the values ob ta ined  in  each of the s ix teen  blood 
samples withdrawn over th e  e ig h t hours were added to g e th e r 
and th i s  sum en tered  in  the  T able. The in d iv id u a l t o t a l s  
were then  added and the  response o f the  s ix  r a b b its  to  the 
to  the  base under exam ination thus found.
The average blood le v e ls  observed are  given in  Table 
I I I  which was c a lc u la te d  from Table I I .  The sum to ta l s  of 
th e  in d iv id u a l r a b b its  over e ig h t hours was d iv ided  by 
s ix te e n , the  number o f blood samples withdrawn, and the  mean 
blood le v e l fo r  the d u ra tio n  of the t e s t  ob tained . The average 
of the blood le v e ls  found fo r  the in d iv id u a l ra b b its  was then 
taken  fo r  each v e h ic le  o r base and th i s  f ig u re  used as a 
p r a c t ic a l  index o f i t s  e f f ic ie n c y . T h e rap eu tica lly , t h i s  i s  
the  value most l ik e ly  to be a t ta in e d  by the base when ap p lied  
under s tan d ard ised  co n d itio n s .
From th is  va lue  a ta b le  of e f f ic ie n c ie s  was co n stru c ted  
fo r  th e  v e h ic le s  and bases te s te d  w ith  su lphanilam ide. The 
v eh ic le  o r base w ith  th e  low est mean blood leve^ w ater as  a 
f iv e  p e r  cent carboxymethyl c e llu lo se  g e l ,  was taken as u n ity
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and the o th e r v a lu es c a lc u la te d  accord ing ly . In  Table IV 
la rd  was the  most e f f ic ie n t  v e h ic le  or base te s te d  w ith  
su lphan ilam ide, being  approxim ately tw o-and-a-half tim es 
more e f f ic ie n t  than  w ater as a carboxymethyl c e llu lo s e  g e l . 
Propylene g ly c o l, hydrous ointm ent, w hite so f t  p a r a f f in  and 
e th y l o le a te  gave roughly the same e ff ic ie n c y  value and were 
alm ost tw ice as e f f ic ie n t  as the  aqueous g e l .  Em ulsifying 
ointm ent, l iq u id  p a ra f f in ,  hydrous em ulsifying ointm ent and 
w oolfat were only s l ig h t ly  more e f f ic ie n t  than  the g e l .
These values a re  rep resen ted  d iagram m atically  in  F igure I I I .
Comparison of fou r modes o f ad m in is tra tio n  of sulphanilam ide 
Four methods o f ad m in is te rin g  sulphanilam ide were 
examined by comparing the blood le v e ls  a t ta in e d  fo llow ing 
the  o ra l ad m in is tra tio n  of a sulphanilam ide t a b le t ,  an 
in travenous in je c t io n  and a subcutaneous in je c t io n  w ith  the  
average of the blood le v e ls  a t ta in e d  from em ulsify ing  ointm ent 
which contained te n  p er cent su lphanilam ide. While the  blood 
le v e ls  a t ta in e d  o r a l ly  and by in je c t io n  could be v a r ie d  by 
a l te r in g  the  co n cen tra tio n  of sulphanilam ide adm in istered , 
an es tim ate  of th e  ra p id i ty  w ith  which th e  drug was removed 
from the c i rc u la t io n  was obtained . The blood le v e ls  from 
em ulsify ing  ointm ent were chosen s in ce  th e i r  values l i e  
between those fo r  th e  most e f f ic ie n t  and the  le a s te f f ic ie n t
Figure III
The mean response o f r a b b i ts  to  
s e le c te d  v eh ic le s  and bases 
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rabbits following the application of the selected vehicles and
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v eh ic le  o r hase and they  can th e re fo re  he c i te d  as average 
fo r  th e  to p ic a l  p re p a ra tio n s  te s te d  w ith  su lphanilam ide.
The hlood le v e ls  a t ta in e d  hy th ese  methods a re  
i l l u s t r a t e d  in  F igure IV. Those fo r  the  o ra l ly  adm in istered  
su lphanilam ide were th e  h ig h e s t o f the  fo u r modes examined. 
Each p o in t on the  graph was the average o f the  v alues 
ob ta ined  from s ix  r a b b i ts .  The blood le v e l o f su lphanilam ide 
reached a value o f 12 mg./lOO ml. a f t e r  o m -and-a-half hours 
and dropped to  4 mg./lOO ml. a f t e r  e ig h t hours. The "depot" 
e f f e c t  o f th e  subcutaneous in je c t io n  can be observed.
The le v e l o f su lphanilam ide r i s e s  to  2 mg./lOO ml. a f t e r  
t h i r t y  m inutes, r i s e s  fu r th e r  to  3 mg./lOO m l. a t  which i t  
rem ains fo r  fo u r h o u rs , and slow ly f a l l s  to  1.5  mg./lOO ml. 
a f t e r  e ig h t hours. The h igh  i n i t i a l  v a lu es  fo r  the  
in travenous in je c t io n  l a s t  f o r  two hours and then  f a l l  
throughout the  rem ainder o f the e ig h t hours to  0.7  mg./lOO ml,
The blood le v e ls  p lo t te d  fo r  th e  percutaneous 
ab so rp tio n  o f su lphanilam ide from em ulsify ing  ointm ent a re  
the  average of e ig h teen  in d iv id u a l samples. The blood 
co n cen tra tio n  remains f a i r l y  co n s tan t and f lu c tu a te s  around 
a value of 0.5  mgi/lOO ml. This i s  to  be expected s in ce  the 
amount o f drug p ass in g  to  the  dermal c a p i l l a r i e s  w il l  be 
p ro p o rtio n a l to  the  number of h a i r  f o l l i c l e s  in  the  a rea  of
Figure IV
The blood le v e l s  of Sulphanilam ide 
observed in  r a b b i ts  fo llow ing  

















Hours a f t e r  A d m in istra tio n
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a p p lic a tio n . When th e  ointm ent has p e n e tra te d  to  th e  hase 
o f a f o l l i c l e  th e  t r a n s f e r  o f su lphanilam ide to  the  
c a p i l l a r i e s  w i l l  occur a t  a co n s tan t r a t e .  As the  ointm ent 
f i l l s  each f o l l i c l e  in  the  ano in ted  a re a , th e  o v e ra ll  r a te  
o f t r a n s f e r  to  th e  bloodstream  w il l  g rad u a lly  reach  a 
l im it in g  v a lu e . The co n cen tra tio n  o f drug in  the  hlood 
w il l  r i s e  to  a maximum ahout which f lu c tu a tio n s  occur.
The hlood le v e ls  a t ta in e d  hy o r a l ,  in trav en o u s and 
subcutaneous ad m in is tra tio n  f e l l  to  zero w ith in  fo r ty -e ig h t  
hou rs. Follow ing percutaneous a d m in is tra tio n  only t r a c e s  
o f th e  drug could he d e tec ted  a f t e r  f iv e  days although 
estim ab le  le v e ls  rem ained fo r  a longer p e rio d  than  the  o th e r  
modes o f a d m in is tra tio n , presumably s in ce  the ointm ent in  
the  h a i r  f o l l i c l e s  could no t he removed hy washing.
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3 . The A bsorption o f v a rio u s drugs through the In ta c t  
Skin of the R abbit from th re e  v eh ic le s  and b a se s .
The r e s u l t s  o f th ese  experim ents a re  shown in  ta b le s  
s im ila r  to  those fo r  su lphanilam ide. The r e s u l t s  o f a l l  
t e s t s  a re  summarised in  Table V. The base a p p lied , the  drug 
and ra b b it  l i t t e r  used , and the  sum to ta l s  a re  given.
Since the  experim ents were d u p lic a ted , the  average of two 
r e s u l t s  i s  en te red . S im ila r ly , ta b le s  were constru c ted  
to  show the order o f e f f ic ie n c y  o f the th ree  b ases , la rd , 
em ulsifying ointm ent and w ater as a f iv e  p e r cent 
carboxymethyl c e llu lo se  g e l ,  co n ta in in g  s a l ic y l ic  a c id , 
su lphanilam ide, copper a c e ty l-a c e to n a te  and copper su lp h a te .
The in d iv id u a l t o t a l  o f each drug absorbed by the 
r a b b its  over e ig h t hours from the  th ree  v eh ic le s  and bases 
under examination i s  noted in  Table VI and the  mean blood 
le v e ls  a t ta in e d  by th ese  d if fe re n t  drugs in  th ese  v eh ic le s  
and bases a re  shown in  Table V II. The e f f ic ie n c y  of the 
th ree  v e h ic le s  and bases fo r  each of the fou r drugs a re  
shown in  Table V III. In  th is  ta b le ,  w ater as a f iv e  per 
cent carboxymethyl c e llu lo se  g e l was taken as u n ity  fo r  
the group of a p p lic a tio n s  con ta in ing  a drug since  i t  always 
gave the low est blood le v e ls , re g a rd le ss  of the drug 
inco rpo ra ted .
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The com parative e f f ic ie n c ie s  o f th e  a p p lic a tio n s  te s te d  
w ith  the fo u r drugs a re  shown in  Table IX* The blood le v e l 
from copper su lp h a te  in  the  carboxymethyl c e llu lo se  g e l , the 
lowest recorded in  the complete s e r ie s  o f test% was taken as 
u n ity . For a l l  four drugs, la rd  was the most e f f ic ie n t  v eh ic le  
o r base te s te d  and w ater as a f iv e  p e r  cent carboxymethyl 
c e llu lo se  g e l th e  le a s t  e f f i c ie n t .  The degree o f abso rp tion  
of the  inco rpo ra ted  drug can a lso  be seen . S a lic y lic  ac id  
was absorbed more re a d ily  than su lphanilam ide w hile , by 
comparison, the  a c e ty l-a c e to n a te  and the su lp h a te  of copper 
were poorly  absorbed.
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The e f f e c t  o f  an ir r i t a n t  and an a str in g e n t on th e  percutaneous
ab sorp tion  o f  su lphanilam ide
S a l i c y l i c  a c id  and copper su lp h ate  were incorp orated  
in to  sep arate  ointm ents o f  la rd  co n ta in in g  te n  per cen t  
su lphanilam ide and th e  blood co n cen tra tio n  o f  su lphanilam ide  
n oted .
The r e s u l t s  are summarised in  Table X. The sm all 
decrease in  th e  amount o f  su lphanilam ide absorbed from lard  
when s a l i c y l i c  a c id  was a ls o  incorp orated  la y  w e ll w ith in  
th e  l im i t s  o f  error  found between r e p lic a t io n s  and i t  may be 
concluded th a t th e  in co rp o ra tio n  o f  s a l i c y l i c  a c id  w ith  
su lphanilam ide in  la rd  n e ith e r  h in d ers nor promotes 
ab sorp tion  o f  th e  l a t t e r .  The in corp ora tion  o f  copper 
su lp h a te , however, d ecrea ses th e  ab sorp tion  o f  su lphanilam ide  
in  la rd  by tw e n ty -f iv e  per cen t and th e  a s tr in g e n t a c t io n  
o f  th e  su lp h ate  appears to  ex er t a s ig n if ic a n t  h in d erin g  
e f f e c t .
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TABLS I .
T otal Amount o f Sulphanilam ide Observed in  th e  
blood o f Six R abbits from v arious v e h ic le s  and b ases .
The Average o f D uplicated  Experiments E ntered
Mg./lOO ml.
V ehicle or Base L i t t e r R esu lt Average
Water as 5 per cent carboxy
methyl c e llu lo se 96-101 34.36 34.36
Subcutaneous
in je c t io n 102-107 268.57 268.57
Intravenous
in je c t io n 102-107 127.29 127.29
Oral
A dm inistra tion 102-107 837.21 837.21
Hydrous ointm ent 48-53 92.51 : 103.74 98.12
Hydrous ointm ent 96-101 64.90 64.90
Hydrous ointm ent 73-78 94.67 : 45.33 70.00
Emulsif. ointm ent 48-53 73.30 : 74.60 73.95
Emulsif. ointm ent 96-101 44.70 44.70
Emulsif. ointment 73-78 41.39 : 55.02 48.21
Hydrous em u lsif.
ointment 48-53 42.30 : 41.85 42.08
Hydrous em ulsif.
ointment 96-101 40.71 40.71
Hydrous em ulsif.
ointment 73-78 36.17 : 45.35 40.76
Woolfat 96-101 32.36 : 47.29 39.83
Lard 96-101 85.82 : 86.02 85.92
White s o f t  p a ra f f in 96-101 63.23 : 64,45 63.84
Liquid P a ra ff in 96-101 44.73 : 39.11 41.92
Propylene g lyco l 48-53 60.95 : 69.12 65.03
E thyl o le a te 48-53 63.04 63.04
Cetomacrogol
em ulsify ing  wax 96-101 51.94 51.94
66
TABLE II
Comparison o f  Percutaneous A bsorption o f Sulphanilam ide 
in  th e  Rabbit from d if f e re n t  v eh ic le s  and bases
T o ta l Amount Observed in  th e  blood T o ta l Amount 
o f  6 in d iv id u a l r a b b i ts  (each value  Observed
Ease i s  th e  sum o f 16 sam ples; in  s ix  ra b b its






e ig h t hoi 
Mg./lOO
Liquid
p a ra f f in 9.39 9.53 7.71 5.53 6.21 6.32 44.69
White so f t 
p a ra f f in 11.57 11.72 12.02 10.02 9.65 8.85 63.83
Woolfat 8.08 6.84 8.00 6.06 5.61 5 .24 39.83
la rd 14.14 16.05 14.54 16.24 13.03 11.92 85.92
Ethyl
o le a te 12.98 15.60 8.92 6.53 7.89 11.12 63.04
Propylene
g ly co l 17.17 12.19 8.64 8.69 8 .80 9.55 65.04
Water as 
5 p e r  cent 
carho iy  
methyl 
c e llu lo s e 4 .46 4.47 4 .64 7.67 7.19 5.93 34.36
Hydrous
ointm ent 7 .39 12.54 12.29 12.44 9.68 10.56 64.90
Em ulsifying




5.69 5.72 6.28 6.56 6.58 9.88 40.71
Cetamacrogol




Comparison o f  P ercutaneous A bsorption  o f  Sulphanilam ide  
in  th e  Babbit from d if f e r e n t  v e h ic le s  and b ases
Mean Blood Level Observed 
in  s ix  in d iv id u a l r a b b its  
over e i ^ t  hours
Mg./lOO m l.
R abbit Rumber
Mean Blood Level 
Observed in  s ix  
r a b b i ts  over 
e ig h t hours
Mg./lOO ml.
1 2 3 4 5 6
L iquid
p a ra f f in 0.59 0.59 0.48 0.35 0.39 0.39 0.47
White s o f t  
p a ra f f in 0.72 0.73 0.75 0.63 0.60 0.55 0.66
Woolfat 0 .50 0.43 0.50 0.38 0.35 0.33 0.41
Lard 0.88 1 .03 0 .91 1 .02 0.82 0.75 0.89
E thyl o le a te 0.81 0.98 0 .56 0.41 0.49 0.70 0.66
Propylene
g ly co l 1.07 0.76 0 .54 0.54 0.55 0.60 0.68
Water a s  5 
p e r  cent 
carboxy 
methyl 
c e llu lo s e
0.28 0.28 0.29 0.48 0.44 0.37 0.36
Hydrous
ointm ent 0.46 0.78 0.77 0.78 0.60 0.66 0.68
Bm ulsifÿing




0.36 0.36 0.39 0.41 0.41 0.62 0.42
Cetomacrogol 
em ulsify ing  
wax base
0.55 0.52 0.56 0.55 0.44 0.53 0.52
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TABLE IV
Con^arison o f  P ercutaneous A bsorption  o f  Sulphanilam ide  
from d if f e r e n t  v e h ic le s  and b ases in  th e  Rabbit
T able o f  E f f ic ie n c ie s
Base
Lard
Propylene g ly c o l
Hydrous ointm ent
White s o f t  
p a r a ff in
E thyl c le a t e
Cetomacrogol 
e m u ls ify in g  
wax b ase
E m u lsify in g
ointm ent
L iqu id  p a r a f f in
Hydrous
em u ls ify in g
ointm ent
W oolfat
Water as  
5 per cent 
carboxy  
m ethyl 
c e l lu lo s e
Mean Blood L evel 
Observed in  
S ix  R abbits over  




























T ota l Amount o f  th r e e  drugs Observed in  th e  b lood o f  
S ix  R abbits from v a r io u s v e h ic le s  and b ases
The Average o f  D u p licated  Eb^eriments Entered
Mg./lOO m l.
V ehicle of Base Drug L i t t e r B esu lt Average
Lard S a l ic y l ic  Acid G-L 107.50 : 115.93 111.72
White so f t 
p a r a f f in S a l ic y l ic  ac id 102-107 98.50 ! 105.02 101.76
Hydrous
ointm ent S a l ic y l ic  ac id IO2-IÔ7 116.11 : 108.20 112.16
Propylene g ly c o l .S a l ic y l ic  ac id 102-107 129.70 ; 107.92 118.81
Water as 5 p e r
cent carboxy S a l ic y l ic  ac id  
methyl c e llu lo se
G-L 79.91 : 89.26 84.59
Em ulsifying
ointm ent S a l ic y l ic  ac id A-P 86.47  : 101.14 93.81
Water as 5 p er
cent carboxy Copper




su lp h a te 102-107 20.24 : 19.86 20.05
Lard Copper su lpha te 102-107 21.64 : 20.39 21.02
Lard Copper a c e ty l -  
ace to n a te A-P 23.59 : 27.45 26.52
Lard Copper a c e ty l-  
ace to n a te G-L 25.34 : 24.21 24.78
Water as  5 p e r Copper a c e ty l— 
cent carboxy ace to n a te  
methyl c e llu lo s e .
Em ulsifying Copper acetylrr • 









Lard Sulphanilam ide + 
Copper su lpha te G-L 64.77 64.77
Lard Sulphanilam ide + 
S a l ic y l ic  ac id A-P 82.94 82.94
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Table o f  Comparative E f f ic ie n c ie s
The Percutaneous A bsorption o f  four drugs from th ree  
v e h ic le s  o f  b ases in  th e  Rabbit
The blood l e v e l  fo r  Copper su lp h ate  in  
water a s f iv e  per cen t carboxymethyl 
c e l lu lo s e  i s  taken a s u n ity
Lard
E m ulsify ing
ointm ent
V/ater as  
f iv e  per cent 
carboxymethyl 
c e l lu lo s e








Copper a c e t y l -  
a ceton ate 1.42







The E ffec t of an i r r i t a n t  and an a s tr in g e n t on the 
Percutaneous A bsorption of Sulphanilam ide
Mg*/lOO ml.
T o tal Amount 
Sulphani1ami de 
Observed in  the blood 
of Six R abbits 






Lard con tain ing  
ten  per cent 
sulphanilam ide
85.92
Lard con tain ing  
ten  per cent 
suIphani1ami de 
and f iv e  p er cent 
s a l ic y l ic  ac id
82.94 3.5
Lard con tain ing  
ten  p er cent 
sulphanilam ide 




The A n a ly s is  o f  Variance
The r e s u l t s  ob ta in ed  were s t a t i s t i c a l l y  an a lysed  to  
examine a s fa r  as p o s s ib le  th e  fa c to r s  in v o lv ed  in  percutaneous 
a b s o r p t io n .lt  i s  a v a lu a b le  p roperty  o f  var ian ce  th a t i f  a 
p rocess has a number o f  fa c to r s  each making a c o n tr ib u tio n  to  
the varian ce  o f  the f i n a l  r e s u l t ,  then t h i s  t o t a l  var ian ce  i s  
equal to  th e  sum o f  th e  component v a r ia n c e s . T his p roperty  i s c /
t
a d d it iy n e ss  o f  var ian ce  makes p o s s ib le  the technique known
A
as the a n a ly s is  o f  var ian ce  whereby th e  t o t a l  var ian ce  o f  a
p rocess can be ana lysed  in to  i t s  component fa c to r s ,  th e
212r e la t iv e  importance o f  which can then be a s s e s s e d .
A nalysing  the components in  th e se  experim ents c o n s is te d  
o f  examining a s e t  o f  r e s u l t s  to  determ ine the varian ce  between  
b a s e s , between in d iv id u a l r a b b its , between blood samples drawn 
a t d if fe r e n t  t im e s , between male and fem ale r a b b its , between 
r a b b its  o f  d if f e r e n t  w eigh ts and between r a b it s  o f  d if f e r e n t  
b reed s. S evera l o f  th e se  fa c to r s  may in te r a c t  w ith  one another; 
fo r  in s ta n c e , th e  v a lu e s  fo r  a r a b b it-b a s e , a b a se -r a b b it or 
a r a b b it-tim e  in te r a c t io n  f a c to r ,  i f  shown to  be s ig n i f i c a n t ,  
may p la y  an im portant part in  th e  passage o f  drugs th r o u ^  
th e  sk in . When allow ance has been made fo r  the var iou s f a c t o r s ,  
a component known as the r e s id u a l var ian ce  i s  s t i l l  req u ired  
to  c o n s t itu te  the t o t a l  v a r ia n ce . The r e s id u a l may be
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in te rp re te d  as an es tim a te  of experim ental e r ro r ;  the  
sm aller the  value o f the  re s id u a l e r ro r  the  more s e n s it iv e  
the  method.
Three breeds of r a b b i t ,  a: Beveren l i t t e r ,  a Dutch 
l i t t e r  and a Copenhagen White l i t t e r ,  were te s te d  w ith  th ree  
b ases , Hydrous Ointment B .P ., Em ulsifying Ointment B.P. and 
Hydrous Em ulsifying Ointment B .P ., each con ta in ing  10 per 
one su lphanilam ide. L itte r-m a te s  were chosen since i t  has 
been found th a t  the  b io lo g ic a l v a r ia t io n  i s  le s s  in  fa m ilie s  
than  in  anim als drawn a t  random from a p o p u la tio n . A 
complete s t a t i s t i c a l  a n a ly s is  o f varian ce  was c a rr ie d  out 
on the r e s u l t s  ob ta ined  from each l i t t e r .  For comparison 
w ith o th e r v eh ic le s  and bases the r e s u l t s  from the  Copenhagen 
White l i t t e r  were quoted. Due to  the  deaths of two o f the 
t e s t  anim als w hile th e  t e s t s  were being  c a rr ie d  out i t  proved 
im possible to  r e p l ic a te  the  determ inations fo r  sulphanilam ide 
on th e  l i t t e r  o f Copenhagen White r a b b i ts .  Since each base 
had only been te s te d  once the  s t a t i s t i c a l  trea tm ent of th e  
r e s u l t s  were com plicated when th ese  were compared w ith  those 
from the Dutch and Beveren l i t t e r s .  The mean blood le v e ls  
and th e  e f f ic ie n c ie s  o f these  ointm ents te s te d  on each o f the 
l i t t e r s  a re  given in  Table XI.
As the work progressed  i t  was found th a t  the  re s id u a l
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v arian ce  dropped in  value u n t i l  i t  became c o n s tan t. This 
im plied th a t  the  experim ental e r ro r  decreased  u n t i l  
reach in g  a constan t v a lu e . U nfo rtuna te ly , th i s  com plicated 
th e  in te rp r e ta t io n  o f the  r e s u l t s  ob ta ined  from ra b b its  o f  
d if f e re n t  b reed s . A ccordingly i t  cannot be s ta te d  w ith  
c e r ta in ty  th a t  a s ig n if ic a n t  d iffe re n ce  e x is ts  in  the  
response o f ra b b its  from d if fe re n t  breeds since th e  r e s u l t s  
a lso  w arrant the conclusion  th a t  the  v a r ia t io n  may be p a r t ly  
due to  the  la rg e  d iffe re n c e  in  the  re s id u a l v a rian ces  fo r  
each b reed . The f a c t  th a t  th e  re s id u a l fo r  the  Beveren l i t t e r ,  
0 . 35) i s  more than  tw ice th a t  fo r  th e  Dutch, 0 . 15, may be 
explained  by the f a c t  th a t  when c a rr ie d  out on th e  Beveren, the 
experim ental technique had not reached the  stage o f 
refinem ent a t ta in e d  l a t e r  in  th e  t e s t s  conducted on the  Dutch 
and Copenhagen White l i t t e r s .  N ev erth e less , the genera l 
conclusions emerging from the  a n a ly s is  on the  Beveren a re  
s t i l l  o f value and confirm those from the o th e r l i t t e r s .
The f u l l  a n a ly s is  o f variance  fo r  each breed and the 
trea tm ent o f the  r e s u l t s  req u ired  fo r  t h i s  a n a ly s is  are  
shown in  Appendix Two. A summarised ta b le  of the  analyses 
i s  given in  Table X II.
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TABLE XI
Comparison of Percutaneous A bsorption o f Sulphanilam ide 
from th re e  ointm ents in  R abbits of d if fe re n t  b reed s .
Mean Blood Level 
Mg./lOO m l.
Base
























Order o f E ff ic ien cy
2.34  1.78  1.00
1.70 1.18  1.00
1.62  1.12 1.00
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TABLE XII
A summary o f the a n a ly s is  o f v ariance  
c a rr ie d  out on th e  r e s u l t s  ob ta ined  
w ith  sulphanilam ide from th re e  breeds 
of r a b b i t .







4.8105 t*1 . 75i 9
Between ra b b its
*
0.3500 0.2507 0.1258
















Base X  Time 
X  Rabbit 0.4086 0.1207 0.0508
R esidual 0.3489 0.1559 —
The sources o f v a rian ce  which a re  a s te r isk e d  are  
those which give s ig n if ic a n t  v a lu es and which p jay  an 
im portant p a r t  in  th e  percutaneous ab so rp tio n  of sulphanilam ide 
The source of varian ce  between bases i s  s ig n if ic a n t 
in  a l l  th ree  analyses and i t  can th e re fo re  be sa id  th a t  the 
v eh ic le  o r base e x e rts  an im portan t e f f e c t  on the  blood le v e l 
o f sulphanilam ide a t ta in e d . This r e s u l t  e s ta b lish e s  th a t
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v eh ic le s  and hases vary  in  t h e i r  e f f ic ie n c y  as " c a r r ie r s "  
o f sulphanilam ide and th a t  th ese  d iffe re n ce s  are  la rg e  
enough to  be d e tec ted  by the  method used. The source of 
variance between r a b b its  and between tim es a re  shown to  be 
s ig n if ic a n t in  th e  Beveren and Copenhagen White L i t t e r s  
re sp e c tiv e ly . The response between r a b b its  in  the  Beveren 
l i t t e r  i s  sm all, being s ig n if ic a n t  only a t  th e  f iv e  per 
cent le v e l .  Since th e  conclusion  was never confirmed the  
s ig n ific a n c e  of th i s  nega tive  c o r re la tio n  may be ignored 
and i s  almost c e r ta in ly  due to  e r ro rs  in h e ren t in  the  e a r ly  
s tag es  of an experim ental techn ique . The source o f variance 
between tim es in  the  Copenhagen White l i t t e r  shows th a t  the  
response o f the  r a b b its  a t  d if f e re n t  tim es v a ried  s ig n i f ic a n t ly  
and i s  due to  the  f lu c tu a tio n  in  blood co n cen tra tio n s . The 
f lu c tu a tio n s  might be due to  an ir r e g u la r  r a te  o f removal o f 
sulphanilam ide from the  blood to  the  l iv e r  but a t  the p resen t 
tim e the phenomenon cannot be adequately  in te rp re te d .
The s ig n ific an c e  o f  the  in te ra c t io n  fa c to rs  probably 
have se v e ra l causes. The s ig n if ic a n c e  o f the  Base-Time fa c to r  
in  the  Beveren l i t t e r  means th a t  th e  tim e a t  which the 
co n cen tra tio n  o f drug reaches a s p e c if ic  blood le v e l i s  a 
fu n c tio n  o f the  b ase . This f in d in g  was not repea ted  but 
where sharp d iffe re n ce s  in  e f f ic ie n c y  are  observed between
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bases th i s  in te ra c t io n  f a c to r  may be expected since  the  
blood le v e ls  a t  corresponding tim es w il l  a lso  d i f f e r  sh a rp ly .
The d if fe re n c e s  in  e f f ic ie n c y  v alues o f the  th re e  b ases , 
shown in  Table XI,were most c le a r ly  marked w ith  th e  Beveren 
l i t t e r .
The ra b b it-b a se  in te ra c t io n  i s  one which has been 
rep ea ted ly  shown to  be s ig n i f ic a n t  and the source of v a rian ce  
due to  th i s  fa c to r  i s  as  im portant as th a t  due to  the  source 
between b ases . This f in d in g  i l l u s t r a t e s  the  v a r ia t io n  
found in  anim als and shows c le a r ly  th a t  in d iv id u a l anim als 
respond d if f e r e n t ly  to  th e  same b ase . These responses are  
rep resen ted  in  F igure I I .  D espite th i s  d iffe re n c e  in  response, 
the  d iffe re n ce  in  e f f ic ie n c y  between th e  v e h ic le s  and bases 
ap p lied  can s t i l l  be d e tec ted  by the  anim als and the method
may be considered v a l id  as  an a ssay .
The ra b b it- tim e  in te ra c t io n  i s  sm alle r than th e  
re s id u a l in  a l l  th re e  ana lyses and in  the case of the Dutch 
l i t t e r  the r a t io  o f one to  th e  o th e r i s  h ig h ly  s ig n i f ic a n t .
This i s  r e a d ily  exp lained  by a d iffe re n ce  in  time o f response 
to  th e  d if fe re n t  bases and lead s to  n ega tive  c o r re la t io n .
The r e s u l t s  from th e  Dutch l i t t e r  show th a t  where the  blood 
le v e l in  one ra b b it  r i s e s  over a p eriod  o f tim e, the  blood
le v e l in  another ra b b it  f a l l s  in  the  same p erio d  o f tim e.
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Figure V, th e  blood le v e ls  o f sulphanilam ide ob ta ined  on 
r a b b its  74 and 75 fo llow ing  the  a p p lic a tio n  of em ulsify ing  
o in tm ent, i l l u s t r a t e s  t h i s  p o in t .  The f lu c tu a tio n s  are  
"out o f s tep" and n eg a tiv e  c o r re la t io n  r e s u l t s  since  the  
in c rease  in  co n cen tra tio n  in  one ra b b it  i s  g re a te r  than the 
decrease in  the  o th e r r a b b it  a t  the  same tim e. This f a c to r  
aga in  emphasises the  f lu c tu a tio n  in  blood le v e ls  observed 
fo r  drugs ap p lied  p e rç u taneously .
Table X III shows the  a n a ly s is  of variance  c a rr ie d  
out on the  r e s u l t s  o f th e  s e r ie s  of experim ents on 
sulphanilam ide as shown in  Table I I .  Only th e  s ig n if ic a n t  
source o f v arian ce  has been shown. The Standard D eviation 
corresponding to  the  r e s id u a l variance  o f 3.8969 i s  1.97 
g iv in g  a standard  d e v ia tio n  fo r  means of samples of s ix  
equal to  O .8I. This value may be used as a r o u ^  index fo r  
s ig n if ic a n t  d if fe re n c e s  between the  v eh ic le s  and bases 
te s te d  w ith  su lphan ilam ide . A d iffe re n ce  between the 
v e h ic le s  and bases in  th e  mean in d iv id u a l ra b b it  response 
of le s s  than  O.8I i s  u n lik e ly  to  be s ig n i f ic a n t .  A d iffe re n ce  
to  t h i s  response o f more than  O.8I i s  l ik e ly  to  be s ig n if ic a n t
A se p a ra te  a n a ly s is  o f variance  was c a rr ie d  out on 
th e  r e s u l t s  ob ta ined  from the  s e r ie s  o f experim ents w ith  
s a l i c y l i c  a c id , copper a c e ty l-a c e to n a te  and copper su lphate
rThe blood le v e ls  observed in  two R abbits 
fo llow ing  the  a p p lic a tio n  of Em ulsifying 
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in  la rd ,  em ulsify ing  ointm ent and the  f iv e  p e r cent ac^ueous 
carboxymethyl c e llu lo s e  g e l .  This a n a ly s is  i s  given in  
Table XIV. I t  should be noted th a t  the  wide v a r ia t io n  in  
the le v e l o f re a c tio n  to  the d if fe re n t  drugs and the wide 
v a r ia tio n  in  the  v a rian ces  makes the  r e s u l t  o f an a n a ly s is  
o f  v ariance  r a th e r  more d i f f i c u l t  to  in te rp r e t  than  in  the 
orthodox case . Since th e  determ inations fo r  sulphanilam ide 
were not re p lic a te d  on w ater as a methyl c e llu lo se  g e l these  
r e s u l t s  were excluded from the a n a ly s is  which thus became 
a two fa c to r  a n a ly s is  w ith  r e p l ic a t io n .  The d iffe re n c e s  
between drugs was v ery  h ig h ly  s ig n if ic a n t  although the  
d iffe re n ce  between th e  two compounds o f copper as te s te d  
by the  t - t e s t  was not s ig n i f ic a n t .  This im plied th a t  th e re  
was a very  la rg e  d if fe re n c e  between the  v eh ic le s  and bases 
co n ta in in g  s a l i c y l i c  a c id  and those co n ta in in g  copper. The 
drug-base in te ra c t io n  f a c to r  was s ig n if ic a n t  a t  a le v e l 
between P»0.01 and P=0 . 05 . Examination showed th a t  th i s  
was almost e n t i r e ly  due to  the  unexpectedly  high e f f ic ie n c y  
o f the  s a l ic y l ic  a c id - la rd  in te ra c t io n .  The ap p aren tly  la rg e  
d iffe re n c e s  between th e  bases was found to  be due almost 
e n t i r e ly  to  th i s  in te ra c t io n  and when allowance was made fo r  
t h i s ,  the  d if fe re n c e s  between th e  bases was found to  be 
in s ig n if ic a n t .
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In co rp o ra tio n  o f the sulphanilam ide n o n -re p lic a te d  
r e s u l t s  m odified these  conclusions as fo llow s:
( i )  There were s ig n if ic a n t  d if fe re n c e s  between 
s a l ic y l ic  a c id , sulphanilam ide and th e  two 
compounds of copper (although th ese  d id  not 
d i f f e r  s ig n i f ic a n t ly  from each o th e r)
( i i )  Lard i s  p a r t ic u la r ly  e f fe c t iv e  as a " c a r r ie r "  
f o r  both s a l ic y l ic  ac id  and su lphanilam ide.
( i i i )  The experim ents have not been s u f f ic ie n t ly  
s e n s it iv e  to  g ive d if fe re n c e s  between v e h ic le s  
and bases la rg e  enough to  produce s ig n if ic a n t  
r e s u l t s  in  the  a n a ly s is .  N ev erth e less , when 
account i s  taken o f the  manner in  which 
d if fe re n c e s  between th e  bases occur ( la rd  was 
always shown to  be more e f f ic ie n t  than 
em ulsify ing  ointm ent which was always more 
e f f ic ie n t  than th e  f iv e  p er cent acqueous 
carbozymethyl c e llu lo se  g e l)  i t  i s  h ig h ly  
probable th a t  more ex tensive  and re f in e d  
experim ents would show such d iffe re n c e s  between 
bases to  be s ig n i f ic a n t .
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TABLE X III
The A nalysis o f Variance c a rr ie d  out on the 
r e s u l t s  ob tained  w ith  sulphanilam ide in  
v ario u s v eh ic le s  and b ases .
Source o f Sum o f Degree o f
Variance Squares Freedom Variance
Between bases 397•834 10 39-7834
R esidual 214.332 55 3.8969
39-7834 '
P =   = 1 0 . 2 1
3.8969
F = 3-7 corresponds to  P = 0.001
The Standard D eviation  corresponding to  the 
re s id u a l variance  o f 3-8969 i s  1.97  
This g ives a S tandard D eviation  fo r  means o f 
samples o f s ix  equal to  0 . 8l
1-97 
= 0.8059 = 0.81
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TABLE XIV
The A nalysis o f Variance c a rr ie d  out on the  
r e s u l t s  ob tained  w ith  v arious drugs in  
se le c te d  v e h ic le s  and bases
Source o f Sum o f Degree o f Mean
Variance Squares Freedom Square F Remarks
Between drugs 21351 11576 116 F=6l ,3  fo r
P = 0,001
Between bases 489*8 224.9 2.72 F=6.9  fo r
P=0.05
Drug ! Base 
in te ra c t io n  359*6 89.89 4.42
F=3.6  fo r  
P=0.05
F=6.4  fo r  
P=0.01
R esidual 182.8 2 0 .3 1
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DISCUSSION
S a l ic y l i c  a c id , su lp h an ilam id e, copper a c e t y l -  
a ceton ate  and copper su lp h a te , when incorp orated  in  v a r io u s  
v e h ic le s  and b ases p en e tra te  the in ta c t  h e a lth y  sk in  o f  
r a b b its  in  v ary in g  amounts and c ir c u la te  in  th e  bloodstream  
in  m easurable q u a n t i t ie s .  In a l l  ca ses  th e  amount o f  drug 
c ir c u la t in g  in  th e  bloodstream  i s  sm a ll. The h ig h es t  
average b lood le v e l  in  any one ra b b it was observed w ith  
s a l i c y l i c  a c id  in  propylene g ly c o l  as a v e h ic le  and gave 
a va lu e  o f  1 .3 9  mg. s a l i c y la t e  per 100 m l.;  th e  low est  
v a lu e  was th a t observed w ith  copper su lp h ate  in  w ater as  
a f iv e  per cent carboxymethyl c e l lu lo s e  g e l ,  and gave a 
v a lu e  o f  0 .1 8  mg. copper per 100 m l.
H is to lo g ic a l  work has shown th a t th e  p r in c ip le
rou te  o f  percutaneous ab sorp tion  i s  by way o f  the h a ir
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f o l l i c l e s  and sebaceous g la n d s. In  the upper h a lf  o f  th e  
f o l l i c u l a r  canal the h a ir  sh a ft  does not adhere to  the  
f o l l i c u l a r  w a ll ,  the space between b ein g  lo o s e ly  f i l l e d  
w ith  greasy  horny s c a le s  and a ir ;  th e  duct o f  the sebaceous 
gland em pties the sebum, a m ixture o f  t r ig ly c e r r id e s  and 
f a t t y  a c id s ,  in to  t h i s  p a ssa g e .
The a p p lic a t io n  o f  v e h ic le s  and b ases to  in ta c t  
sk in  a llo w s p e n e tra tio n  o f the in corp orated  drug to  th e
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dermis by way o f  the s id e  w a lls  o f  the f o l l i c l e s  and th e  
sebaceous g la n d s. System ic ab sorp tion  can thus occur  
w ithout rupture o f  the ep id erm is. The e f f e c t  o f  th e  v e h ic le ,  
th e  e f f e c t  o f  the drug, and the in te r a c t io n  between th e  two 
are th e  th ree  a sp e c ts  o f  p e n e tra tio n  and ab sorp tion  which  
w i l l  be con sid ered .
The e f f e c t  o f  the v e h ic le  or base i s  shown by th e
r e s u l t s  obtained  fo r  su lphanilam ide which was incorp orated
in  e lev en  v e h ic le s  and b a s e s . T h e o r e t ic a lly , a v e h ic le
promotes ab sorp tion  through th e  f o l l i c l e s  by d im in ish in g
th e te n s io n  between th e  base and the f o l l i c u l a r  p ore ,
a llo w in g  a continuous su rface  la y e r  to  be m aintained , and
by m ech an ica lly  b r in g in g  the drug in to  co n ta ct w ith  the
f o l l i c l e  or p r e ss in g  i t  in to  th e  f o l l i c u l a r  c a n a l. Drugs
are thus brought more r a p id ly  and in  la r g e r  amounts to  the
absorb ing su rface  o f  th e  f o l l i c u l a r  w a lls  and sebaceous 
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g la n d s. This e f f e c t  i s  b e st  ach ieved  w ith  v e h ic le s  and 
b ases which a r e , or become, l iq u id  a t body tem peratures.
The r e s u l t s  in  Table IV support t h i s  v iew . Lard, propylene  
g ly c o l ,  hydrous ointm ent and e th y l  o le a te  from which mean 
blood l e v e l s  o f  su lphanilam ide vary in g  between 0 .6 6  and 
0.89  mg./lOO m l. were ob ta in ed  had h igh  e f f i c ie n c y  v a lu e s .  
These a p p lic a t io n s  were e i th e r  l iq u id  or n o n -v isco u s and
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permeated the o u te r su rface  o f the sk in  r e a d i ly .  An
unexpected f in d in g  was th e  r e la t iv e ly  high e f f ic ie n c y  o f
w hite so f t  p a ra f f in , a r e s u l t  which has been confirmed by
214H adgraft, Somers and W illiams u sin g  d iio d o flu o re sc e in .
I t  has been g en e ra lly  assumed th a t  the  in e r t  hydrocarbons
serve merely as a p ro te c tiv e  coat but the  blood le v e ls  of
drugs a t ta in e d  fo llow ing th e i r  a p p lic a tio n  in  th i s  v eh ic le
may be explained by the f a c t  th a t  th i s  substance i s  l iq u id
a t  body tem perature and consequently  a id s  the tra n sp o r t o f
the drug to  the s i t e  o f ab so rp tio n . On th e  o th e r hand,
w oo lfa t, a th ic k  v iscous v eh ic le  which does not spread
e a s i ly ,  has a low e f f ic ie n c y  value as a c a r r ie r  d e sp ite
the  f a c t  th a t  i t s  chemical composition i s  not d is s im ila r
to  sebum. Presumably w oolfat does not promote ab so rp tio n
because of i t s  v is c o s ity  which may h inder both i t s  p e n e tra tio n
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of the  f o l l i c l e s  and the re le a se  of the drug. Rothman has 
shown th a t abso rp tion  from bases co n ta in in g  c h o le s te ro l , 
a c o n s titu e n t o f w oo lfa t, i s  poorer than  th a t  from bases 
con ta in ing  no c h o le s te ro l . L iquid p a ra f f in  gave a mean 
blood le v e l o f 0.47  mg./lOO ml. and showed com paratively 
low e ff ic ie n c y  as a c a r r ie r  although i t  was a smooth e a s i ly  
ap p lied  a p p lic a tio n . This low value may be explained  by 
assuming th a t  a la y e r  o f m o istu re , formed by in se n s ib le
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p e r sp ir a t io n  on th e  hack o f  the r a b b it ,  forms a th in  l iq u id  
f ilm  between the p a r a ff in  and the sk in . S ince th e  sk in  
i s  w ater r e p e l le n t ,  p en e tra tio n  and ab sorp tion  o f  
su lphanilam ide would be h indered by t h is  a d d it io n a l b a r r ie r .  
I t  i s  a ls o  p o s s ib le  th a t the r a te  a t  which th e  drug 
sep a ra tes from th e  v e h ic le  in  the f o l l i c l e  has a s ig n if ic a n t  
e f f e c t  on th e  degree o f  a b so rp tio n .
A d if fe r e n c e  in  e f f i c ie n c y  was observed between the  
two em ulsion b a ses as c a r r ie r s .  The ab sorp tion  from hydrous 
ointm ent, a w a t e r - in -o i l  em ulsion , gave a mean le v e l  o f  
0 .6 8  mg./lOO m l . ,  a va lu e  approxim ately o n e -a n d -a -h a lf  
tim es g r ea ter  than th a t fo r  hydrous em u lsify in g  o in tm ent, 
an o i l - in -w a te r  em ulsion , which gave a mean b lood  le v e l  o f  
0 .42  mg./lOO m l. A s im ila r  co n c lu sio n  has a lso  been
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rep orted  by H adgraft, Somers and W illiam s, who found hydrous 
ointm ent more than tw ice  as e f f i c i e n t  as hydrous em u lsify in g  
ointm ent when la b e lle d  d iio d o f lu o r e s c e in  was the incorporated  
drug. T his su g g ests  th a t the ab sorp tion  o f  drugs i s  
enhanced when th ey  are p resen ted  to  the in ta c t  sk in  in  an 
o i l  ph ase . S in ce the sk in  su rface  i s  covered w ith  a greasy  
la y er  o f  waxes im pervious to  w ater and aqueous s o lu t io n s ,  
th e  ab sorp tion  o f  su lphanilam ide occu rin g  from the aqueous 
phase must be due to  the p a r t i t io n in g  o f  the drug between
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the aqueous phase and the f a t s  o f  the sebaceous glands  
and f o l l i c l e s  through which the continuous o i l  phase o f  
hydrous ointm ent w i l l  p e n e tra te  w ith  g rea ter  e a se .
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E stim atin g  su lphanilam ide in  sk in  b io p s ie s ,  Strakosch  
found no s ig n if ic a n t  d if fe r e n c e  between o i l- in -w a te r  and 
w a te r - in -o i l  em ulsions but h is  method m erely measured th e  
"depot" o f  each em ulsion lodged in  the sk in  and took no 
account o f  th e  r a te  o f  drug r e le a s e  in to  the blood stream . 
The view  th a t the ab sorp tion  o f  su lphanilam ide i s  enhanced 
when p resen ted  to  the sk in  in  an o i l  phase i s  supported by 
the amount absorbed from w ater as a carboxymethyl c e l lu lo s e  
g e l ,  which as a " carrier"  o f  su lphanilam ide was the l e a s t  
e f f e c t iv e  v e h ic le  t e s t e d ,  having a mean b lood  le v e l  o f  
0 .3 6  mg./lOO m l. This may be regarded as th e  ab sorp tion  
o f  su lphanilam ide from water s in c e  the m ethyl c e l lu lo s e  
served  m erely as a convenient method o f  ap p ly in g  w ater as 
a v e h ic le .  I t  th e re fo re  appears th a t a continuous w ater  
phase h in ders the ab sorp tion  o f  su lphanilam ide through the  
in ta c t  sk in .
The e f f e c t  o f  the drug was estim ated  by comparing 
th e  r e s u l t s  obta in ed  when four d if f e r e n t  drugs, s a l i c y l i c  
a c id , su lp h an ilam id e, copper a c e ty l-a c e to n a te  and copper 
su lp h a te , were incorp orated  in  th ree  d if fe r e n t  v e h ic le s
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and b a se s , la r d , E m u lsify in g  Ointment and w ater as a f iv e  
per cent carboxymethyl c e l lu lo s e  g e l .  From T ables VI and 
VII i t  i s  seen  th a t s a l i c y l i c  a c id  i s  absorbed in  g rea ter  
amounts than the o th er  drugs. The mean blood le v e l  fo r  
the p rep aration s t e s t e d  w ith  s a l i c y l i c  a c id  range from 0 .8 8  
to  1 .24  mg./lOO ml . ;  th o se  fo r  su lphanilam ide from O.36 to  
0 .89  mg./lOO ml . ;  th ose  fo r  copper a c e ty l-a c e to n a te  from 
0 .1 9  to  0 .26  mg./lOO ml . ,  and th ose  fo r  copper su lph ate  
from 0 .18  to  0 .22  mg./lOO m l. Table IX, a summary o f  the  
comparative e f f i c i e n c i e s  o f  the drugs and v e h ic le s  and 
b a se s , show roughly s ix  tim es as much s a l i c y l i c  a c id , th ree  
tim es as much su lph an ilam ide, one-an d -a-q u arter  tim es as  
much copper a c e ty l-a c e to n a te  absorbed as copper su lp h a te .
Each o f  the copper compounds was e stim ated  as copper. The 
d if fe r e n c e s  in  e f f ic ie n c y  are i l lu s t r a t e d  in  F igures VI 
and V II.
The m olecular w eigh ts o f  s a l i c y l i c  a c id , su lp h an ilam id e, 
copper a c e ty l-a c e to n a te  and copper su lp h ate  are 1 3 8 .1 3 ,
172 . 2 1 , 261.78 and 249*70 r e s p e c t iv e ly .  I t  can be seen  th a t  
were the b lood le v e l s  c a lc u la te d  on a molar b a s is  the  
r e la t iv e  r a te s  o f  ab sorp tion  o f  the four compounds would 
occur in  the same ord er.
Figure VI
Comparison o f th e  percutaneous a b sorp tion  o f  
four drugs from s e le c te d  v e h ic le s  and bases
-a 1*2 .  §
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I t  i s  p o ss ib le  to  o f fe r  an exp lanation  o f th e  
d iffe re n ce s  in  th e  amounts of the  fo u r drugs absorbed from 
th e  th re e  bases in  term s of t h e i r  lo c a l a c tio n  and l ip id  
s o lu b i l i t i e s .  A re la tio n s h ip  between the  drug and th e  
l iv in g  c e l l  was f i r s t  p o s tu la te d  in  1902 by Meyer and Overton 
who claimed th a t th e  c e l l  membrane, which a drug must permeate 
before being absorbed sy s tem ica lly , was l ip id  in  n a tu re  since  
only those substances so lu b le  in  l ip id s  p en e tra ted  the  c e l l  w a ll. 
T heir degree o f p en e tra tio n  appeared to  depend on th e i r  
degree of s o lu b i l i ty  in  l ip id s .  Based mainly on th e  
ab so rp tion  of a lco h o ls , aldehydes, ketones and l ip id  so lub le  
n a rc o tic s , the theory  was found to  have many exceptions and 
th e  c e l l  membranee was then  thought to  be a mosaic o f l ip id  
and p ro te in  p a r t i c le s .  Although th i s  theo ry  f a i le d  to  explain  
many experim ental r e s u l t s  i t  seems to  be firm ly  e s ta b lish e d  
th a t  th e  r a t io  of the  s o lu b i l i ty  o f a substance in  w ater 
to  th a t  in  l ip id s  p lay s an im portant p a r t  in  i t s  passage 
through th e  c e l l  and consequently through th e  f o l l i c u la r  w alls and
94
sebaceous g la n d s.
Compared w ith  th e  o th er  drugs t e s t e d ,  th e  h igh
blood  l e v e l s  ob ta in ed  fo r  s a l i c y l i c  a c id  may w e ll  be due
to  i t s  l ip id  s o l u b i l i t y ,  shown by the rea d in ess  w ith  which
the a c id  d is s o lv e s  in  a lc o h o l,  e th e r , g ly c e r o l and
chloroform . This prop erty  w i l l  ea se  the passage o f  th e
a c id  through the f a t s  and waxes o f  the sebum and f o l l i c u l a r
w a l ls .  Further ev id en ce fo r  t h i s  v iew  was advanced by
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Kahlenberg and Barwasser who noted th a t sodium s a l i c y la t e
was never observed to  p en e tra te  in ta c t  sk in . D escrib in g
the p en e tra tio n  o f  t o p ic a l  agen ts in to  dead human sk in ,
216
F le sc h , Satanove and Brown found s a l i c y l i c  a c id  to  p en etra te
most r a p id ly  w h ile  no passage o f  th e  sodium s a l t  was
ob served . M oreover, the i r r i t a n t  and k e r a to ly t ic  a c tio n
o f  the a c id  on the sk in  and i t s  d e s tr u c tio n  o f  the e p i t h e l ia l
c e l l s  which so fte n  and desquamate fo llo w in g  the a c id 's
a p p lic a t io n  are fa c to r s  which w i l l  tend  to  in c re a se  system ic  
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c o n c e n tr a tio n s . Damage by s a l i c y l i c  a c id  to  th e  ou ter  
la y e r  o f  the sk in  may a llo w  g r ea ter  p e n e tra tio n  o f  the  
epiderm is w h ile  th e  i r r i t a n t  e f f e c t  produces dermal hyperaemia 
and a l t e r s  the tr a n s fe r  grad ien t in  favour o f  g rea ter  drug 
passage when the a c id  has p en etra ted  to  th e  v a scu la r  bed . 
L oca lised  v a so d ila ta t io n  was observed a f t e r  rem ova l,o f the
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s a l i c y l ic  ac id  p rep a ra tio n s  from the  hacks of the  an im als. 
Sulphanilam ide, although l ip id  so lu b le , i s  n e u tra l  and 
appears to  ex e rt n e i th e r  an i r r i t a n t  nor an a s tr in g e n t 
e f fe c t  when ap p lied  to p ic a l ly  and probably produced no 
re a c tio n s  which would in c rease  or decrease percutaneous 
ab so rp tio n . The lower blood le v e ls  o f sulphanilam ide 
ob ta ined  in  comparison w ith  those o f s a l i c y l ic  ac id  may 
be exp lained  on th i s  b a s is .  In  c o n tra s t ,  copper i s  a s tr in g e n t 
and i s  used lo c a lly  fo r  i t s  p re c ip i ta n t  a c tio n  on p ro te in .
This a c tio n  a f f e c ts  th e  su rface c e l l s  and consequently 
reduces p e rm e ab ility . The low amounts o f copper absorbed 
in to  th e  blood stream  0.18  to  0.26  mg./lOO m l., tend  to  
confirm th i s  e f f e c t .  The s l ig h t ly  h igher system ic le v e ls  
o f copper a c e ty l-a c e to n a te , 0.19  to  0.26  mg./lOO m l., might 
be due to  the  non-ion ic  ch a ra c te r  o f the copper which i s  
ch e la ted  w ith  ace ty l-ace to n e  m olecules to  in c rease  i t s  
l i p id  s o lu b i l i ty  in  c o n tra s t to  th e  io n ic  c h a rac te r  and 
l ip id  in s o lu b i l i ty  o f the su lphate  which gave blood le v e ls  
of 0 . l 8 to  0.22  mg./lOO ml. Apart from the  l ip id  
in s o lu b i l i ty  o f the  su lp h a te , the  e l e c t r i c a l ly  negative  
charge on the  o u te r su rface  o f the  sk in  would tend  to  re p e l 
the  p o la ris e d  su lpha te  and reduce even fu r th e r  the  amount 
o f copper absorbed.
96
I t  should be s ta te d  th a t th e  e stim a tio n  o f  copper 
and s a l i c y l i c  a c id  in v o lv e  a ssa y in g  su bstan ces norm ally  
presen t in  th e  body# W hile la r g e  numbers o f  b lood  blanks 
were assayed to  a llow  fo r  t h i s ,  th e  absorp tion  o f  sm all 
q u a n t it ie s  may remain u n d etected  because o f  th e  f lu c tu a t io n  
o f  th ese  su b stan ces in  the animal c ir c u la t io n *  C onsequently, 
th e  a ssay  o f  both s a l i c y l i c  a c id  and copper la c k  the  
s p e c i f i c i t y  o f  th a t fo r  su lp h an ilam id e, a fa c to r  to  be 
con sid ered  in  the ev a lu a tio n  o f  th e  r e su lts#  N e v e r th e le ss ,  
th a t in d iv id u a l drugs d i f f e r  g r e a t ly  in  th e ir  a b i l i t y  to  
p en etra te  in ta c t  sk in  i s  c le a r ,  and t h i s  d if fe r e n c e  i s  more 
marked than th e  d if fe r e n c e s  in  e f f i c ie n c y  between th e  
v e h ic le s  or b ases as " carriers"  in  which the drugs are  
in corp orated . T his f in d in g  confirm s the co n c lu sio n  o f
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B l is s  who s ta te d  th a t "the p r o p e r tie s  and powers o f  the drug
i t s e l f  ra th er  than the ointm ent v e h ic le  are the major
determ ining fa c to r s  in  absorp tion  from the skin" and o f  
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P le in  and P le in  who noted th a t "drugs vary g r e a t ly  in  th e ir  
a b i l i t y  to  p en etra te  through normal in ta c t  sk in" .
A r e s u lt  o f  great in t e r e s t  was th e  in te r a c t io n  
between drug and b a se . From a s e t  o f  observed r e s u l t s  i t  
i s  p o s s ib le  to  co n stru ct a ta b le  o f  t h e o r e t ic a l  v a lu es  and, 
on comparing th e se  w ith  the observed v a lu e s , p lo t  a ta b le
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showing th e  p o s i t iv e  and n e g a tiv e  percentage d e v ia t io n  
o f  th e  observed from th e t h e o r e t ic a l .  I f  an observed  
va lu e d i f f e r s  s ig n i f i c a n t ly  from i t s  th e o r e t ic a l  va lu e  
then an in te r a c t io n  fa c to r  i s  sa id  to  be fu n c tio n in g .  
S ig n if ic a n t ly  p o s i t iv e  d e v ia tio n  was noted  fo r  th e  
s a l i c y l i c  a c id : la r d , su lp h an ilam id e:lard  and copper  
su lp h a te :w a ter , as a carboxymethyl c e l lu lo s e  g e l ,  in te r a c t io n s ,  
t h i s  meaning th a t th e  in te r a c t io n  o f  th e se  drugs w ith  th e se  
b a ses promoted t h e ir  percutaneous ab sorp tion  in  amounts 
g r e a te r  than th a t which would have been expected  on 
th e o r e t ic a l  grounds. S ig n if ic a n t ly  n eg a tiv e  d e v ia t io n  was 
n oted  fo r  th e  copper su lp h a te :la rd  and th e  s a l i c y l i c  a c id :  
w ater , as a carboxymethyl c e l lu lo s e  g e l ,  in te r a c t io n s ,  t h i s  
meaning th a t l e s s  was absorbed than would have been  
t h e o r e t i c a l ly  exp ected . These c o n c lu s io n s  im ply th a t w h ile  
th e  p r o p e r tie s  o f  the drug and th e  base are o f  grea t  
im portance, th e  in te r a c t io n  between th e  two a ls o  determ ines 
th e  b lood  l e v e l s  subsequently  a tta in e d . In th e se  experim ents, 
th e  in te r a c t io n s  occurred p o s i t iv e ly  when th e  in corp orated  
drug was so lu b le  in  th e  b a se , and n e g a t iv e ly  when the  
in corp orated  drug was in s o lu b le  in  th e  b a se . Coper su lp h a te , 
f r e e ly  so lu b le  in  w ater, i s  r e a d ily  so lu b le  in  th e  m ethyl 
c e l lu lo s e  g e l  and in s o lu b le  in  la rd . S im ila r ly  s a l i c y l i c  a c id ,  
b e in g  l i p i d  s o lu b le , d is s o lv e s  in  la rd  and remains in s o lu b le  
in  w ater a s a carboxym ethyl c e l lu lo s e  g e l .  T h is s tr o n g ly
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suggests th a t  a l ip id  so lu b le  drug inco rpo ra ted  in  a 
l ip id  base w i l l  be absorbed in  g re a te r  q u a n t i t ie s  than  a 
l ip id  in so lu b le  drug in  a l i p i d  base. On th i s  ground, the 
in te ra c tio n  of th e  drug w ith  th e  base must be considered 
a f a c to r  o f importance in  percutaneous abso rp tion  through 
in ta c t  sk in .
vVhen compared w ith o r a l ,  subcutaneous and in travenous 
ad m in is tra tio n , percutaneous the rapy  must be considered  
in e f f ic ie n t  and v a r ia b le  on th e  b a s is  o f the r e s u l t s  quoted.
As shown in  F igure IV, the o ra l  method was s ix teen  tim es and 
the  subcutaneous and in travenous methods s ix  and f iv e  tim es 
re sp e c tiv e ly  more e f f ic ie n t  than the  percutaneous ro u te . 
Furtherm ore, th ese  d if fe re n c e s  could be increased  simply 
by in je c t in g  a concen tra ted  so lu tio n  of so lub le  sulphonamides 
o r by in c re as in g  the  o ra l  dose. The le v e ls  a t ta in e d  
percutaneously  from th ese  t e s t s  v a ried  between 0.18  and 
1,24  mg./lOO ml. f o r  a l l  drugs and b ases , and u n le ss  the  
o u te r  la y e rs  o f the  sk in  were damaged the le v e ls  o f drug 
ob tained  percu taneously  i s  u n lik e ly  to  r i s e  above 2 o r  3 m g./ 
100 ml. Blood le v e ls  which have been rep o rted  over 3 mg./lOO ml. 
fo llow ing  the  to p ic a l  a p p lic a tio n  of substances to  in ta c t  
sk in  should be viewed w ith  cau tio n  but where the  sk in  i s  
wounded, burned o r d iseased ,system ic co n cen tra tio n s o f th i s  
o rder and h igher may be expected. I t  i s  in te r e s t in g  
to  note th a t  f o r  prophylax is the  blood le v e l o f sulphanilam ide
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considered adequate i s  2 to  3 mg./lOO m l., fou r to  s ix  
tim es h ig h er than the average le v e l observed fo r  t h i s  drug 
when app lied  in  eleven sep ara te  v eh ic le s .
However, a drug e x e r tin g  a pharm acological a c tio n  a t  
low system ic l e v e l s ,  may f in d  lim ite d  u se in  percutaneous
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therapy. S evera l workers have observed pharm acological
e f f e c t s  fo llo w in g  th e  percutaneous a p p lic a t io n  o f  sex
hormones. To ex er t th e ir  c h a r a c te r is t ic  a c t io n , th e se
hormones, th e  m ajority  o f  which are l ip o id  s o lu b le , req u ire
a b lood  le v e l  as low a s , or  even low er than 0 .5  mg./lOO ml.
Judging by the r e s u l t s  ob ta in ed  in  th e  above experim ents,
i t  i s  more than probable th a t such a l e v e l  was a tta in e d  w ith
s o f t  p a r a ff in , e th er  and benzene, th e  v e h ic le s  and so lv e n ts
in  which th e se  workers incorp orated  th e  hormones used .
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V a le tte  and E tcheverry have r e c e n tly  noted  th e  a n a lg e s ic  
e f f e c t  o f  morphine and p e th id in e  when a p p lied  in  p-cymene, 
ançj. organic s o lv e n t , to  the in ta c t  sk in  o f  m ice. The blood
' I
l e v e l s  req uired  to  produce such a pharm acological response  
are l e s s  than O.5  mg./lOO m l . ,  again  one which appears to  
be e a s i ly  a tta in e d  w ith  organic s o lv e n ts .  There i s  
gen era l agreement th a t th e  b lood  l e v e l s  obta in ed  from drugs 
a p p lied  to  in ta c t  sk in  in  organ ic  so lv e n ts  are h igh er  than  
th ose  obta in ed  fo llo w in g  the use o f  con ven tion a l ointm ent 
b a ses .
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For system ic co n cen tra tio n s g re a te r  than 
approxim ately 1 mg./lOO m l,, percutaneous m edication 
through in ta c t  sk in , on the b a s is  o f the  r e s u l t s  obtained 
in  these  experim ents, must be considered  of dubious value, 
the more so since  i t  i s  almost im possible to  co n tro l 
q u a n ti ta t iv e ly . The conclusions of Zondek, Bromberg and
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Shapiro, th a t  the  "concen tra tion  of sulphanilam ide in  the 
blood of r a b b its  fo llow ing  i t s  percutaneous ad m in is tra tio n  
i s  as high as th a t  obtained a f t e r  i t s  o ra l ad m in is tra tio n "  
and th a t  "the percutaneous use of sulphanilam ide may serve 
as an a u x il ia ry  method of chem otherapeutic trea tm en t in  
c e r ta in  cases" cannot be su b s ta n tia te d  from the  r e s u l t s  
quoted h ere . These workers found a maximum sulphanilam ide 
blood le v e l as  high as 8 mg./lOO ml. a f t e r  applying the  
drug in  an acetone-soap so lv en t. Y/hen allowance i s  made 
fo r  the  g re a te r  e f f ic ie n c y  of organic so lv e n ts , such le v e ls  
s t i l l  seem remarkably h igh .
Owing to  th e  v a r ia tio n  in  technique used , i t  i s  
d i f f i c u l t  to  compare s t r i c t l y  th e  r e s u l ts  from the  experim ents 
described  w ith  those of o th e r workers in  the  f i e ld  of 
percutaneous m edication. Systemic abso rp tion  ha^ been 
s tu d ied  by es tim a tin g  the co n cen tra tio n  of ap p lied  drug 
e i th e r  in  the  blood o r the  u r in e . I t  has a lso  been expressed
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as a percentage o f  th e  amount t o p ic a l ly  a p p lie d ,
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e s p e c ia l ly  in  experim ents u s in g  r a d io -a c t iv e  t r a c e r s .
The major disadvantage o f  t h i s  c a lc u la t io n  l i e s  in  the  
fa c t  th a t the amount ap p lied  t o p ic a l ly  i s  in  e x c e ss  o f  
the amount absorbed, V/hile t h i s  e x c e ss  may be v a r ied  the  
amount p e n e tra tin g  remains approxim ately  con stan t and 
consequ en tly  t h i s  v a r ia t io n  in  th e  e x c e ss  a p p lied  a f f e c t s
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any q u a n tity  exp ressed  as a p ercen tage. Woodward and o th e r s ,  
fo r  in s ta n c e , showed th a t fo r  su lphanilam ide no in crea se  
in  blood l e v e l s  r e su lte d  from in c r e a s in g  th e  s tr en g th  o f  
the ointm ent from f iv e  per cent to  tw enty per c e n t.
E xpressing  th e  amount absorbed as a p ercen ta g e , the r e s u lt s  
w i l l  show a fo u r - fo ld  d if fe r e n c e  fo r  a system ic  con cen tra tion  
which i s  the same fo r  both o in tm en ts. T his method o f  
ex p r ess io n , c a u t io u s ly  in te r p r e te d , i s  u s e fu l  in  th a t i t  
i l l u s t r a t e s  the in e f f ic ie n c y  o f  percutaneous m ed ication  as 
a mode o f  a d m in istra tio n .
Table XV shows the b lood l e v e l s  observed by o th er  
workers fo llo w in g  th e  percutaneous a p p lic a t io n  o f  c e r ta in  
drugs. S ince the drug e x e r ts  an e f f e c t  g r ea ter  than th e  
v e h ic le  in  which i t  i s  a p p lie d , th e  b a ses  used have been 
om itted  and th e  range o f  blood l e v e l s  en tered .
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TABLE XV
The Blood L evels ob ta in ed  fo llo w in g  th e  a p p lic a t io n  
o f  c e r ta in  Drugs to  In ta c t  Skin,
Workers
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Zondek e t  a l .
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P le in  and P le in
Drug used
Sulphanilam ide
S a l i c y l i c  ac id







B o r e l l i
S a l i c y l i c  ac id  









0 .0 1  -  0 .0 5
Table XVI shows th e  order o f  e f f ic ie n c y  obta in ed  
by two groups o f  workers from v a r io u s v e h ic le s  and b ases in  
which d if fe r e n t  drugs were in corp orated . The l e a s t  e f f i c i e n t  
base in  both s e t s  o f  r e s u l t s ,  hydrous em u lsify in g  ointm ent, 
was taken as u n ity  and although th e  experim ental techn iqu es  
were not s t r i c t l y  comparable the r e s u l t s  are o f  some va lu e  
fo r  gen era l com parative purposes.
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TABLE XVI
Comparison o f  Percutaneous A bsorption o f  two 
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Hydrous e m u lsify in g  
ointm ent
H adgraft, 214 
Somers & W illiam s













The order o f  e f f i c ie n c y  o f  the same v e h ic le s  and 
b ases t e s t e d  w ith  var iou s drugs by se v e r a l workers are shov/n 
in  Table XVII
TABLE XVII
The Comparative E f f ic ie n c y  o f  th ree  b ases  
t e s t e d  w ith  var iou s drugs by se v e r a l workers.
154 190
217 Wild and Gemme11 and Brown and 176
Workers B lis s Robert s M orrison S cott Sauerland
Drug Methyl s a l . M ercuric Sulphanil--  Methyl Methyl Spiro
oxide amide s a l ic y la te s a l . so l
Base
Lard 1 .09 3 .47 2 .15 0 .9 5 1 .46 0 .1 1
Soft paraffin I .0 4 1 .17 1 .6 0 0 .9 2 1 .37 0 .8 0
Lanolin 1 .00 1 .0 0 1 .00 1 .00 1 .00 1 .00
104
In Table XVII, th e  r e s u l t s  between workers vary  
co n sid era b ly , t h i s  b e in g  due to  the drug and the experim ental 
method used . I t  may be s ta te d  th a t la r d  was g e n e r a lly  found  
to  be more e f f i c i e n t  than s o f t  p a r a f f in . The r e s u l t s  found  
fo r  th e  e f f ic ie n c y  o f  la n o lin  are more c o n f l ic t in g .  The 
f in d in g s  o f  B l i s s ,  Brown and S c o tt and Sauerland, i l l u s t r a t e  
th e  v a r ia t io n  encountered when th e  same drug, methyl 
s a l i c y l a t e ,  i s  t e s t e d  in  th e  same v e h ic le s  by d if fe r e n t  
w orkers. D esp ite  t h i s ,  th e  d if fe r e n c e  in  the a b i l i t y  o f  
in d iv id u a l drugs to  p en etra te  in ta c t  sk in  can be seen to  be 
c o n sid er a b le .
A fu r th e r  source o f  error  in  the r e s u lt s  o f  experim ents 
rep o rtin g  the e f f i c ie n c y  o f  v e h ic le s  and b ases l i e s  in  th e  
f a c t  th a t on ly  one or a few b lood  sam ples were withdrawn from  
the t e s t  an im als. The v a r ia t io n  w ith in  in d iv id u a l anim als 
i s  wide and r e l ia b le  e stim a tes  o f  the e f f i c ie n c y  o f  to p ic a l  
p rep aration s can be made on ly  i f  la r g e  numbers o f  samples 
are assayed . H ith erto  workers appear to  have eva lu ated  
v e h ic le s  and b a ses on a few b lood  sam ples but never in  
numbers la rg e  enough to  a llow  fo r  th e  v a r ia t io n  occu rrin g . 
S in ce  the system ic  co n cen tra tio n s have been observed to  
f lu c tu a te  and show between one and s ix  hundred per cen t  
d if fe r e n c e s  in  corresponding sam ples, any ev a lu a tio n  o f  the  
e f f i c ie n c y  o f  a v e h ic le  or base estim a ted  on a few blood
105
samples must be judged m ean in g less.
The r e s u l t s  ob ta in ed  fo r  s a l i c y l i c  a c id , su lph an ilam ide, 
copper a c e ty l-a c e to n a te  and copper su lp h a te , when in corp orated  
in  var iou s v e h ic le s  and b a se s , emphasise th a t th e  in ta c t  
h ea lth y  sk in  o f  the rab b it p resen ts  an e f f e c t iv e  and alm ost 
impermeable b a r r ie r  to  the passage o f  drugs a p p lied  to  i t ,  
e s p e c ia l ly  when i t  i s  con sid ered  th a t the area exposed to  
the a p p lic a t io n s , 24 square in c h e s , approxim ates to  o n e - f i f t h  
o f  th e  body area o f  the anim als under t e s t .
C onclusions
Three main co n c lu sio n s emerge from t h i s  work.
F ir s t l y ,  i t  can be seen th a t th e  degree o f  percutaneous 
absorp tion  o f  drugs i s  in flu e n c ed  by the v e h ic le  or  base in  
'which the drug i s  p resen ted  to  th e  sk in . N e v e r th e le ss , the  
r e la t iv e  e f f i c i e n c i e s  o f  v e h ic le s  and b ases as c a r r ie r s  o f  
drugs through in ta c t  sk in  must n ot be overestim ated  s in ce  
the amount o f  drug absorbed, even under th e  most su ita b le  
c o n d it io n s , i s  so sm all th a t any d if fe r e n c e s  in  e f f i c ie n c y  
are o f  l i t t l e  p r a c t ic a l  v a lu e . In s e le c t in g  v e h ic le s  or  
b ases to  promote or d elay  ab sorp tion  o f  medicaments through  
in ta c t  sk in , the ch o ice  may be determ ined by convenience  
and e leg a n ce .
Secondly , th ere  i s  proof th a t th e  a b i l i t y  o f  d if f e r e n t
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drugs to  p en etra te  in ta c t  sk in  and be absorbed s y s te m ic a lly  
v a r ie s  co n sid era b ly . The ch o ice  o f  drugs s e le c te d  in  t h i s  
work was in e v ita b ly  l im ite d  by th e  ease  and accuracy w ith  
which th ey  cou ld  be d e tec ted  in  m inute q u a n t it ie s  in  the  
bloodstream , but i t  i s  probable th a t g rea ter  d if fe r e n c e s  
than th o se  observed between s a l i c y l i c  a c id , su lph an ilam ide, 
copper a c e ty l-a c e to n a te  and copper su lp h a te , w i l l  be d e tec ted  
w ith  o th er  drugs where a s u ita b le  a ssay  e x i s t s .
T h ird ly , th ere  i s  ev id en ce th a t the in te r a c t io n  o f  
a drug w ith  th e  base or v e h ic le  in  which i t  i s  incorporated  
may e ith e r  h in d er or promote th e  percutaneous absorp tion  o f  
th a t drug. T his in te r a c t io n  appears to  be r e la te d  to  the  
s o lu b i l i t y  o f  the drug in  th e  b a se . Where a l ip i d  so lu b le  
drug, fo r  example s a l i c y l i c  a c id , i s  in corp orated  in  a l ip i d  
so lu b le  v e h ic le  such as la r d , th e  two tend to  promote 
ab sorp tion  and t h e ir  p r o p e r tie s  may be sa id  to  be a d d it iv e .  
Where both  drug and base are l ip i d  in s o lu b le , f o r  example 
copper su lp h ate  and w ater as a f i v e  per cen t carboxymethyl 
c e l lu lo s e  g e l ,  th e  two p r o p e r tie s  tend to  h in der absorption  
and low blood  l e v e l s  con seq u en tly  r e s u l t .  Where the l ip i d  
s o lu b i l i t y  o f  th e  drug i s  the o p p o site  o f  th a t fo r  the b a s e , 
fo r  example copper su lp h ate  in  la r d , th e  amount o f  drug 
absorbed p ercu tan eou sly  appears to  be d ecreased .
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SUMMARY
1 . A review  o f  th e  methods used  to  e stim a te  th e  
r e le a s e  o f  m ed icin a l su bstances from to p ic a l  a p p lic a t io n s  
has been c a rr ie d  o u t,
2 . An in  v iv o  t e s t  has been design ed  to  e stim a te  the  
e f f ic ie n c y  o f  to p ic a l  a p p lic a t io n s  as " carr iers"  o f  drugs 
through in ta c t  sk in . The blood le v e l  a tta in e d  by the ap p lied  
drug was taken a s the c r i t e r io n  o f  e f f i c ie n c y .
3 . Sulphanilam ide was t e s t e d  in  e le v en  v e h ic le s  and bases  
and, ta k in g  th e  l e a s t  e f f i c i e n t  v e h ic le  as u n ity , the  
fo llo w in g  com parative v a lu e s  ob ta in ed : la rd  ( 2 . 48 ) ,  
propylene g ly c o l ( I . 89) ,  Hydrous Ointment B .P. ( I . 89) ,  w hite  
s o f t  p a r a ff in  ( I . 83) ,  e th y l o le a te  ( I . 8 3 ) ,  cetom acrogol 
em u lsify in g  wax base (1 .4 4 )?  E m u lsify in g  Ointment B .P. ( I . 31) ,  
l iq u id  p a r a ff in  ( I . 31) ,  Hydrous E m u lsify in g  Ointment B .P. 
( 1 . 17) ,  w oo lfa t ( 1 . 14) ;  w ater as a f i v e  per cen t carboxymethyl 
c e l lu lo s e  g e l  (l.O O ).
4 . S a l i c y l i c  a c id , su lp h an ilam id e, copper a c e ty l-a c e to n a te  
and copper su lp h ate  were r e s p e c t iv e ly  incorp orated  in  la r d .  
E m u lsify in g  Ointment B .P . and w ater as a f iv e  per cent 
carbodymethyl c e l lu lo s e  g e l ,  and the b lood  l e v e l s  o f  th e
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drugs n oted . S a l i c y l i c  a c id  and su lphanilam ide were 
r e s p e c t iv e ly  f i v e  and fou r tim es more e f f i c i e n t  than th e
two compounds o f  copper. The r e s u l t s  o f  a l l  experim ents
were s t a t i s t i c a l l y  analysed  and th e  s ig n if ic a n t  sou rces
o f  varian ce n oted .
5* The v e h ic le  or hase in f lu e n c e s  th e  b lood  l e v e l  
a tta in e d  by th e  incorp orated  drug but s in c e  th e  amount 
absorbed through in ta c t  sk in  i s  so sm a ll, th e se  d if fe r e n c e s  
in  e f f i c ie n c y  are o f  l i t t l e  im portance. The a b i l i t y  o f  
d if fe r e n t  drugs to  p en etra te  in ta c t  sk in  and be absorbed  
sy s te m ic a lly  v a r ie s  co n sid era b ly . The in te r a c t io n  o f  a 
drug w ith  the v e h ic le  or base in  which i t  i s  incorp orated  
may e ith e r  h inder or promote th e  percutaneous ab sorp tion  
o f  th a t drug.
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Base: Water as 5 per cent carboxy methyl cellu lose containing 10 per cent
Sulphanilamide •
Sulphanilam ide C oncentration 
Mg./lOO ml.
Rabbit No. 96 97 98 99 100 101
Weight (Kg.) 2.450 2.900 2.650 3.700 3.450 2.925 Row
Sex Female Female Female Female Female Female T o ta l:
Hours a f t e r  
A p p lica tio n
0 .0 0.00 0.00 0.00 0.00 0.00 0 .00 0.00
0 .5 0 .41 0.45 0.60 0.31 0.41 0 .38 2.56
1.0 0.10 0.46 0.55 0.61 0.52 0 .29 2.53
1 .5 0.21 0.35 0.43 0.49 0.50 0 .30 2.28
2.0 0 .30 0.23 0.15 0 .51 0.61 0.29 2.09
2 .5 0 .28 0.26 0 .24 0.56 0 .71 0.45 2.50
3.0 0.10 0.25 0 .51 0.31 0.58 0.50 2.25
3.5 0.31 0.31 0.38 0.49 0.50 0.46 2.45
4 .0 0.25 0.30 0.21 0.68 0.38 0.52 2.34
4 .5 0.21 0.14 0.23 0.49 0.41 0.31 1.79
5.0 0.35 0.11 0.00 0.37 0.37 0.47 1.67
5.5 0.15 0.31 0.14 0.42 0.40 0.33 1.75
6.0 0.47 0.36 0.40 0.50 0.45 0.49 2.67
6.5 0.40 0.31 0.13 0.43 0.30 0.45 2.02
7.0 0 .21 0.15 0.31 0.59 0.41 0.25 1.92
7.5 0.31 0.18 0.21 0.41 0.38 0.24 1.73
8.0 0.40 0.30 0.15 0.50 0.26 0.20 1.81
Column
T o ta ls 4 .46 4.47 4.64 7.67 7.19 5.93 34.36
In trav en o u s In je c t io n  o f Sulphanilam ide (5 m g./m l.)
Sulphanilam ide C oncentration 
Mg./lOO m l.
R abbit No. 102 103 104 105 106 107
W e i^ t  (Kg.) 3.200 3.150 2.600 3.400 3.350 2.650
Row
Sex Female Female Female Female Male Male T o ta ls
Hours a f t e r 60 mg. 80 mg. 65 mg. 85 mg. 85 mg. 65 mgw
In je c t io n in je c te d in je c te d in je c te d in je c te d in je c te d in je c te d
0 .0 0 .00 0.00 0.00 0.00 0.00 0.00  0.00
0 .5 2.95 2.70 2.76 2.31 2.06 2.12 14.90
1 .0 2.63 2.69 2.53 1.93 2.06 1.76 13.60
1 .5 2.46 2.33 2.23 1.81 1.73 1.53 12.09
2 .0 1.98 2.10 2.06 1.55 1.36 1.48 10.53
2 .5 1.76 1.79 1.78 1.31 1.33 1.26 9.23
3 .0 1.66 1.65 1.63 1.26 1.30 1.20 8.70
3.5 1.60 1.60 1.45 1.18 1.18 1.08 8.09
4 .0 1.23 1.50 1.30 1.06 1.15 0.93 7.17
4 .5 1.20 1.30 1.20 1.03 1.15 0.95 6.83
5 .0 1.11 1.20 1.15 1.03 1.03 0.90 6.42
5 .5 0.98 1.16 1.08 1.00 0.85 0.85 5.92
6 .0 0.93 1.08 0.98 0.95 0.70 0.75 5.39
6.5 0.90 1.06 0.96 0.81 0.68 0.68  5.09
7 .0 0.90 1.00 0.91 0.78 0.61 0.61 4.81
7.5 0.87 0.96 0.71 0.73 0.57 0.60  4 .44
6 .0 0.81 0.80 0.63 0.71 0.57 0.56 4.08
Column
T ota ls 23.97 24.92 23.36 19.45 18.33 17.26 127.29
123,
Subcutaneous Injection of Sulphanilamide (8 mgns./ml.)
Sulphanilamide Concentration 
Mg./lOO ml*
Rabbit No. 102 103 104 105 106 107
W e i^ t (Kg.) 3.150 3.150 2.650 3.300 3.300 2.650
Row
Sex Female Female Female Female Male Male Totals
Hours a f te r 130 mg. 130 mg. 110 mg. 135 mg. 135 mg. 110 mg.
In je c tio n in je c te d In je c te d in je c te d in je c te d in je c te d in je c te d
0.0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 2.85 2.56 2.20 1.56 2.31 2.20 13.68
1.0 4.50 3.36 2.86 2.46 3.91 2.25 19.34
1.5 4.48 3.75 3.40 3.08 3.73 2.93 21.37
2.0 4.50 4.10 3.18 3.35 3.46 3.60 22.19
2.5 3.98 3.65 3.18 4.16 3.53 4.13 22.83
3 .0 4.33 3.88 2.61 3.71 3.33 3.25 21.11
3.5 3.93 3.89 2.70 3.36 3.20 3.36 20.44
4 .0 3.70 3.70 2.65 3.48 2.85 2.78 19.16
4 .5 3.75 3.85 2.60 2.93 2.66 2.78 18.57
5 .0 3.13 2.75 2.53 2.98 2.75 3.18 17.32
5.5 3.28 2.46 2.50 2.36 2.00 2.20 14.80
6.0 2.70 2.38 2.35 2.30 1.78 2.30 13.81
6.5 2.46 2.45 1.76 1.93 1.63 2.75 12.98
7 .0 2.38 2.20 1.71 1.81 1.48 1.66 11.24
7.5 1.90 2.05 1.58 1.73 1.30 1.60 10.16
8 .0 1.88 1.85 1.56 1.80 1.25 1.23 9.57
Column
T ota ls 53.75 49.08 39.37 43.00 41.17 42.20 268.57
124.
Oral Absorption of Sulphanilamide Concentration 
500 mg. Tablet of Sulphanilamide per rabbit 
Sulphanilamide Concentration 
Ug./lOO ml.
Babbit No. 102 103 104 105 106 107
Wei^t (Kg.) 3.250 3.100 2.650 3.425 3.350 2.650
Sex Female Female Female Female Male Male
Hours after 
Administration
0 .0 0 .00 0 .00 0.00 0 .00 0 .00 0 .0 0
0 .5 9.89 11.50 11.19 8.02 6.61 7.21
1 .0 14.46 13.13 11.90 10.10 9.03 8.46
1 .5 12.83 14.56 10.35 12.01 10.66 13.05
2 .0 12.35 13.03 10.56 13.14 8.68 10.83
2 .5 11.90 13.53 9.21 11.96 9.31 11.16
3 .0 12.30 11.70 9.15 11.66 8.88 10.96
3.5 11.53 11.20 8 .83 11.50 7.56 9 .70
4 .0 10.33 11.60 8 .63 10.96 8.33 10.51
4 .5 9.89 10.91 7 .96 9.78 7.75 7.43
5.0 9.67 10.98 7.81 8.66 7.25 6.66
5 .5 8.55 9.65 7.83 8.01 6.36 5.55
6.0 7.43 9.66 7.10 7.96 5.44 5.41
6 .5 6.53 7.66 6.70 7.50 5.60 4 .68
7 .0 6.33 6.53 5.83 6.25 4 .56 4 .03
7 .5 5.10 6.35 4 .51 5.73 4.40 3.48
8 .0 4.47 5.21 4 .18 5.00 3.82 3.11
Column






















Base: Hydrous Ointment B.P. containing 10 per cent Sulphanilamide.
Sulphanilam ide C oncentration
Mg./lOO ml.
Rabbit No. 48 49 50 51 52 53
Weight (Kg.) 2.400 2.650 2.600 3.150 3.250 2.950
Row
Sex Male Male Male Female Female Female .T o ta ls
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 1.44 1.07 1.68 1.47 1.57 1.58 8.81
1 .0 2.75 1.65 0.81 1.92 0.74 1.79 9.66
1.5 1.70 0.45 1.40 0.86 0.89 0.86 6.16
2 .0 0.25 0.23 1.05 2.63 0.85 0.86 5.87
2 .5 1.75 0.12 0.00 0.53 0.65 0.46 3.51
3 .0 1.39 1.21 0.93 0.35 0.65 0.56 5.09
3 .5 0.43 1.82 1.06 2.92 1.26 0.93 8.42
4-0 3.48 0.40 0.61 1.01 1.30 0.90 7.70
4.5 1.02 0.41 2.78 1.21 1.29 1.04 7.75
5 .0 0.95 0.56 0.94 1.51 0.95 0.79 5.70
5.5 1.68 0.31 1.59 2.54 2.04 1.52 9.68
6.0 3.37 0.40 2.58 3.62 2.46 1.73 14.16
Column
T ota ls 20.21 8.63 15.43 20.57 14.65 13.02 92.51
126.
B ase: Hydrous O intm ent B .P . c o n ta in in g  10 p e r  c e n t S u lp h a n ila m id e .
Sulphanilamide Concentration.





Weight (Kg.) 2.475 2.525 2.900 2.850 3.500 2.925 Row
Sex Male Male Male Female Female Female T o ta ls
Hours a f t e r  
A pp lica tion
0 .0 0.00 0 .00 0.00 0.00 0.00 0.00 0.00
0 .5 2.86 3.58 2.57 0.60 0.46 0.96 11.03
1.0 2.04 5.56 0.42 3.10 1.55 2.96 15.63
1.5 2.38 1.08 1.09 2.80 1.14 0.85 9.34
2 .0 2.94 0.71 0.64 1.64 1.90 1.22 9.05
2.5 0.91 0.51 1.49 0.54 0.40 1.02 4.87
3 .0 2.13 0.76 1.41 1.18 0.65 0.94 7.07
3.5 0.82 1.02 0.54 0.55 0.75 1.25 4.93
4 .0 1.33 0.73 1.44 1.36 0.71 1.41 6.98
4.5 1.32 0.60 0.72 0.72 0.39 0.75 4.50
5 .0 1.88 0.82 1.24 0.72 0.83 0.75 6.24
5 .5 1.80 1.07 3.55 1.80 0.84 1.73 10.79
6 .0 3.37 0.68 1.36 4.50 2.46 0.94 13.31
Column
T o ta ls 23.78 17.12 16.47 19.51 12.08 14.78 103.74
127.
B ase : Hydrous O intm ent c o n ta in in g  10 p e r  c e n t  S u lp h an ilam id e
Sulphanilam ide C oncentration 
:#/ioo ml#
H ahhit No# 96 97 98 99 100 101
W e i^ t (Kg#) 2#425 2.850 2.600 3.700 3.425 2.900
Sex Female Female Female Female Female Female Total
Hours a f t e r  
A p p lica tio n
0#0 0#00 0.00 0.00 0.00 0 .00 0.00 0.00
0#5 0.78 0 .70 0.86 0.58 0 .5 6 0.68 4.16
1#0 0.56 0.71 1.03 0.58 0.65 0.49 4.02
1.5 0.40 0 .55 1.08 0.90 0 .49 0 .63 4.05
2#0 0.43 1.31 0.90 1.15 0.49 0.80 5.08
2.5 0.40 0.75 0.70 1.00 0 .80 1.03 4.68
3.0 0.33 0,65 0 .83 1.10 1.05 0 .70 4*66
3.5 0.41 0.99 1.00 0.70 0 .55 0.80 4.45
4 .0 0.51 0.63 0.66 0.66 1.17 0 .45 4.08
4 .5 0.33 0 .56 0 .63 0.80 0.33 0 .7 6 3.41
5.0 0.40 0 .61 1.00 1.45 0.59 0 .53 4.58
5 .5 0.45 0 .80 0 .71 0.63 0 .56 1.21 4.36
6#0 0.31 1.44 0.65 0 .60 0.33 0.40 3.73
6# 5 0.98 0 .80 0.56 0.66 0.40 0 .55 3.95
7.0 0.60 0 .55 0 .56 0.33 0.60 0.73 3.37
7.5 0.25 0.50 0.63 0.80 0.45 0.40 3.03
8#0 0.25 0.99 0.49 0.50 0 .6 6 0 .40 3.29
Column
T o ta ls 7.39 12.54 12.29 12.44 9.68 10.56 64.90
128 .
Base: Hydrous Ointment B.P. containing 10 per cent Sulphanilamide
Sulphanilam ide C oncentration .





Weight (Kg.) 2.900 2.875 2.875 3.000 2.950 2.925 Row
Sex Male Male Male Female Female Male T o ta ls
Hours a f te r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.68 0.31 1.83 0.94 0.00 1.00 4.76
1 .0 0.51 0.89 1.65 1.02 0.86 0.72 5.65
1.5 0.26 0.40 2.05 0.97 0.63 1.40 5.71
2 .0 0.40 0.46 0.84 0.43 1.01 0.69 3.83
2.5 0.94 1.12 1.35 1.09 0.63 0.36 5.49
3 .0 0.93 0.79 1.03 0.91 0.91 1.20 5.77
3.5 0.26 0.73 1.09 1.10 0.60 0.79 4.57
4 .0 0.60 0.94 1.09 1.25 1.00 1.07 5.95
4 .5 1.17 0.95 1.09 2.38 1.14 0.55 7.28
5 .0 1.36 1.39 1.84 1.03 0.83 0.70 7.15
5 .5 1.54 0.50 1.32 1.20 1.11 0.96 6.63
6 .0 1.01 0.20 1.44 0.83 0.89 0.83 5.20
6.5 1.02 1.06 1.16 1.30 1.02 1.17 6.73
7 .0 0.89 0.79 1.44 0.88 1.62 1.35 6.97
7 .5 1.00 1.14 3.40 1.47 1.14 0.68 8.83
8 .0 0.56 0.45 0.88 0.53 1.20 0.53 4.15
Column
T o ta ls 12.13 12.12 23.50 17.33 14.59 14.00 94.67
129.
B ase : Hydrous O intm ent B .P . c o n ta in in g  10 p e r  c en t S u lp h a n ila m id e .
Sulphanilam ide C oncentration 
Mg./lOO ml.
R abbit No. 73 74 75 76 77 78
Weight (Kg.) 2.975 2.975 2.950 23650 2.825 2.775
Row
Sex Male Male Male Female Female Male T o ta ls
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.89 0.36 0.46 0.12 0.43 0.51 2.77
1.0 0.25 0.22 0.26 0.24 0.40 1.87 3.24
1.5 0.43 0.35 0.23 0.40 0.35 0.33 2.09
2 .0 0.31 0,46 0.43 0.27 0.10 0.48 2.05
2.5 0.30 0.26 0.43 0.56 0.03 0.47 2.05
3.0 0.31 0.22 0.61 0.48 0.23 0.35 2.20
3.5 0.25 0.45 0.53 0.55 0.36 0.45 2.59
4 .0 0.63 0.26 0.15 0.38 0.23 0.50 2.15
4 .5 0.28 0.45 2.60 0.76 0.45 0.60 5.14
5.0 0.36 0.30 0.36 0.20 0.38 0.20 1.80
5.5 0.48 0.53 0.26 0.23 0.53 0.48 2.51
6.0 0.53 0.40 0.12 0.20 0.56 0.35 2.16
6.5 0.48 0.37 0.60 0.36 0.83 0.71 3.35
7 .0 0.41 0.61 0.40 1.29 0.17 0.94 3.82
7.5 0.40 0.46 0.36 0.30 1.00 0.65 3.17
8 .0 0.61 0.51 0.50 0.93 0.50 1.19 4.24
Column
T o ta ls 6.92 6.21 8.30 7.27 6.55 10.08 45.33
130.
B ase : E m u ls ify in g  O in tm ent B .P . c o n ta in in g  10 p e r  c e n t  S u lp h a n ila m id e
Sulphanilam ide C oncentration 
Mg./lOO ml.
R ahhit No. 48 49 50 51 52 53
Weight (Kg.) 2.450 2.750 2.600 3.025 3.150 2.775 Row
Sex Male Male Male Female Female Female T o ta ls
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0 .00 0.00 0.00
0 .5 0.63 0 .98 0.84 0.71 1.40 0.95 5.51
1.0 0.88 1.55 1.64 0.07 2.48 1.25 7.87
1.5 0.00 1.29 0.58 0.23 1.63 0.23 3.96
2.0 0.91 0.00 0.87 0.47 1.41 0 .23 3.89
2.5 0.39 0.62 0.12 0.47 1.24 0.23 3.07
3.0 0.78 0 .98 0.26 0.78 2.66 0.43 5.89
3.5 0.79 1.88 0.38 0.60 1.61 0.39 5.65
4.0 1.16 2.04 0.37 1.17 2.81 0.26 7.81
4 .5 1.13 2.40 2.86 0.55 1.83 0.10 8.87
5.0 1.55 1.58 1.32 0.66 1.83 0.24 7.18
5.5 0.46 0.91 1.40 0.88 2.41 0.21 6.27
6.0 0.71 2.53 1.02 1.02 1.40 0.65 7.33
Column
T o ta ls 9.39 16.76 11.66 7.61 22.71 5.17 73.30
131.
B ase ; E m u ls ify in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t S u lp h a n ila m id e .
/ Sulphanilam ide C oncentration 
Mg./lOO ml.
Rahhit No. 48 49 50 51 52 53
Weight (Kg.) 2.475 2.500 2.850 2.850 3.500 2.925 Row
Sex Male Male Male Female Female Female T o tals
Hours a f te r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 1.05 1.00 2.34 0.11 1.36 0.61 6.47
1 .0 0.62 0.83 1.14 1.33 0.83 1.33 6.08
1.5 0.41 0.44 1.36 0.19 2.05 2.05 6.50
2 .0 0.47 1.55 1.68 0.83 0.57 1.07 6.17
2.5 0.44 1.03 1.21 0.44 0.03 0.19 3.34
3.0 1.15 0.80 2.10 2.14 2.37 1.00 9.56
3.5 0.98 0.74 1.66 1.31 1.38 2.44 8.51
4 .0 0.66 0.61 0.63 1.47 0.50 0.82 4.69
4.5 0.33 0.80 3.08 1.22 1.25 1.24 7.92
5.0 0.47 0.66 0.82 0.87 0.62 0.97 4.41
5.5 0.37 0.43 0.90 0.72 1.04 0.80 4.26
6.0 0.19 1.18 1.58 1.00 1.08 1.66 6.69
Column
T o ta ls 7.14 10.07 18.50 11.63 13.08 14.18 7 4 .6 0
132.
B ase : E m u ls ify in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t S u lp h a n ila m id e .
Sulphanilam ide Concentration
R ahhit No. 96 97
Mg./lOO ml. 
98 99 100 101
Weight (Kg.) 2.350 2.800 2.600 3.600 3.400 2.750
Sex Female Female Female Female Female Female
Row
T otals
Hours a f te r  
A pplication
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.80 0.61 0.66 0.50 1.40 0.35 4.34
1.0 0.66 0.85 0.65 0.43 0.30 0.25 3.14
1.5 0.61 0.99 0.30 0.33 0.83 0.30 3.36
2 .0 0.85 0.66 0.43 0.30 0.23 0.40 2.87
2.5 0.27 0.50 0.41 0.56 0.26 0.24 2.24
3 .0 0.50 0.40 0.46 0.30 0.30 0.21 2.17
3.5 0.38 0.56 0.36 0.41 0.51 0.71 2.93
4 .0 0.68 0.78 0.38 0.51 0.31 0.20 2.86
4 .5 0.26 0.46 0.30 0.41 0.60 0.23 2.26
5 .0 0.51 0.40 0.76 0.36 0.60 0.23 2.86
5.5 0.45 0.48 0.60 0.56 0.65 0.56 3.30
6 .0 0.28 0.71 1.25 0.48 0.33 0.63 3.68
6.5 0.33 0.36 0.86 0.21 0.45 0.30 2.51
7.0 0.56 0.36 0.35 0.30 0.43 0.25 2.25
7.5 0.20 0.63 0.30 0.20 0.25 0.45 2.03
8 .0 0.28 0.33 0.36 0.41 0.26 0.26 1.90
Column
T o ta ls 7.62 9.08 8.45 6.27 7.71 5.57 44.70
133.
B a se : S m ils i f y in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t  S u lp h an ilam id e
Sulphanilam ide C oncentration  
: ./ io o  m l.
Hours A fte r  
A p p lica tio n
Babbit No. 73 74 75 76 77 78
Weight (Kg.) 2.950 2.925 2.875 2.900 3.000 2.975 Row
Sex Male Male Male Female Female Male Totals
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.00 0.26 0.00 0.30 0.65 0.33 1.54
1.0 0.30 0.98 0.56 0.74 0.48 0.50 3.56
1 .5 0.00 0.60 0 .26 0.45 0.47 0.23 2.01
2.0 0.51 0.05 1.26 0.42 0.60 0.20 3.04
2.5 0.61 0.00 0.73 0.28 0.43 0.53 2.58
3.0 0.25 0.38 0.40 0.33 0.46 0.30 2.12
3 .5 0.69 0.20 1.44 0.12 0.41 0.33 3.19
4 .0 0.86 0.00 0.20 0.74 0.28 0.61 2.69
4 .5 0.31 0.69 0.19 0.33 0.46 0.30 2.28
5 .0 0.15 0.45 0.25 0.26 0.19 0.81 2.11
5 .5 0.86 0.30 0.20 0.23 0 .41 0.46 2.46
6.0 0.10 0 .46 0.12 0.13 0.40 0.35 1.56
6.5 0.51 0.50 0.00 1.00 0.17 0.65 2.83
7.0 0.43 0.30 0.30 0.38 0 .45 1.45 3.31
7.5 0 .46 0.50 0.00 0.23 0.30 0.84 2.33
8 .0 2.56 0.40 0.15 0.22 0.15 0.30 3.78
Column
T o ta ls 8.60 6.07 6.06 6.16 6.31 8.19 41.39
134.
B ase : E m u ls ify in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t S u lp h a n ila m id e .
Sulphanilam ide C oncentration 
Mg./lOO ml.
R abbit No. 73 74 75 76 77 78
Weight (Kg.) 2.800 2.800 2.750 2.550 2.700 2.575
Row
Sex Male Male Male Female Female Male T o ta ls
Hours a f te r  
A p p lica tio n
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.69 0.73 0.33 1.83 0.46 1.19 5.23
1 .0 1.32 1.17 0.40 1.20 0.56 0.41 5.06
1 .5 0.70 0.83 0.27 0.63 0.23 0.58 3.24
2 .0 0.61 0.53 0.33 0.94 0.28 0.31 3.00
2 .5 0.72 0.64 0.33 1.21 0.34 0.53 3.77
3 .0 0.45 0.32 0.24 0.74 0.29 0.28 2.32
3 .5 0.51 0.48 0.32 0.58 0.10 0.25 2.24
4 .0 0.31 0.47 0.33 0.84 0.45 0.26 2.66
4 .5 0.81 0.78 0.55 0.33 0.84 0.25 3.56
5 .0 0.35 0.61 1.24 1.34 0.46 0.56 4.56
5 .5 0.64 0.56 0.40 0.68 0.45 0.29 3.02
6 .0 0.64 1.06 0.33 0.83 0.51 0.22 3.59
6.5 0.63 0.50 1.32 0.69 0.38 0.65 4.17
7 .0 0.23 0.33 0.78 1.04 0.68 0.23 3.29
7.5 0.30 0.41 1.06 0.91 0.54 0.64 3*86
8 .0 0.22 0.28 0.41 0.46 0.00 0.08 1.45
Column
T o ta ls 9.13 9.70 8.64 14.25 6.57 6.73 55.02
135.
B ase : Hydrous E m u ls ify in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t  S u lp h an ilam id e
Sulphanilam ide C oncentration 
Mg./lOO ml.
Rahhit No. 48 49 50 51 52 53
W e i^ t (Kg.) 2.550 2.900 2.750 3.175 3.275 2.950 Row
Sex Male Male Male Female Female Female T o ta ls
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0 .00 0.00 0 .00
0 .5 0.69 0.50 0.20 0 .28 0 .68 0 .98 3.33
1.0 0.94 1.12 0 .74 0.48 0.36 0 .84 4.48
1.5 0.33 1.44 0.00 0.33 0.50 0.66 3.26
2.0 0 .71 1.17 1.49 0.36 0.79 0.55 5.07
2.5 0.43 0.66 0.00 0.12 1.12 0.40 2.73
3.0 0.63 0.58 0.35 0.68 0.00 0.48 2.72
3.5 0.26 0.41 0.53 0.31 0.15 0 .78 2.44
4 .0 0.78 0.40 1.16 0 .36 0.98 0.91 4.59
4.5 0.97 0.30 0.21 0.96 • 0 .84 0.66 3.94
5.0 0.61 0.78 1.22 0.40 0.91 0.58 4.50
5.5 0 .36 0.20 0.41 0 .18 0.38 0.61 2.14
6.0 0.60 0.50 0.89 0.58 0 .25 0 .28 3.10
Column
T o ta ls 7.31 8.06 7.20 5.04 6.96 7.73 42.30
136.
B ase : H ydreus E m u ls ify in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t S u lp h an ilam id e
Sulphanilam ide C oncentration 
Mg./lOO ml.
Rahhit No. 48 49 50 51 52 53
Weight (Kg.) 2.400 2.650 2.600 3.150 3.250 2.950 Row
Sex Male Male Male Female Female Female T o ta ls
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.50 1.50 0.51 0.86 0.78 0.71 4.86
1.0 0.96 0.99 0.51 1.12 0.78 0.55 4.91
1 ,5 0.53 1.78 0.00 0.89 0.46 1.68 5.34
2.0 0.10 2.08 0.23 0.36 1.06 0.63 4.46
2.5 0.78 0.91 0.60 0.00 0.53 0.51 3.33
3.0 0.41 0.74 0.79 0.53 0.69 0.61 3.77
3.5 0.40 0.17 0.23 0.00 0.61 0.58 1.99
4 .0 0.49 0.00 0.20 0.50 0.86 0.45 2.50
4 .5 0.25 0.16 0.38 0.38 0.56 0.63 2.36
5.0 0.66 0.45 0.18 0.43 0.78 0.61 3.11
5.5 0.20 0.91 0.41 0.18 0.41 0.50 2.61
6.0 0.02 1.32 0.03 0 .35 0.66 0.23 2.61
Column
T o ta ls 5.30 11.01 4.07 5.60 8.18 7.69 41.85
I j f ,
B ase : H ydrous E m u ls ify in g  O intm ent c o n ta in in g  10 p e r  c e n t  S u lp h a n ila m id e .
Hours a f t e r  
A pp lica tion
Sulphanilam ide C oncentration  
Mg./lOO ml.
R ahhit No. 96 97 98 99 100 101
Weight (Kg.) 2.400 2.800 2.600 3.600 3.400 2.950
Row
Sex Female Female Female Female Female Female T o ta ls
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.85 0.41 0.35 0.71 0.88 0.73 3.93
1 .0 0.30 0.57 0.47 0.53 0.24 0.64 2.75
1 .5 0.31 0.30 0.81 0.68 0.23 0.53 2.86
2 .0 0.28 0.22 0.31 0.31 1.09 0.47 2.68
2.5 0.10 0.27 0.27 0.44 0.18 0.48 1.74
3 .0 0.29 0.38 0.16 0.29 0.35 1.17 2.64
3.5 0.20 0.47 0.48 0.36 0.41 0.50 2.42
4 .0 0.25 0.29 0.55 0.60 0.20 0.60 2.49
4 .5 0.35 0.31 0.26 0.40 0.46 1.06 2.84
5 .0 0.51 0.44 0.37 0.26 0.50 0.41 2.49
5 .5 0.43 0.29 0.74 0.47 0.33 0.78 3.04
6 .0 0.29 0.33 0.42 0.35 0.20 0.33 1.92
6 .5 0.58 0.40 0.27 0.21 0.31 0.43 2.20
7.0 0.31 0.51 0.38 0.31 0.58 0.64 2.73
7 .5 0.39 0.21 0.16 0.29 0.29 0.83 2.17
8 .0 0.25 0.32 0.28 0.35 0.33 0.28 1.81
Column
T ota ls 5.69 5.72 6.28 6.56 6.58 9.88 40.71
138.
B ase : H ydreus E m u ls ify in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t  S u lp h an ilam id e
Sulphanilamide Concentration 
Mg./lOO ml.
Rahhit No. 73 74 75 76 77 78
Vfeight (Kg.) 2.950 2.975 2.875 2.850 2.900 2.925 Row
Sex Male Male Male Female Female Male T o ta ls
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.58 0.21 0.73 0.46 0.64 0.89 3.51
1 .0 0.20 0.35 0.31 0.48 0.48 0.64 2.46
1.5 0.35 0.31 0.48 0.73 0.38 0.30 2.55
2 .0 0.10 0.18 0.23 0.35 0.33 0.33 1.52
2 .5 0.41 0.55 0.69 0.46 0.25 0.28 2.64
3.0 0.26 0.10 0.20 0.35 0.58 0.38 1.87
3.5 0.40 0.51 0.46 0.35 0.35 0.33 2.40
4 .0 0.10 0.30 0.25 0.21 0.13 0.33 1.32
4 .5 0.36 1.08 0.74 0.40 0.30 0.35 3.23
5 .0 0.40 0.29 0.26 0.26 0.29 0.46 1.96
5 .5 0.30 0.58 0.40 0.30 0.35 0.64 2.57
6.0 0.29 0.30 0.12 0.36 0.12 0.55 1.74
6.5 0.23 0.21 0.26 0.35 0.46 0.73 2.24
7 .0 0.20 0.29 0.25 0.38 0.50 0.40 2.02
7 .5 0.30 0.43 0.35 0.41 0.45 0.40 2.34
8 .0 0.10 0.23 0.17 0.20 0.44 0.66 1.80
Column
T o ta ls 4 .58 5.92 5.90 6.05 6.05 7.67 36.17
139.
B ase : Hydrous E m u ls ify in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t S u lphan ilam ide#
Sulphani1 amide C oncentration  
Mg*/lOO ml.
R abbit No. 
Weight (Kg.) 
Sex
Hours a f t e r  



















T o ta ls
73 74 75 76 77 78
3.000 2.950 2.875 2.800 2.900 2.825
Male Male Male Female Female Male
0.00 0.00 0.00 0.00 0.00 0.00
1.40 0.33 0.64 0.88 1.17 0.48
0.74 0.81 0.74 1.09 0.00 0.21
0.38 1.82 0.53 0.91 0.33 0.94
0.26 0.43 0.68 0.23 0.12 0.58
0.33 0.36 0.33 0 .2 4 1.23 0.28
0.18 0.46 0.43 0.10 0.43 0.35
0.17 0.61 0.21 0.23 0.50 0 .36
0.43 0.58 0.44 0.18 0.40 0.23
0.15 0.71 0.30 0 .23 0.39 0.86
0.33 0.61 0.66 0.31 0.26 0.20
0.22 1.82 0.43 0 .28 0.48 0.20
0.60 0.37 0.58 0 .28 0.21 0.19
0.15 0.99 0.36 0.10 0.22 0.23
0.61 0.33 0.50 0.35 0.61 0.20
0.73 0.41 0.53 0.20 0.35 0.20
0.36 0.89 0.56 0.41 0.33 0.30




4 . 9 0
3.59
4 . 9 1
2.30
2.77













B ase : W ooIf a t  c o n ta in in g  10 p e r  c e n t S u lp h an ilam id e
Sulphanilam ide C oncentration 
Mg./lOO ml.
Rabbit No. 96 97 98 99 100 101
W e i^ t (Kg.) 2.500 3.400 2.450 2.800 2.450 2.500 Row
Sex Female Female Female Female Female Female Tota]
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 1.05 0.45 0.31 0.31 0.40 0.26 2.78
1.0 0.58 0.46 0.71 0.28 0.21 0.26 2.50
1.5 1.15 0.30 0.33 0.30 0.33 0.21 2.62
2.0 0.63 0.43 0.23 0.20 0.25 0.35 2.09
2 .5 0.28 0.31 0.25 0.20 0.31 0.35 1.42
3.0 0.35 0.26 0.51 0.18 0.20 0.25 1.75
3.5 0.30 0.93 0.21 0.16 0.26 0.21 2.07
4.0 0.20 0.26 0.26 0.50 0.31 0.25 1.78
4.5 0.40 0.36 0.38 0.25 0.75 0.28 2.42
5.0 0.46 0.56 0.25 0.36 0.28 0.20 2.11
5.5 0.20 0.55 0.93 0.21 0.30 0.15 2.34
6.0 0.66 0.20 0.28 0.23 0.30 0.18 1.85
6.5 0.31 0.30 0.16 0.00 0.28 0.30 1.35
7.0 0.23 0.31 0.16 0.10 0.23 0.16 1.19
7.5 0.71 0.21 0.20 0.31 0.35 0.40 2.18
8.0 0.30 0.30 0.26 0.31 0.23 0.23 1.63
Column
T ota ls 7.81 6.19 5.43 3.90 4.99 4*04 32.36
14Z,
B ase: W oolfa t c o n ta in in g  10 p e r  c e n t  S u lp h a n ila m id e .
Sulphanilam ide C oncentration 
Mg./lOO ml.
R abbit No. 96 97 98 99 100 101
Weight (Kg.) 2.550 3.425 2.475 2.850 2.450 2.600
Sex Female Female Female Female Female Female
Hours a f t e r  



















T o ta ls
Row
T otals
0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.78 0.45 0.48 0.66 0.68 0.38 3.43
0.83 0.36 1.01 0.63 0.45 0.38 3.66
0.23 0.33 0.95 0.62 0.30 0.45 2.88
0.63 0.35 0.73 0.40 0.28 0.41 2.80
0.67 0.35 0.83 0.62 0.36 0.35 3.18
0.30 0.35 0.45 0.41 0.41 0.80 2.72
1.25 0.50 0.37 0.38 0.96 0.36 3.82
0.40 0.22 0.40 0.33 0.51 0.48 2.34
0.38 0.23 0.28 0.38 0.25 0.28 1.80
0.15 0.62 0.55 0.62 0.40 0.31 2.65
0.48 0.45 1.09 1.02 0.28 0.50 3.82
0.45 0.66 0.50 0.56 0.25 0.30 2.72
0.45 0.53 0.41 0.50 0.41 0.40 2.70
0.30 0.50 0.98 0.31 0.21 0.35 2.65
0.75 0.88 0.63 0.55 0.28 0.30 3.39
0.30 0.71 0.91 0.23 0.20 0.38 2.73
8.35 7.49 10.57 8.22 6.23 6.43 47.29
143.
Bases L ard c o n ta in in g  10 p e r  c e n t S u lphan ilam ide*
Sulphanilam ide C oncentration 
Mg. / loo ml.
R abbit No. 96 97 98 99 100 101
Weight (Kg.) 2.475 3.300 2.525 2.950 2.500 2.550
Row
Sex Female Female Female Female Femal e Female T o ta ls
Hours a f t e r  
A pplication
0.0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 1.08 0.78 0.85 0.50 1.10 0.38 4.69
1.0 0.87 1.43 1.05 0.83 1.30 0.55 6.03
1.5 0.15 0.60 0.78 0.97 0.60 0.31 3.41
2.0 0.60 0.77 0.77 0.98 0.61 0.28 4.01
2.5 0.77 1.31 0.69 0.51 0.53 0.63 4.44
3.0 1.48 0.99 1.05 1.30 0.73 0.53 6.08
3.5 1.41 0.87 1.28 0.70 1.18 1.20 6.64
4.0 1.02 0.71 1.11 0.90 1.25 1.35 6.34
4.5 1.14 0.35 0.98 0.93 0.35 0.94 4.70
5.0 1.27 0.67 0.89 1.35 0.82 0.46 5.46
5.5 1.30 1.08 1.03 1.03 1.25 1.31 7.00
6.0 1.17 0.70 0.71 0.88 0.76 0.99 5.21
6.5 1.09 1.10 1.15 1.13 0.00 1.00 5.47
7.0 1.21 0.67 0.92 1.30 0.86 1.21 6.17
7.5 1.04 0.63 0.51 0.95 0.76 1.10 4.99
8.0 1.00 0.95 0.53 1.13 0.76 0.81 5.18
Column
T o ta ls 16.60 13.61 14.30 15.39 12.86 13.06 85.82
144.
Bases L ard  c o n ta in in g  10 p e r  c e n t S u lp h a n ila m id e .
Sulphanilam ide Concent r a t  ion





W e i^ t (Kg.) 2.550 3.300 2.500 2.875 2.550 2.550 Row
S ex Female Female Female Female Female Female T o ta ls
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 1.00 1.41 0.90 1.41 1.31 0.76 6.79
1 .0 0.67 0.65 0.83 1.15 0.63 0.73 4.66
1.5 0.70 0.83 1.11 1.40 0.73 0.51 5.28
2 .0 0.40 1.23 0.47 0.93 1.23 0.40 4.66
2 .5 0.55 1.05 0.85 1.08 0.58 0.40 4.51
3.0 0.40 1.51 0.70 0.35 0.76 0.58 4.30
3.5 0.55 1.25 0.83 0.96 1.21 1.08 5.88
4 .0 0.83 1.13 0.51 1.31 0 .96 1.25 5.99
4 .5 0.49 1.25 0.80 1.45 0 .73 0.99 5.71
5 .0 1.20 1.50 0.63 1.33 0.89 0.80 6.35
5 .5 1.49 1.35 1.14 1.18 1.43 0.80 7.39
6 .0 0.78 1.15 1.55 0.93 0.53 0.80 5.74
6.5 0.73 0.78 1.45 0.83 0.45 0.43 4.67
7 .0 0.72 1.02 1.51 0.50 0.51 0.40 4.66
7.5 0.40 1.23 0.53 1.38 0 .71 0.40 4.65
8 .0 0.77 1.15 0.96 0.90 0.55 0.45 4.78
Column
T o ta ls 11.68 18.49 14.77 17.09 13.21 10.78 86.02
145.
Bases W hite S o f t  P a r a f f in  c o n ta in in g  10 p e r  c e n t  Sulphanilam i.de
Sulphanilam ide C oncentration  
Mg./lOO m l.
Rabbit No. 96 97 98 99 100 101
Weight (Kg.) 2.575 3.275 2.500 2.800 2.525 2.500 Row
Sex Female Female Female Female Female Female Total
Hours a f te r  
A pplication
0.0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 1.43 1.21 1.30 1.63 1.35 1.46 8.38
1.0 0.56 0.71 0.91 0.61 0.95 0.51 4.25
1.5 0.57 0.84 0.63 0.70 0.55 0.41 3.90
2.0 0.72 0.63 0.84 0.50 0.53 0.48 3.70
2.5 0.15 0.60 0.58 0.61 0.81 0.35 3.10
3.0 0.75 0.51 0.70 0.58 0.75 0.43 3.72
3.5 0.93 0.38 0.51 0.63 0.53 0.45 3.43
4.0 0.70 0.43 1.15 0.49 0.41 0.75 3.93
4 .5 0.68 0.80 1.00 0.55 0.33 1.00 4.36
5.0 0.81 0.72 0.79 0.70 0.50 0.40 3.92
5.5 0.70 0.81 0.68 0.76 0.41 0.60 3.96
6.0 0.55 0.75 0.80 0.46 0.45 0.46 3.47
6.5 0.64 0.53 0.60 0.71 0.56 0.30 3.34
7.0 0.68 0.51 0.42 0.71 0.30 0.41 3.03
7.5 0.30 0.58 0.72 0.51 0.61 0.38 3.10
8.0 0.82 0.50 0.71 0.50 0.64 0.47 3.64
Column
T ota ls 10.99 10.51 12.54 10.65 9.68 8.86 63.23
14b.
Bases W hite S o f t  P a r a f f in  c o n ta in in g  10 p e r  c e n t S u lp h a n ila m id e .
Sulphanilam ide C oncentration 
Mg./lOO ml.
Rabbit No. 96 97 98 99 100 101
Weight (Eg.) 2.500 3.400 2.525 2.850 2.600 2.550
Row
Sex Female Female Female Female Female Female T o ta ls
Hours a f t e r  
A pplication
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 1.31 0.90 0.69 0.78 0.88 0.60 5.16
1 .0 1.00 1.08 0.76 0.75 0.73 0.60 4.92
1.5 0.68 0.58 0.45 1.10 0.70 0.86 4.37
2.0 0.65 0.70 0.75 0.51 0.40 0.60 3.61
2.5 0.60 0.63 0.55 0.46 0.61 0.40 3.25
3.0 0.49 0.81 1.01 0.45 0.40 0.25 3.41
3.5 0.83 0.75 0.90 0.68 0.61 0.29 4.06
4 .0 0.73 0.80 0.60 0.37 0.51 0.53 3.54
4.5 0.70 0.90 0.75 0.40 0.83 0.50 4.08
5.0 0.83 0.93 0.56 0.55 0.61 0.58 4.06
5.5 0.65 1.12 0.80 0.43 0.41 0.73 4.14
6.0 0.91 0.87 0.71 0.60 0.79 0.56 4.44
6.5 0.60 0.86 0.83 0.56 0.36 0.63 3.84
7 .0 0.85 0.73 0.60 0.37 0.71 0.40 3.66
7.5 0.66 0.68 0.60 0.65 0.40 0.58 3.57
8.0 0.66 0.59 0.95 0.73 0.68 0.73 4.34
Column
T ota ls 12.15 12.93 11.51 9.39 9.63 8.84 64.45
147,
Bases L iq u id  P a r a f f i n  c o n ta in in g  10 p e r  c e n t S u lp h an ilam id e
Sulphanilam ide C oncentration 
Mg./lOO m l.
Rabbit No. 96 97 98 99 100 101
Weight (Kg.) 2.425 2.925 2.650 3.800 3.500 2.950 How
Sex Female Female Female Female Female Female Tota]
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 1.40 1.52 1.45 0.68 0.48 0.36 5.89
1.0 0 .25 0.89 0.35 0.40 0.10 0.41 2.40
1.5 0.61 0.63 0.10 0.10 0.60 0 .30 2.34
2.0 0.25 1.62 0.40 0.23 0.25 0.31 3.06
2.5 0.69 0.48 0.30 0.27 0.10 0.73 2.57
3.0 1.10 0.56 0.10 0.10 0.46 0.56 2.88
3.5 0.48 1.77 0.41 0.76 0.20 0 .26 3.88
4 .0 0.36 0.91 0.55 0.61 0.60 0.36 3.39
4 .5 0.41 0.10 0.30 0 .28 0.26 0.26 1.61
5.0 0.10 0.45 0.23 0.40 0.28 0.23 1.69
5.5 0,31 0.18 0.30 0.15 0 .26 0.53 1.73
6.0 0.45 0.43 0.23 0.28 0.25 0.15 1.79
6.5 1.51 0.33 1.12 0.20 0.45 0.30 3.91
7.0 1.82 0.18 0.25 0.30 0.10 0.20 2.85
7.5 1.44 0.33 0.35 0.21 0.00 0.10 2,43
8.0 0 .58 0.20 0.51 0.56 0.20 0.26 2.31
Column
T o ta ls 11.76 10.58 6.95 5.53 4.59 5.32 44.73
148.
Bases L iquid  P a ra ff in  co n ta in in g  10 p e r  cen t Sulphanilam ide,
Sulphanilam ide C oncentration 
Mg./lOO ml.
R abbit No. 96 97 98 99 100 101
Weight (Kg.) 2.500 2.475 2.425 3.025 2.775 Row
Sex Female Female Female Female Female T otals
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 1.00 0.41 0.50 0.60 0.26 2.77
1.0 0.38 0.36 0.15 0.61 0.43 1.93
1 .5 0.43 0.26 0.63 0.46 0.46 2.24
2.0 0.30 0.46 0.53 0.21 0.23 1.73
2 .5 0.30 0.45 0.28 0.35 0.26 1.64
3.0 0..33 0.46 0.35 0.55 0.56 2.25
3 .5 0.32 0.41 0.73 0.81 1.06 3.33
4 .0 0.75 0.65 0.50 0.50 0.81 3.21
4 .5 0.33 0.50 0.31 0.68 0.41 2.23
5.0 0.53 0.00 0.43 0.50 0.43 1.89
5.5 0.25 0.30 0.33 0.28 0.38 1.54
6.0 0.26 0.46 0.48 0.53 0.26 1.99
6.5 0.26 0.91 0.51 0.41 0.30 2.39
7 .0 1.11 1.16 0.75 0.53 0.28 3.83
7 .5 0.21 0.86 1.31 0.31 0.43 3.12
8 .0 0.26 0.83 0.68 0.50 0.75 3.02
Column
T o ta ls 7.02 8.48 8.47 7.83 7.31 39.11
149.
Bases P ro p y le n e  G lyco l c o n ta in in g  10 p e r  c en t S u lp h an ilam id e
Sulphanilam ide C oncentration  
Mg./lOO m l.
Rabbit No. 48 49 50 51 52 53
Weight (Kg.) 2.475 2.950 2.625 3.325 3.475 3.075 Row
Sex Male Male Male Female Female Female Tota]
Hours a f t e r  
A pp lica tion
0.0 0.00 0.00 0.00 0.00 0,00 0.00 0.00
0.5 0.96 1.29 0 .58 0 .55 0.40 0.46 4.24
1.0 0.83 0.75 0 .45 0.60 0.26 0.23 3.32
1.5 1.79 0.61 0 .30 0.51 0.41 0.31 3.93
2.0 1.56 0.78 0 .36 0.53 0.47 0.53 4.23
2.5 1.34 0.71 0.33 0 .47 0.56 0.85 4.26
3.0 0.99 0.40 0 .31 0 .25 0,25 0.66 2.86
3.5 1.12 0.43 0.28 0.47 1.40 0.65 4.35
4.0 1.59 0.93 1.87 1.32 0.45 1.11 7.27
4.5 1.04 1.01 0.30 0 .29 0.50 0.73 3.87
5.0 0.93 0.96 0 .25 0.30 0.40 0 .35 3.19
5.5 0.55 0.41 0.33 0.51 0.41 0.41 2.62
6.0 0.63 0.59 0.33 0.22 0.80 0.41 2.98
6.5 1.27 0.96 0.18 0.43 0.32 0 .15 3.31
7.0 0.68 1.50 0.56 1.01 0.26 0.23 4.24
7.5 0.43 0.40 1.00 1.54 0.36 0.23 3.96
8.0 0.60 0.26 0.26 0.36 0.61 0.23 2.32
Column
T otals 16.31 11.99 7.69 9.56 7.86 7.54 60.95
B ases P ro p y len e  G lyco l c o n ta in in g  10 p e r  c e n t S u lp h an ilam id e
Sulphanilam ide C oncentration  
Mg/lOO ml.
R abbit No. 48 49 50 51 52 53
W e i^ t (K g.) 2.525 2.750 2.450 3.300 3.375 3.025 Row
Sex Male Male Male Female Female Female T o ta ls
Hours a f t e r  
A p p lica tio n
0 .0 0 .00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 1.17 0.40 0.63 0.66 0.75 0.69 4.30
1 .0 0.64 1.21 2.06 0.55 1.70 0.45 6.61
1.5 0.73 . 0.91 0.76 0.41 0.51 1.22 4.54
2 .0 1.16 0.23 0.73 0.44 0.53 0.58 3.67
2.5 0.51 0.57 0.40 0.41 0.45 0.61 2.95
3.0 1.32 0.41 0.51 0.26 0.45 0.51 3.46
3.5 2.21 0.46 0.52 0.66 0.58 1.55 5.98
4 .0 2.38 0.76 0.60 0 .36 0.45 0.83 5.38
4 .5 0.91 0.69 0.33 1.20 0.66 0.51 4 .30
5.0 0.81 1.55 0.64 0.67 0.80 0.48 4.95
5.5 1.27 1.02 0.52 0.53 0.40 0.58 4.32
6 .0 2.23 0.98 0.79 0.40 0.50 0.73 5.63
6.5 0.53 0.76 0.10 0.31 0.58 0.76 3.04
7.0 0.71 1.24 0.40 0.25 0.45 0.58 3.63
7.5 0.88 0.56 0.10 0.50 0.45 0.89 3.38
8.0 0.58 0.63 0.51 0.20 0.48 0.58 2.98
Column
T o ta ls 18.04 12.38 9.60 7.81 9.74 11.55 69.12
i p l
Bases E th y l 01e a te  c o n ta in in g  10 p e r  c en t S u lp h a n ila m id e .
Sulphanilamide C oncentration  
Mg./lOO ml.
R abbit No. 48 49 50 51 52 53
Weight (Kg.) 2.450 2.925 2.700 3.350 3.475 3.050
Row
Sex Male Male Male Female Female Female T o ta ls
Sours a f te r  
A pp lication
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.81 0.69 0.56 0.33 0.66 0.55 3.60
1 .0 0.66 0.98 0.63 0.25 1.34 0.66 4.52
1.5 0.71 0.89 0.63 0.40 0.73 0.94 4.30
2 .0 0.93 0.93 0.43 0.36 0.51 0.56 3.72
2.5 0.63 0.25 0.56 0.56 0.96 1.38 4.34
3.0 0.47 0.65 0.61 0.50 0.31 0.56 3.10
3.5 0.94 0.55 0.63 0.31 0.50 0.25 3.18
4.0 0.51 0.91 0.56 0.65 0.31 0.89 3.83
4 .5 0.73 1.59 0.33 0.28 0.33 0.25 3.48
5.0 0.89 1.43 0.41 0.36 0.40 0.65 4.14
5.5 0.80 1.40 0.58 0.30 0.35 0.45 3.88
6.0 1.03 1.27 0.63 0.40 0.45 0.66 4.44
6.5 1.11 1.03 0.62 0.56 0.15 0.80 4.27
7.0 1.19 0.98 0.60 0.51 0.28 1.26 4.82
7 .5  ■ 0.89 1.20 0.63 0.33 0.28 0.75 4.O8
8.0 0.68 0.88 0.51 0.43 0.33 0.51 3.34
Column
T ota ls 12.98 15.60 8.92 6.53 7.89 11.12 63.04
152.
Bases C etom acrogol E m u ls ify in g  Wax c o n ta in in g  10 p e r  c e n t S u lp h an ilam id e
Sulphanilam ide C oncentration 
Mg./lOO m l.
Rabbit No. 96 97 98 99 100 101
W e i^ t (Kg.) 2.450 2.800 2.650 3.650 3.300 2.850 Row
Sex Female Female Female Female Female Female Tota]
Hours a f te r  
A pplication
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.70 0.73 0.51 0.45 0.43 0.40 3.22
1.0 0.81 0.80 0.45 0.53 0 .66 0.80 4.05
1.5 0.66 1.00 0.58 0.61 0.90 0.55 4.30
2.0 0.58 0.61 0.61 0.66 0.63 0.78 3.87
2.5 0.53 0.23 0.78 0.81 0.53 0.58 3.46
3.0 0.61 0.33 0.83 0.70 0.10 0.55 3.12
3.5 0.38 0.45 0.61 0.60 0.40 0.80 3.24
4.0 0.40 0.56 0.79 0 .45 0.50 0.80 3.50
4 .5 0.48 0.76 0.66 0.55 0.45 0 .85 3.75
5.0 0.53 0.55 0.70 0.66 0.46 0.80 3.70
5.5 0.88 0.68 0.50 0 .46 0 .15 0.74 3.41
6.0 0.51 0.50 0.61 0.50 0 .36 0.51 2.99
6.5 0.53 0.36 0.46 0.33 0.41 0.53 2.62
7.0 0.33 0.28 0.43 0.41 0.38 0.71 2 .54
7.5 0.48 0.18 0.28 0.36 0.28 0.40 1.98
8.0 0.41 0.28 0.21 0.68 0.33 0.28 2.19
Column
T otals 8.82 8.30 9.01 8.76 6.97 10.08 51.94
I5j'
Base: Lard containing 5 per cent sa licy lic  acid*
S a lic y la te  C oncentration  
Mg*/lOO ml*
Rabbit No* G H I J K L
Weight (Kg*) 3.350 3.400 3.300 3.650 3.450 3.500
Sex Male Male Male Female Female Female
Row
T o ta ls
Hours a f te r  
A pp lica tion
0*0 0*00 0*00 0*00 0*00 0*00 0*00 0*00
0.5 1.31 1.20 1*22 1*01 1.51 1.35 7.60
1*0 1*10 1.11 1.31 0.90 1.29 1.36 7.07
1.5 0.91 1*32 1.27 0*60 0.80 0.91 5.81
2.0 0*72 0*84 1*18 1.52 0.75 1*24 6.25
2.5 0*83 1*27 0*71 1.31 0*74 1.24 6*10
3.0 1*46 0*77 0*75 1*48 1.17 0*84 6*47
3.5 0*41 1*26 0*99 1*10 0*89 0*85 5.50
4.0 0*99 1.44 1.34 0*92 1.34 0.93 6*96
4.5 1*21 0*91 0*91 0.81 0*79 0*89 5.52
5.0 0*72 1.13 0*80 1.35 0*80 1*41 6.21
5.5 0*83 1*24 1.43 1*82 1.41 1*63 8*36
6*0 0*85 0*71 1*56 1*64 1.41 1.42 7 .59
6.5 1*01 0.93 1*78 1*65 1*62 1.77 8*76
7.0 0*92 1.44 1*04 1*41 1.43 1*50 7.74
7.5 1*32 0*88 0*92 0*83 0*91 0.95 5*81
8*0 0*69 1*03 1*18 0*88 0*74 1.23 5.75
Column
T otals 15.28 17.48 18*39 19.23 17.60 19.52 107.50
154.
B ase : L ard  c o n ta in in g  5 p e r  c e n t s a l i c y l i c  a c id .
S a l ic y la t e  C oncentration  
Mg,/lOO m l.
R abbit No, A B C D E F
Weight (Kg,) 3.425 3.550 3.500 3.475 3.250 3.475 Row
Sex Female Female Female Female Male Male T otals
Hours a f t e r  
A p p lica tio n
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.71 1.23 1.00 1.07 1.56 0.81 6.38
1 .0 1.43 0.90 1.43 1.51 1.71 1.42 8.40
1.5 0.92 1.01 1.10 1.67 1.21 1.63 7.54
2 .0 1.03 1.13 1.21 1.77 1.31 1.51 7.96
2.5 1.17 1.64 1.10 2.03 0.81 1.82 8.57
3 .0 1.23 0.70 1.11 1.21 0.71 0.78 5.74
3 .5 1.09 0.96 1.42 1.34 1.43 0.69 6.93
4 .0 0.98 1.39 1.00 1.29 0.69 0.96 6.31
4 .5 1.44 1.19 1.67 1.31 0.91 1.15 7.67
5 .0 1.39 1.54 1.72 1.04 1.43 1.05 8.17
5.5 1.52 1.09 1.83 0.74 1.51 1.38 8.07
6.0 1.09 1.03 1.20 0.98 1.43 0.97 6.70
6.5 1.51 1.07 1.28 1.21 1.02 1.12 7.21
7 .0 1.10 1.51 1.80 0.63 1.16 0.78 6.98
7.5 1.83 1.19 0.71 0.78 0.92 1.04 6.47
8 .0 1.40 1.01 1.63 1.03 0.88 0.88 6.83
Column
T o ta ls 19.84 18.59 21.21 19.61 18.69 17.99 115.93
155.
Base: White S oft P a ra f f in  co n ta in in g  5 p e r  cent s a l i c y l i c  ac id
S a l ic y la t e  C oncentration  
Mg./lOO m l.
Rabbit No. 102 103 104 105 106 107
Weight (Kg.) 3.250 3.200 2.650 3.400 3.300 2.700
Sex Female Female Female Female Female Female
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 1 .89 1.41 1.44 1.47 1.50 1.59
1.0 1.51 0.80 1.39 1.81 1.41 0.90
1 .5 0 .95 0.91 0.76 1.93 1.48 1.00
2.0 1.64 1.47 1.44 1.33 1.61 0.71
2 .5 1.17 0.81 0.94 1.78 1.77 1.67
3.0 1.22 0.88 0.93 1.47 1.42 1.34
3.5 1.00 1.51 0.71 1.10 1.01 0.92
4.0 0 .90 0.51 0.96 1.54 0.52 0.71
4 .5 0.90 0 .74 1.72 0.81 0.73 0.94
5.0 1.24 1.21 1.24 1.31 0.91 0.50
5.5 0 .96 0 .84 0.42 0.49 0.96 0.51
6.0 0.96 0.77 0.55 0.41 0.98 0.20
6.5 0 .84 0.50 0.53 0.53 1.11 0.51
7.0 1.04 0.82 0.53 0.31 1.31 0.67
7.5 0.62 0.61 0.38 0.72 0.63 0.74
8.0 0.89 1.36 1.61 0 .91 1.28 0.61
Column






















B ase : W hite S o f t  P a r a f f in  c o n ta in in g  5 p e r  c e n t s a l i c y l i c  a c id .
S a l ic y la t e  C oncentration  
Mg./lOO m l.
R abbit No. 102 103 104 105 106 107
W e i^ t (Kg.) 3.100 3.050 2.600 3.300 3.300 2.600 Row
Sex Female Female Female Female Female Female T o ta ls
Hours a f t e r  
A p p lica tio n
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.80 1.00 0.56 1.25 1.27 0.64 5.52
1.0 1.89 1.29 0.58 0.88 1.38 0.41 6.43
1 .5 2.14 0.46 0.33 1.33 1.64 0.62 6.52
2 .0 2.32 0.20 0.97 0.95 1.50 1.64 7.58
2 .5 1.76 1.25 1.00 1.26 1.66 1.30 8.23
3.0 1.50 1.56 0.67 0.94 1.28 1.52 7.47
3.5 1.29 1.35 0.56 1.62 1.28 1.50 7.60
4 .0 1.38 0.50 0.57 0.45 1.72 0.95 5.57
4 .5 1.70 0.47 0.65 0.66 0.91 1.25 5.64
5 .0 2.05 1.42 1.02 0.51 1.30 0.95 7.25
5.5 1.31 0.40 1.45 0.98 1.17 1.10 6.41
6.0 1.50 0.97 0.75 0.50 1.02 1.44 6.18
6.5 0.70 1.31 0.94 0.90 0.99 0.96 5.80
7 .0 0.49 1.52 1.01 1.32 1.53 0.73 6.60
7.5 0.91 0.91 0.90 1.02 0.95 0.61 5.30
8 .0 0.89 0.82 1.21 1.40 1.33 1.27 6.92
Column
T o ta ls 22.63 15.43 13.17 15.97 20.93 16.89 105.02
-LPf .
Base: Hydrous Ointment B.P. containing 5 per cent sa licy lic  acid.
S a lic y la te  C oncentration  
Mg./lOO ml.
R abbit No. 102
Weight (Kg.) 3.300
Sex Female
Hours a f t e r  






































103 104 105 106 107
3.200 2.600 3.300 3.300 2.700
Female Female Female Female Female
0.00 0.00 0.00 0.00 0.00
1.36 1.01 1.64 1.84 1.71
1.49 1.78 1.35 1.52 1.36
1.71 1.17 1.43 1.39 1.07
1.67 1.21 1.07 0.48 1.36
1.34 0.87 1.56 0.22 1.33
1.19 1.64 1.29 0.69 1.21
0.87 1.39 1.47 0.91 1.49
0.67 1.45 1.88 1.43 0.63
1.04 1.15 1.00 1.37 1.22
1.23 0.92 1.57 0.52 1.01
1.31 1.04 1 .44 1.43 1.29
1.45 1.27 1.30 1.07 1.38
1.62 1.51 1.41 1.24 1.51
1.30 1.51 1.97 1.19 1.24
0.90 1.20 1.17 0.99 1.30
0.87 1.43 0.71 1.18 0.70
20.02 21.35 22.26 17.47 19.81
Rov/




















B ase: Hydrous O intm ent B .P . c o n ta in g  5 p e r  c e n t s a l i c y l i c  a c id
S a lic y la te  C oncentration
Rabbit No. 102 103
Mg./lOO m l.
104 105 106 107
Weight (Kg.) 3.200 3.150 2.600 3.300 3.250 2.700 Row
Sex Female Female Female Female Female Female Tota]
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 1.79 1.71 1.73 1.68 1.35 1.28 9.54
1.0 1.36 1.29 1.39 1.30 1.25 1.41 8.00
1.5 1.12 1.07 1.14 1.32 1.43 0.60 6.68
2.0 1.09 1.00 1.24 1.33 1.39 0 .58 6.63
2.5 1.54 1.50 1.09 1.17 1.45 1.20 7.95
3.0 1.21 0.93 0.51 0.92 1.43 0.79 5.79
3.5 1.29 1.26 1.08 1.41 1.62 0.51 7.17
4.0 1.29 0.76 1.13 1.04 1.58 0.63 6.43
4.5 0.81 1.56 0.62 1.67 1.33 0.59 6.58
5.0 1.18 1.17 1.20 1.35 0.83 0.55 6.28
5.5 1.37 1.31 1.08 1.22 1.08 0.70 6.76
6.0 1.28 1.31 1.36 1.41 1.22 1.02 7.60
6.5 1.05 0.59 1.07 1.03 1.49 0.21 5.44
7.0 1.21 1.19 0.63 1.48 0.80 0.60 5.91
7.5 0.75 0.81 0.90 1.02 1.59 0.71 5.78
8.0 0.73 0.71 0.67 1.38 0.71 1.46 5.66
Column
T ota ls 19.07 18.17 16.84 20.73 20.55 12.84 108.20
160.
B ase : P ro p y len e  G lyco l c o n ta in in g  5 p e r  c e n t s a l i c y l i c  a c id ,
S a lic y la te  C oncentration 
llg*/lOO ml.
R abbit No. 102 103 104 105 106 107
Weight (Kg.) 3.100 3.000 2.700 3.450 3.300 2.600
Row
Sex Female Female Female Female Female Female T o ta ls
Hours a f te r  
A pplication
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 1.97 1.81 1.50 1.35 1.29 1.67 9.59
1.0 1.61 1.31 1.54 1.04 1.37 1.41 8.28
1 .5 1.63 1.47 1.81 1.70 0.54 1.69 8.84
2.0 1.82 0.71 1.75 1.41 1.35 1.71 8.75
2 .5 1.31 1.69 1.54 1.86 1.48 0.92 8.80
3.0 1.07 0.74 1.20 1.86 1.68 1.71 8.26
3.5 1.22 0.53 1.46 1.39 1.70 1.67 7.97
4 .0 0.84 0.78 1.54 0.98 1.70 1.51 7.35
4 .5 0.91 1.01 1.71 0.76 1.86 0.81 7.06
5.0 0.99 1.51 1.91 . 0.80 1.51 0.83 7.55
5.5 1.07 1.31 1.52 1.82 0.41 1.69 7.82
6.0 1.74 0.72 1.85 1.42 1.58 1.54 8.85
6.5 1.54 0.61 1.30 1.47 1.61 1.50 8.03
7 .0 1.34 0.64 1.29 0.79 1.57 1.99 7.62
7 .5 1.00 1.50 0.58 1.51 1.72 1.53 7.84
8.0 0.89 1.27 0.81 0.96 1.39 l a i 7.09
Column 
T o ta ls 20.95 17.61 23.31 21.12 22.76 23.95 129.70
161.
B ase : P ro p y len e  G lyco l c o n ta in in g  5 p e r  c e n t  s a l i c y l i c  a c id .
S a lic y la te  C oncentration  
Mg./lOO ml.
Rabbit No. 102 103 104 105 106 107
Weight (Kg.) 3.200 3.150 2.650 3.350 3.350 2,600
Sex Female Female Female Femal e Female Female
Row
T o ta ls
Hours a f t e r  
A pplication
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.91 1.70 1.72 1.43 1.33 1.12 8.21
1 .0 1.47 0.81 1.70 1.92 1.90 1.84 9.64
1.5 1.91 0.57 1.60 1.44 1.40 1.26 8.18
2.0 0.50 0.46 1,64 1.71 0.87 1.87 7.05
2.5 0.71 0.75 1.57 1.51 0.80 1.01 6.35
3.0 0.43 0.77 0.90 1.19 0.94 0.94 5.17
3.5 0.49 0.50 0.46 1.18 1.65 0.76 5.04
4.0 1.38 0.81 1.02 1.80 0.90 0.89 6.80
4.5 0.61 1.21 0.87 1.48 0.83 0.98 5.98
5.0 1.35 1.37 0.44 1.11 0.96 1.76 6.99
5.5 1.57 0.99 1.21 0.87 1.17 1.11 6.92
6 .0 0.68 1.44 1.50 1.17 1.10 1.38 7.27
6.5 0.50 0.84 0.67 1.34 0.71 1.14 5.20
7.0 0.55 0.69 0.89 1.56 0.66 1.23 5.58
7.5 1.00 1.31 0.87 1.44 0.83 1.55 7 .00
8.0 0.97 0.92 1.60 0.88 0.54 1.64 6.55
Column
T otals 15.03 15.14 18.66 22.03 16.59 20,48 107.92
162 ,
B ase: W ater a s  5 p e r  c en t carboxy  m ethy l c e l lu lo s e  c o n ta in in g  5 p e r  cen t
s a l i c y l i c  a c id
S a lic y la te  C oncentration 
Mg./lOO m l.
Rabbit No. G H I J K L
Weight (Kg.) 3.400 3.425 3.350 3.600 3.500 3.450 Row
Sex Male Male Male Female Female Female Total
Hours a f t e r  
A pplication
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.91 0.86 1.14 0.60 0.63 1.18 5.32
1.0 0.61 1.01 0.83 0.83 1.11 0.71 5.10
1.5 0.76 0.73 0.71 0.77 0 .94 0 .99 4.90
2.0 1.02 0.99 0.51 0.91 0.90 0.99 5.32
2.5 0.81 0.71 0.63 1.13 1.02 0.81 5.11
3.0 0.61 0.65 0.75 0.88 1.14 0.43 4.46
3.5 0.42 0.69 0.71 1.26 1.07 0.60 4.75
4.0 1.04 0.61 0.63 0.94 1.04 0.30 4.56
4.5 1.09 1.06 0.48 0.68 0.67 0.26 4.24
5.0 0.74 0.77 0.89 0.92 1.55 0.88 5.75
5.5 0.41 0.77 0,98 1.24 0.98 0.81 5.19
6.0 1.03 0.67 0.91 0.88 1.09 0.90 5.48
6.5 0.62 1.14 0.99 0.72 1.54 0.70 5.71
7.0 0.70 0.99 0.62 1.00 0.81 0.61 4.73
7.5 0.78 0.96 0.67 0.41 0.91 0.99 4.72
8.0 0.91 1.04 0.54 0.57 0.84 0.67 4.57
Column
T otals 12.46 13.65 11.99 13.74 16.24 11.83 79.91
163.
B ase; W ater a s  5 p e r  c e n t  carboxy  m ethyl c e l lu lo s e  c o n ta in in g  5 p e r  c e n t
s a l i c y l i c  a c id .
S a lic y la te  C oncentration  
Mg./lOO ml.
R abbit No. G H I J K L
Weight (K g.) 3.375 3.400 3.350 3.550 3.450 3.425 Row
Sex Male Male Male Female Female Female Totals
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 1.07 0.91 0.94 0.81 1.26 0.89 5.88
1 .0 1.06 1.09 0.66 1.60 0.95 1.18 6.54
1.5 0.72 0.52 0.77 1.19 0.73 0.91 4.84
2 .0 1.62 1.69 1.05 0.64 0.59 0.85 6.44
2 .5 1.10 1.07 0.92 0.90 0.62 1.08 5.69
3.0 1.61 0.83 0.51 0.83 0.41 1.04 5.23
3.5 1.32 1.00 0.61 1.38 0.69 0.71 5.71
4 .0 1.33 0.64 1.04 1.62 0.83 0.39 5.85
4.5 0.91 0.72 1.33 1.49 1.08 0.85 6.38
5 .0 0.54 0.91 0.98 1.08 1.18 0.61 5.30
5.5 1.19 0.77 0.81 0.92 0.83 0.65 5.17
6.0 0.80 0.97 0.70 1.42 0.58 0.89 5.36
6.5 0.51 0.69 1.27 1.88 0.67 0.59 5.61
7 .0 0.60 0.89 0.92 1.72 0.71 0.22 5.06
7.5 0.92 1.11 0.80 1.00 1.13 0.41 5.37
8 .0 1.14 0.83 0.75 0.61 1.05 0.45 4.83
Column
T o ta ls 16.44 14.64 14.06 19.09 13.31 11.72 89.26
164.
B ase : E m u ls ify in g  O intm ent B .P . c o n ta in in g  5 p e r  c e n t s a l i c y l i c  a c id ,
S a lic y la te  C oncentration
Mg./lOO ml.
Rabbit No. A B c D E F
Weight (Kg.) 3.425 3.500 3.450 3.450 3.300 3.400
Row
Sex Female Female Female Female Male Male Totals
Hours a f te r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.62 0.76 0.95 0.79 0.55 1.42 5.09
1 .0 0.85 0.72 1.58 0.79 0.70 0.95 5.59
1.5 0.69 0.74 0.71 1.06 0.94 0.93 5.07
2 .0 0.68 0.65 0.95 1.03 1.42 0.51 5.24
2.5 0.52 0.57 0.64 0.74 1.60 0.96 5.03
3.0 0.77 0.58 0.88 1.36 1.39 1.30 6.28
3.5 0.74 0.58 1.31 0.99 1.37 1.54 6.53
4 .0 0.69 0.54 1.47 1.32 1.37 1.34 6.73
4.5 0.86 0.74 1.53 1.46 0.69 Ô.97 6.45
5.0 0.78 0.65 0.91 1.56 0.83 1.21 5.94
5.5 0.98 0.67 0.91 0 .70 0.61 1.27 5.14
6.0 0.86 0.80 0.69 1.49 0.35 0.81 5.00
6.5  ■ 0.75 0.47 0.75 0.95 0.94 0.76 4.62
7 .0 0.51 0.56 0.75 0.86 0.90 0.53 4.11
7.5 0.64 0.57 0.86 0.75 0.61 0.91 4.34
8.0 0.59 0.64 1.09 1.22 0.75 1.02 5.31
Column
T ota ls 11.53 10.24 15.98 17.07 15.22 16.43 86.47
165.
B ase : E m u ls ify in g  Ointm ent B .P . c o n ta in in g  5 p e r  c e n t  s a l i c y l i c  a c id
S a lic y la te  C oncentration 
ÿ./ÏOO ml.
Rabbit No. A B C D E F
Weight (Kg.) 3.400 3.450 3.500 3.525 3.350 3.425 Row
Sex Female Female Female Female Male Male Total
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.71 0.82 1.50 0.74 0.72 0.91 5.40
1 .0 0.51 1 .04 1.41 1.12 0.94 1.42 6 .44
1.5 1.03 1.23 0.84 0.91 1.23 1.02 6.26
2 .0 1.20 0.90 0.73 0.88 1.20 1.40 6.31
2.5 0.81 1.21 0.75 0.61 1.31 1.33 6.02
3.0 1.20 1.01 0.84 0.74 1.43 1.23 6.45
3.5 0.94 0.73 0.71 1.31 1.43 1.14 6.26
4 .0 0.81 0.99 1.21 0.94 1 .04 0.73 5.72
4 .5 1.20 1.18 1.18 0.86 1.74 0.60 6.76
5 .0 1.30 1.39 0.91 0.86 1 .90 1.05 7.41
5.5 0.72 0.91 1.34 1.03 1.82 1.17 6.99
6.0 0.83 1.62 0.81 0.93 0.86 1.28 6.33
6 .5 1.33 0.93 1.12 0.82 1.09 1.26 6.55
7 .0 1.20 0.42 0.97 1.20 0.90 1.32 6.01
7.5 1.17 1.11 0.95 0.71 0.73 1.31 5.98
8 .0 0.92 1.20 1.11 0.99 1.10 0.93 6.25
Column
T o ta ls 15.88 16.69 16.38 14.65 19.44 18.10 101.14
166,
B ase : W ater a s  5 p e r  c e n t carB ozy m ethyl c e l lu lo s e  c o n ta in in g  10 p e r  c e n t
co p p er s u lp h a te .
Copper C oncentration 
: ./ io o  ml.
Rabhit Ro. 102 103 104 105 106 107
Weight (Kg.) 3.000 3.100 2,500 3.250 3.200 2.550 Row
Sex Female Female Female Female Male Male Totals
Hours a f t e r  
A p p lica tio n
0 ,0 0,00 0,00 0,00 0,00 0,00 0.00 0,00
0.5 0,19 0,22 0,26 0,16 0.17 0,23 1.23
1,0 0,22 0,27 0,26 0,21 0,22 0,16 1.34
1.5 0,14 0.16 0,16 0.13 0.18 0,29 1,06
2,0 0.09 0.14 0,09 0,22 0.18 0,21 0.93
2.5 0,12 0.07 0,16 0.18 0.23 0.18 0,94
3.0 0.23 0,11 0.21 0.19 0.16 0.14 1,04
3.5 0.16 0,00 0.14 0,27 0.18 0.17 0,92
4.0 0.15 0.16 0,12 0,30 0,23 0,19 1.15
4.5 0,27 0,22 0.12 0,21 0,27 0,21  . 1 .30
5 .0 0,20 0,34 0,18 0,16 0,14 0,34 1,36
5.5 0,14 0.16 0,21 0,15 0,15 0,21 1,02
6.0 0,13 0,11 0.14 0,11 0,09 0,10 0,68
6.5 0,00 0,21 0,22 0,21 0,21 0,26 1,11
7 .0 0,12 0.17 0,22 0,23 0,16 0.17 1.07
7.5 0,19 0,21 0,11 0,16 0,13 0,00 0,80
8,0 0,23 0,14 0.15 0,16 0.17 0,13 0,98
Column
T o ta ls 2.58 2,69 2.75 3.05 2,87 2.99 16,93
167.
B ase : W ater a s  5 p e r  c en t ca rb o x y  m ethy l c e l lu lo s e  in  10 p e r  c en t
copper s u lp h a te .
Copper Concentration 
Mg./lOO ml.
R abbit ITo. 102 103 104 105 106 107
Weight (Kg.) 3.200 3.100 2.600 3.350 3.300 2.650
Row
Sex Female Female Female Female Male Male T o tals
Hours a f t e r  
A pp lica tion
0.0 0.00 0,00 0.00 0.00 0.00 0.00 0,00
0.5 0.29 0.19 0.23 0.26 0.18 0.21 1,36
1 .0 0.32 0.21 0.21 0.35 0.22 0.18 1.49
1.5 0.16 0.33 0.19 0.14 0,22 0.27 1.31
2 .0 0.15 0.21 0.27 0.11 0.17 0.14 1,05
2.5 0.11 0.18 0.25 0.21 0.25 0.18 1.18
3.0 0.22 0.19 0.16 0.31 0.23 0.21 1.32
3.5 0.23 0.22 0.22 0,16 0.22 0.31 1.36
4-0 0.14 0.00 0.14 0,22 0.16 0.26 0.92
4 .5 0.26 0.14 0.13 0,14 0.18 0.18 1.03
5 .0 0.19 0.11 0.10 0.09 0.14 0.14 0.77
5.5 0.17 0.22 0.14 0,00 0.21 0,22 0,96
6 .0 0.23 0.19 0.21 0,15 0,11 0,33 1,22
6.5 0.18 0.13 0.13 0,18 0,20 0,20 1,02
7 .0 0.23 0.20 0.00 0,21 0.14 0.11 0.89
7 .5 0.30 0.13 0.19 0.16 0.10 0,16 1.04
8 .0 0.21 0.16 0.21 0.14 0.17 0.19 1.08
Column
T o ta ls 3.39 2.81 2.78 2.83 2.90 3.29 18.00
168 .
B ase: E m u ls ify in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t co p p er su lp h a te
Copper C oncen tration  
Mg. / loo ml.
R abbit Ho. 102 103 104 105 106 107
V/eight (Kg.) 3.250 3.200 2.700 3.450 3.450 2.750 Row
Sex Female Female Female Female Male Male T o ta ls
Hours a f te r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.23 0.20 0.30 0.19 0.26 0.36 1.54
1 .0 0.27 0.35 0.25 0.23 0.27 0.21 1.58
1 .5 0.25 0.29 0.17 0.21 0.16 0.22 1.30
2.0 0.24 0.16 0.20 0.22 0.21 0.24 1.27
2.5 0.18 0.19 0.16 0.34 0.26 0.17 1.30
3.0 0.11 0.16 0.22 0.19 0.24 0.16 1.08
3.5 0.19 0.16 0.24 0.18 0.25 0.19 1.21
4 .0 0.14 0.25 0.27 0.25 0.13 0.27 1.31
4.5 0.26 0.29 0.19 0.22 0.19 0.31 1.46
5.0 0.20 0.23 0.11 0.18 0.14 0.14 1.00
5.5 0.17 0.22 0.09 0.17 0.15 0.17 0.97
6.0 0.24 0.19 0.21 0.26 0.17 0.28 1.35
6.5 0.23 0.17 0.25 0.24 0.24 0.15 1.28
7.0 0.19 0.20 0.17 0.19 0.26 0.31 1.32
7.5 0.15 0.20 0.22 0.23 0.11 0.20 1.11
8 .0 0.27 0.15 0.14 0.20 0.21 0.19 1.16
Column
T o ta ls 3.32 3.41 3.19 3.50 3.25 3.57 20.24
1 6 9 .
B ase: E m u ls ify in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t copper s u lp h a te .
Copper C oncentration  
Mg./lOO ml.
R abhit Ho. 102 103 104 105 106 107
Weight (Kg.) 3.200 3.100 2.650 3.350 3.300 2.700 Row
Sex Female Female Female Female Male Male Totals
Hours a f t e r  
A p p lica tio n
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.26 0.31 0.33 0.30 0.19 0.23 1.62
1.0 0.20 0.24 0.36 0.25 0.21 0.19 1.45
1.5 0.18 0.20 0.22 0.24 0.28 0.22 1.34
2 .0 0.14 0.26 0.14 0.19 0.16 0.27 1.16
2.5 0.23 0.18 0.20 0.16 0.22 0.14 1.13
3.0 0.10 0.13 0.16 0.20 0.25 0.23 1.07
3.5 0.22 0.20 0.23 0.10 0.14 0.34 1.23
4.0 0.19 0.26 0.20 0.00 0.14 0.21 1.00
4.5 0.16 0.18 0.16 0.13 0.19 0.19 1.01
5 .0 0.20 0.19 0.24 0.21 0.23 0.26 1.33
5.5 0.22 0.21 0.17 0.31 0.22 0.21 1.34
6.0 0.25 0.17 0.22 0.21 0.11 0.18 1.14
6.5 0.27 0.21 0.26 0.16 0.13 0.33 1.36
7.0 0.23 0.28 0.24 0.13 0.20 0.27 1.35
7.5 0.20 0.19 0.21 0.20 0.19 0.25 1.24
8.0 0.16 0.19 0.17 0.12 0.23 0.22 1.09
Column
T o ta ls 3.21 3.40 3.51 2.91 3.09 3.74 19.86
170.
B ase : L ard c o n ta in in g  10 p e r  c e n t  copper s u lp h a te .
Copper C oncentration 
Mg./lOO m l.
Rabbit Ho. 102 103 104 105 106 107
Weight (Kg.) 3.100 3.100 2.600 3.300 3.250 2.650
Row
Sex Female Female Female Female Male Male T o ta ls
Hours a f t e r  
A pp lication
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.35 0.31 0.33 0.27 0.19 0.35 1.80
1 .0 0.22 0.26 0.29 0.30 0.24 0.24 1.55
1.5 0.25 0.29 0.14 0.22 0.18 0.19 1.27
2 .0 0.19 0.15 0.16 0.14 0.22 0.25 1.11
2.5 0.15 0.21 0.21 • 0.11 0.27 0.15 1.10
3.0 0.19 0.16 0.27 0.16 0.33 0.17 1.28
3.5 0.31 0.21 0.28 0.19 0.26 0.26 1.51
4 .0 0.14 0.11 0.20 0.27 0.24 0.31 1.27
4 .5 0.21 0.16 0.31 0.14 0.17 0.22 1.21
5 .0 0.22 0.20 0.33 0.26 0.23 0.23 1.47
5.5 0.14 0.23 0.19 0.22 0.25 0.27 1.30
6 .0 0.22 0.18 0.27 0.17 0.29 0.34 1.47
6.5 0.16 0.21 0.25 0.17 0.11 0.23 1.13
7.0 0.17 0.26 0.18 0.24 0.21 0.30 1.36
7.5 0.24 0.22 0.22 0.27 0.30 0.19 1.44
8 .0 0.27 0.14 0.22 0.23 0.19 0.32 1.37
Column
T ota ls 3.43 3.30 3.85 3.36 3.68 4.02 21.64
171.
Bases L ard  c o n ta in in g  10 p e r  c e n t  copper s u lp h a te
Copper C oncentration 
Mg./lOO ml.
R ahhit Ho. 102 103 104 105 106 107
Weight (Kg.) 3.100 3.100 2.550 3.300 3.300 2.650 Row
Sex Female Female Female Pemale Male Male Total
Hours a f t e r  
A pplication
0.0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.39 0.40 0.30 0.21 0.33 0.35 1.98
1 .0 0.32 0.30 0.15 0.22 0.39 0.22 1.60
1 .5 0.21 0.18 0.31 0.16 0.22 0.17 1.25
2 .0 0.14 0.27 0.22 0.20 0.16 0.19 1.18
2.5 0.17 0.23 0.16 0.21 0.20 0.24 1.21
3.0 0.21 0.24 0.18 0.15 0.14 0.16 1.08
3.5 0.22 0.16 0.20 0.10 0.23 0.27 1.18
4 .0 0.11 0.16 0.17 0.19 0.25 0.26 1 .14
4.5 0.19 0.22 0.14 0.21 0.17 0.22 1.15
5 .0 0.24 0.09 0.16 0.21 0.14 0.20 1.04
5.5 0.25 0.23 0.10 0.18 0.27 0.14 1.17
6 .0 0.12 0.21 0.27 0.21 0.32 0.18 1.31
6.5 0.25 0.13 0.18 0.25 0.26 0.22 1.29
7 .0 0.18 0.15 0.14 0.20 0.27 0.31 1.25
7.5 0.22 0.28 0.13 0.18 0.26 0.26 1.33
8 .0 0.15 0.18 0.28 0.11 0.27 0.24 1.23
Column
T o ta ls 3.37 3.43 3.09 2.99 3.88 3.63 20.39
172.
B ase ; L ard  c o n ta in in g  10 p e r  c e n t  copper a c e ty l - a c e to n a te ,
Copper C oncentration 
Mg./lOO ml.
Rabbit Ho. A B C D B F
W e i^ t (Eg.) 3.450 3.500 3.350 3.400 3.350 3.525 Row
Sex Female Female Female Female Male Male Totals
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.36 0.28 0.36 0.31 0.23 0.30 1.84
1.0 0.24 0.20 0.23 0.26 0.19 0.29 1.41
1.5 0.30 0.19 0.24 0.21 0.29 0.18 1.41
2.0 0.33 0.27 0.26 0.27 0.20 0.22 1.55
2.5 0.24 0.26 0.22 0.25 0.28 0.30 1.55
3.0 0.32 0.23 0.25 0.30 0.27 0.22 1.59
3.5 0.35 0.27 0.28 0.27 0.32 0.20 1.69
4 .0 0.22 0.24 0.33 0.20 0.19 0.24 1.42
4.5 0.36 0.21 0.25 0.25 0.24 0.33 1.64
5.0 0.32 0.27 0.27 0.23 0.23 0.15 1.47
5.5 0.18 0.21 0.28 0.25 0.21 0.30 1.43
6.0 0.17 0.18 0.20 0.27 0.23 0.20 1.25
6.5 0.24 0.27 0.29 0.28 0.21 0.26 1.55
7.0 0.14 0.22 0.18 0.18 0.20 0.22 1.14
7.5 0.19 0.25 0.23 0.26 0.24 0.25 1.42
8.0 0.29 0.18 0.18 0.22 0.15 0.21 1.23
Column
T o ta ls 4.25 3.73 4.05 4.01 3.68 3.87 23.59
173.
B ase; L ard  c o n ta in in g  10 p e r  c e n t copper a o e ty l - a o e to n a te .
Copper C oncentration  
Mg./lOO ml.
Rabbit Ho. A B C D E F
Weight (Kg.) 3.500 3.550 3.350 3.375 3.300 3.500
Row
Sex Female Female Female Female Male Male Total
Hours a f t e r  
A pp lication
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.27 0.51 0.54 0.25 0.14 0.60 2.31
1.0 0.18 0.15 0.27 0.28 0.54 0.19 1.61
1.5 0.31 0.19 0.18 0.51 0.24 0.39 1.82
2 .0 0.19 0.42 0.40 0.21 0.18 0.24 1.64
2.5 0.16 0.21 0.31 0.46 0.51 0.50 2.15
3.0 0.47 0.27 0.18 0.30 0.30 0.26 1.78
3.5 0.15 0.44 0.00 0.21 0.54 0.40 1.74
4.0 0.19 0.20 0.16 0.48 0.12 0.24 1.39
4.5 0.40 0.21 0.09 0.21 0.17 0.17 1.25
5.0 0.25 0.39 0.14 0.18 0.53 0.20 1.69
5.5 0.26 0.21 0.46 0.15 0.14 0.31 1,53
6.0 0.47 0.19 0.15 0.41 0.36 0.09 1.67
6.5 0.26 0.46 0.36 0.19 0.60 0.33 2.20
7.0 0.58 0.15 0.47 0.09 0.29 0.45 2.03
7.5 0.23 0.13 0.29 0.22 0.17 0.18 1.22
8 .0 0.25 0.19 0.16 0.19 0.38 0.25 1.42
Column
T o ta ls 4.62 4.32 4.16 4.34 5.21 4.80 27.45
174.
B ase : L ard  c o n ta in in g  10 p e r  c e n t copper a c e ty l - a c e to n a te
Copper C oncentration  
Mg./lOO m l.
Rabbit Ho. G H I J K L
Weight (Kg.) 3.325 3.375 3.300 3.750 3.425 3.600 Row
Sex Male Male Male Female Female Female Total
Hours a f t e r  
A p p lica tio n
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.28 0.42 0.33 0.20 0.27 0.39 1.89
1 .0 0.33 0.19 0.23 0.33 0.21 0.31 1.60
1 .5 0.32 0.28 0.18 0.20 0.24 0.25 1.47
2.0 0.18 0.27 0.29 0.25 0.38 0.30 1.67
2 .5 0.31 0.29 0.33 0.27 0.21 0.26 1.67
3 .0 0.28 0.22 0.24 0.22 0.20 0.28 1 .44
3.5 0.37 0.27 0.35 0.23 0.28 0.19 1.69
4.0 0.27 0.24 0.25 0.32 0.31 0.30 1.69
4.5 0.20 0.22 0.32 0.26 0.24 0.20 1.44
5 .0 0.14 0.26 0.24 0.21 0.26 0.32 1.43
5.5 0.20 0.21 0.37 0.31 0.24 0.19 1.52
6 .0 0.26 0.26 0.20 0.22 0.30 0.30 1 .54
6.5 0.24 0.32 0.52 0.19 0.24 0.27 1.78
7 .0 0.16 0.17 0.32 0.30 0.21 0.20 1.36
7 .5 0.27 0.22 0.24 0.25 0.37 0.21 1.56
8.0 0.33 0.22 0.31 0.21 0.23 0.29 1.59
Column
T o ta ls 4.14 4.06 4.72 3.97 4.19 4.26 25.34
175.
B ase : L ard  c o n ta in in g  10 p e r  c e n t  copper a c e ty l - a c e to n a te .
Copper C oncentration  
Mg./lOO ml.
R abbit Ho. G H I J K L
Weight (Kg. ) 3.300 3.350 3.250 3.800 3.400 3.700 Row
Sex Male Male Male Female Female Female Totals
Hours a f t e r  
A p p lica tio n
0.0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 .5 0.23 0.31 0.36 0.27 0.24 0.33 1.74
1.0 0.29 0.27 0.32 0.38 0.31 0.29 1.86
1.5 0.33 0.33 0.21 0.25 0.19 0.22 1.53
2.0 0.18 0.22 0.41 0.19 0.22 0.23 1.45
2.5 0.26 0.27 0.22 0.23 0.27 0.29 1.54
3.0 0.22 0.19 0.29 0.37 0.23 0.17 1.47
3.5 0.31 0.21 0.25 0.24 0.19 0.24 1.44
4 .0 0.24 0.26 0.26 0.23 0.24 0.31 1.54
4.5 0.17 0.34 0.16 0.25 0.19 0.22 1.33
5.0 0.29 0.26 0.37 0.36 0.14 0.40 1.82
5.5 0.29 0.27 0.29 0.29 0.28 0.21 1.63
6.0 0.19 0.23 0.27 0.30 0.25 0.36 1.60
6.5 0.21 0.20 0.31 0.31 0.21 0.23 1.47
7.0 0.20 0.19 0.18 0.27 0.11 0.14 1.09
7.5 0.14 0.27 0.28 0.31 0.18 0.27 1.45
8 .0 0.23 0.22 0.17 0.16 0.26 0.21 1.25
Column
T o ta ls 3.78 4.04 4.35 4.41 3.51 4.12 24.21
I ' f b .
Bases Water as  5 p e r  cen t carboxy methyl c e llu lo se  co n ta in in g  10 p e r cent 
copper a c e ty l-a c e to n a te
Copper C oncentration 
Mg./LOO ml.
Rabbit Ho. A B C D E F
Weight (Eg.) 3.500 3.550 3.425 3.350 3.200 3.450 Row
Sex Female Female Female Female Male Male Tota]
Hours a f t e r  
A pp lica tion
0.0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.30 0.27 0.31 0.22 0.31 0.20 1.61
1 .0 0.28 0.16 0.21 0.22 0.11 0.18 1.16
1.5 0.26 0.18 0.00 0.14 0.21 0.27 1.06
2.0 0.20 0.23 0.17 0.15 0.18 0.16 1.09
2.5 0.22 0.20 0.14 0.20 0.16 0.15 1.07
3.0 0.21 0.12 0.20 0.19 0.19 0.18 1.09
3.5 0.19 0.27 0.13 0.23 0.27 0.20 1.29
4.0 0.14 0.27 0.17 0.24 0.24 0.15 1.21
4.5 0.22 0.20 0.15 0.16 0.15 0.11 0.99
5.0 0.16 0.17 0.10 0.14 0.12 0.17 0.86
5.5 0.14 0.14 0.22 0.12 0.00 0.24 0.86
6.0 0.13 0.21 0.15 0.21 0.09 0.13 0.92
6.5 0.19 0.12 0.16 0.20 0.17 0.17 1.01
7.0 0.00 0.13 0.21 0.18 0.22 0.21 0.95
7.5 0.10 0.19 0.18 0.11 0.14 0.24 0.96
8.0 0.15 0.17 0.18 0.18 0.25 0.16 1.09
Column
T o ta ls 2.89 3.03 2.68 2.89 2.81 2.92 17.22
I f f .
Bases Water as 5 p er cent carbozy methyl c e llu lo se  con ta in ing  10 p er cent 
copper a c e ty l-a c e to n a te •
Copper C oncentration 
Mg./lOO ml.
Rabbit Ho. A B c D E F
Weight (Kg.) 3.550 3.575 3.500 3.350 3.200 3.400
Row
Sex Female Female Female Female Male Male T o ta ls
Hours a f t e r  
A pp lica tion
0.0 0.00 0 .00 0.00 0.00 0.00 0.00 0.00
0.5 0.30 0 .30 0.33 0.27 0.26 0.34 1.80
1.0 0.31 0.21 0.24 0.24 0.21 0.21 1.42
1.5 0.24 0.25 0.22 0.22 0.26 0.24 1.43
2.0 0.20 0.17 0.23 0.23 0.23 0.19 1.25
2.5 0.18 0.15 0.19 0.23 0.19 0.17 1.11
3.0 0.19 0.22 0.24 0.22 0.00 0.14 1.01
3.5 0.17 0.13 0.15 0.22 0.14 0.14 0.95
4 .0 0.12 0.19 0.17 0.11 0.18 0.11 0.88
4 .5 0.17 0.21 0.17 0.00 0.15 0.21 0.91
5.0 0.13 0.15 0.21 0.15 0.16 0.23 1.03
5.5 0.15 0.18 0.18 0.17 0.19 0.16 1.03
6.0 0.20 0.24 0.20 0.13 0.11 0.14 1.02
6.5 0.18 0.00 0.19 0.22 0.08 0.21 0.88
7 .0 0.19 0.15 0.16 0.18 0.17 0.30 1.15
7.5 0.27 0.20 0.22 0.16 0.23 0.18 1.26
8 .0 0.17 0.15 0.20 0.23 0.16 0.11 1.02
Column
T o ta ls 3.17 2.90 3.30 2.98 2.72 3.08 18.15
17Ü ,
Bases E m u ls ify in g  O intm ent B .P . c o n ta in in g  10 p e r  c e n t co p p er a c e ty l - a c e to n a te .
Copper C oncentration 
Mg./lOO ml.
Rabbit No. G H I J K L
Weight (Kg. ) 3.250 3.325 3.250 3.800 3.450 3.900 Row
Sex Male Male Male Female Female Female Totals
Hours a f t e r  
A pp lica tion
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.27 0.29 0.16 0.26 0.25 0.19 1.42
1.0 0.31 0.29 0.19 0.24 0.19 0.27 1.49
1.5 0.24 0.18 0.51 0.21 0.19 0.24 1.57
2.0 0.21 0.27 0.25 0.22 0.15 0.23 1.33
2.5 0.17 0.26 0.23 0.39 0.21 0.10 1.36
3.0 0.26 0.17 0.14 0.22 0.16 0.19 1.14
3.5 0.21 0.22 0.23 0.19 0.17 0.28 1.30
4.0 0.25 0.21 0.21 0.20 0.20 0.18 1.25
4.5 0.26 0.11 0.17 0.28 0.14 0.26 1.22
5 .0 0.23 0.20 0.23 0.26 0.19 0.23 1.34
5.5 0.25 0.18 0.26 0.22 0.13 0.20 1.24
6.0 0.14 0.13 0.24 0.21 0.27 0.34 1.33
6.5 0.23 0.25 0.17 0.18 0.16 0.19 1.18
7.0 0.26 0.24 0.12 0.15 0.17 0.18 1.12
7.5 0.17 0.20 0.14 0.22 0.28 0.26 1.27
8.0 0.17 0.18 0.21 0.25 0.20 0.18 1.19
Column
T o ta ls 3.63 3.38 3.46 3.70 3.06 3.52 20.75
179.
Bases E m u ls ify in g  O intm ent B.P* c o n ta in in g  10 p e r  c e n t copper a o e ty l- a c e to n a te
Copper C oncentration  
Mg./lOO ml.
R abbit Ho. G H I J K L
Weight (Kg.) 3.350 3.250 3.275 3.500 3.475 3.475 Row
Sex Male Male Male Female Female Female Tota]
Hours a f te r  
A pplication
0.0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.32 0.24 0.33 0.18 0.23 0.29 1.59
1.0 0.27 0.29 0.21 0.30 0.22 0.28 1.57
1.5 0.18 0.40 0.24 0.20 0.27 0.20 1.49
2.0 0.29 0.20 0.23 0.23 0.25 0.20 1.40
2.5 0.29 0.23 0.25 0.25 0.33 0.22 1.57
3 .0 0.21 0.23 0.31 0.17 0.21 0.24 1.37
3.5 0.23 0.24 0.18 0.23 0.23 0.24 1.35
4 .0 0.21 0.26 0.25 0.13 0.20 0.32 1.37
4 .5 0.20 0.23 0.27 0.20 0.23 0.18 1.31
5 .0 0.24 0.15 0.16 0.21 0.33 0.24 1.33
5.5 0.30 0.21 0.34 0.19 0.22 . 0.24 1.50
6 .0 0.23 0.34 0.28 0 . l 6 0.25 0.23 1.49
6 .5 0.24 0.27 0.22 0.19 0.23 0.29 1.44
7 .0 0.16 0.21 0.29 0.19 0.26 0.34 1.45
7.5 0.22 0.21 0.32 0.14 0.15 0.24 1.28
8 .0 0.19 0.24 0.22 0.17 0.29 0.23 1.34
Column
T o ta ls 3.78 3.95 4,10 3.14 3.90 3.98 22.85
180,
Bases L ard  c o n ta in in g  10 p e r  c e n t su lp h a n ila m id e  and 10 p e r  c en t copper su lp h a te .
Sulphanilam ide C oncentration  
Mg./lOO m l.
Rahhit Ho. G H I J K L
Weight (Kg.) 3.500 3.550 3.450 3.700 3.550 3.600
Row
Sex Male Male Male Female Female Female Totals
Hours a f te r  
A pplication
0 .0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.60 0.95 0.68 1.14 0.68 0.65 4.70
1.0 0.61 1.03 0.85 0.70 0.69 0.80 4.68
1.5 0.54 0.72 0.67 0.53 0.74 0.83 4.03
2 .0 0.43 0.84 0.61 0.67 1.07 0.72 4.34
2.5 0.63 0.79 0.55 0.31 0.84 0.94 4.06
3.0 0.84 0.81 0.65 0.91 0.67 0.90 4.78
3.5 0.50 0.74 0.75 0.88 0.99 0.54 4.40
4 .0 0.35 0.62 0.93 0.60 0.80 0.79 4.09
4.5 0.53 0.81 1.02 0.42 0.85 0.81 4.44
5.0 0.20 0.51 0.70 0.63 0.63 0.72 3.39
5.5 0.29 0.70 0.89 0.81 0.44 0.34 3.47
6.0 0.15 0.61 0.32 0.75 0.67 0.65 3.15
6.5 0.71 0.83 0.46 0.77 0.82 0.41 4.00
7.0 0.62 0.72 0.69 0.51 0.91 0.38 3.83
7.5 0.66 0.50 0.80 0.34 0.88 0.84 4.02
8 .0 0.53 0.64 0.51 0.47 0.78 0.46 3.39
Column
T ota ls 8.19 11.82 11.08 10.44 12.46 10.78 64.77
181.
Bases L ard c o n ta in in g  10 p e r  c e n t su lp h a n ila m id e  and 5 p e r  c e n t s a l i c y l i c  a c id
Sulphanilam ide C oncentration  
Mg./lOO ml.
R abhit Ho. A B C B E F
Weight (Kg.) 3.550 3.575 3.400 3.425 3.400 3.525 Row
Sex Female Female Female Female Maie Maie Tota]
Hours a f te r  
A pp lica tion
0.0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.54 0.95 0.71 1.21 0.72 0.67 4.80
1 .0 0.78 0.72 0.89 1.09 1.17 0.81 5.46
1.5 1.23 0.64 1.14 0.83 0.91 1.16 5.91
2.0 0.99 0.70 1.02 1.12 0.50 0,73 5.06
2.5 0.46 1.18 0.87 0.11 1.21 0.91 5.40
3.0 1.15 0.51 0.91 0.43 1.31 0.81 5.22
3.5 0.95 0.61 0.47 0.91 0.81 1.03 4.78
4 .0 1.13 1.15 0.92 1.20 1.08 1.15 6.63
4 .5 0.72 0.52 1.12 0.94 1.28 0.83 5.41
5.0 0.80 0.73 0.84 0.33 1.23 0.95 4.93
5.5 0.91 1.03 0.77 0.56 1.14 0.43 4.84
5.0 1.10 0.89 0.92 0.9c 1.00 0.67 5.48
6.5 1.02 1.12 0.83 1.07 0.56 0.31 4.91
7 .0 0.91 0.71 0.41 1.11 0.72 0.40 4.26
7.5 1.27 0.83 0.91 1.03 0.66 0.65 5.35
8 .0 0.75 0.57 1.04 0.88 0.93 0.33 4.50
Column





The Analysis of Variance
Thi^ ee complete analyses of variance v/ere carried out 
on the results obtained from Hydrous Ointment B.P., Emulsifying 
Ointment B.P. and Hydrous Emulsifying Ointment B.P.% on a Dutch,
B ever en and Copenhagen ViThite litter of rabbits.
Prom the results obtained in each litter, three tables 
were constructed. The first compared the response of each of the 
six rabbits to each of the three bases, the second compared the 
response of the six rabbits at corresponding times, and the third 
compared the amount absorbed from each of the three bases at 
corresponding times.
On each of these three tables an analysis of variance 
into components due to Rows, Columns and a Residual was carried 
out. These three two-factor analyses were drawn together and 
combined in a three factor analysis and each term tested for 
significance. The three factor analyses obtained for the Butch, 
Beveren and Copenhagen White breeds are given and the sources 
of variance shown to be significant are marked.
The implication and possible cause of their significance 
are discussed in the results.
183,
The A nalyses o f  V ariance on th e  r e s u l t s  
o b ta in ed  from  Hydrous Ointment B .P .,  
E m u lsify in g  Ointm ent B .P ,,  and Hydrous 
E m ulsify ing  Ointment B .P ., c o n ta in in g  te n  
p e r  c e n t su lp h a n ila m id e , a p p lie d  to  s ix  
Dutch r a b b i t s
Source of 
Variance




Between bases 2 9.6210 4.8105 Significant
Between rabbits 5 1.2539 0.2507 Not significant
Between times 15 3.2698 0.2179 Not significant
Base X Time 30 4.2827 0.1428 Not significant
Base X Rabbit 10 4.0881 0.4088 Significant
Time x Rabbit 75 5.2016 0.0694 Significant
Base X Time x 
Rabbit 150 18.1288 0.1207 Not significant
Residual 288 45.3252 0.1574
Total 575 136.4963
184.
The A nalyses o f V ariance on th e  r e s u l t s  
o b ta in e d  from  Hydrous Ointment B .P ., 
E m u lsify in g  Ointment B .P ., and Hydrous 
E m u lsify in g  Ointment B .P ,, c o n ta in in g  te n  
p e r  c e n t su lp h a n ila m id e , a p p lie d  to  s ix  









Between bases 2 3.5308 1.7519 Significant
Between rabbits 5 0.6288 0.1258 Not Significant
Between times 15 1.5172 0.1011 Significant
Base X Time 30 1.1396 0.0380 Not Significant
Base X Rabbit 10 1.9874 0.1985 Significant
Rabbit x Time 75 3.2520 0.0434 Not Significant
Base X Time x 
Rabbit 150 7.6205 0.0508 Not Significant
Total 287 19.6466
Since the  r e s u l t s  o f  t h i s  experim en t cou ld  n o t be 
d u p lic a te d  th e  Base x  Time x R abb it i n t e r a c t i o n  f a c to r  i s  th e  
b e s t  e s t im a te  o f  a  R esid u a l w hich can  be made.
185.
The A nalyses o f  V ariance on th e  r e s u l t s  
o b ta in ed  from  Hydrous Ointment B.P#, 
E m ulsify ing  O intm ent B .P .,  and Hydrous 
E m u lsify in g  O intm ent B .P .,  c o n ta in in g  te n  
p e r  c e n t su lp h a n ila m id e , a p p lie d  to  s ix  
Beveren r a b b i t s
Source o f  
V ariance
Degrees o f  
Freedom




Between b ases 2 43.9078 21.9539 S ig n if ic a n t
Between r a b b i t s  5 1.7501 0.3500 Not S ig n if ic a n t
Between tim es 11 16.1366 1.2851 Not S ig n if ic a n t
Base X  Time 22 24.0431 1.0929 S ig n if ic a n t
Base X R abbit 10 24.1965 2.4197 S ig n if ic a n t
R abb it x  Time 55 19.5705 0.3558 Not S ig n if ic a n t
Base X Time x  
R abbit 110 44.9525 0.4086 Not S ig n if ic a n t
R esid u a l 216 75.0986 0.3489
T o ta l 431 249.6557
186.
Comparisoh o f the Means o f Male and Female 
Rahhits By S t u d e n t t - t e s t
' .
T his was u n d erta k en  on th e  r a h h i t s  o f  th e  Dutch l i t t e r
317.93
Mean r e s u l t  f o r  th e  s ix  r a h h i t s  = ■ ■■ = 0.5520
576
213.75
Mean r e s u l t  f o r  male r a b b i t s  = —  —  = 0.5568
384
104.18
Mean r e s u l t  f o r  fem ale r a b b i t s  —  « 0.5426
R esid u a l V ariance f o r  th e  t e s t s  0.1574
^ 0.5569 - 0.5426 _/3&4 X 192








This value i s  not s ig n if ic a n t  a t the 5 p e r  cent l e v e l .
I t  may therefore he concluded that there i s  no s ig n if ic a n t  
d ifferen ce  in  the percutaneous absorption  o f sulphanilam ide by 
male and fem ale r a b b its .
Since no large d iffe r e n c e s  between the sexes were ever  
apparent in  subsequent t e s t s ,  t h is  con clu sion  may j u s t i f ia b ly  be 
extended to  a general p r in c ip le .
187.
The Comparison of r e s u l t s  from th e  Dutch and Copenhagen l i t t e r s
Mean response of Dutch l i t t e r  « - - - - - -  ** 0*5520
576
150.31
Mean response of Copenhagen l i t t e r   -----------  0*5219
268
D ifference "between means = 0*5520 -  0*5219 = 0*0301
13.9996 + 0.7432 14.7428
Variance  ---------————   ---------------  0,0171
862 862
0.0171
To allow  fo r  numbers in  samples, d iv id e  by 192 = ---- —
192 
« 0.000089
T herefore, th e  stan d ard  d ev ia tio n  = / 0*000089 = 0*009438
0*0301
Therefore, th e  d iffe re n c e  between means  ----------------  3.1892
0*009438
This value i s  s ig n if ic a n t and i t  may be concluded th a t  
th e re  i s  a s ig n if ic a n t  d iffe re n ce  in  th e  response o f r a b b its  o f 
d if fe re n t breeds* For accuracy i t  i s  th e re fo re  d e s ira b le  th a t  
a l l  experim ents be conducted on ra b b its  o f th e  same breed . As 
a r e s u l t  o f th i s  f in d in g  a l l  subsequent t e s t s  were c a rr ie d  out 
on Copenhagen White rabb its*
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1 » A review o f  the laethdfal *##d to  e a t l n t e  the
roloaeo o f  irtedicinaX rihntrnijta from to p lea l applications  
has boan carried o u t, v
Z* An in  vivo t e s t  has b##m deiigjued to  estim ate the  
o ffio ien o y  o f  to p ic a l a p p lio # lo n s as ''carriers" o f  drugs 
t iiro u ^  in ta c t skin# The b l# d  le v e l  a tta ined  by the applied
drug was taken as the oritorlim  o f  e ff ic ien cy #
3 , Sulphanllanido was to # e d  in  eleven  v eh ic le s  and bases
and, taking the le a s t  e f f i o l e #  v eh ic le  as u n ity , the
follow ing ooirparativG valuos èbtainedi lard ( 2 ,48 ) ,  
propylene g ly co l ( 1 , 89) ,  Hydreus Ointiasnt B,P* ( 1 , 89) ,  white  
so ft  p araffin  ( 1 . 83) ,  othyl o leate  ( 1 , 83) ,  cetom crogol 
e m ls ify in g  wax base ( 1 ,44 ) ,  # e s ls ify in g  Ointment B,P,  ( l , 3l ) ,  
liq u id  paraffin  ( 1 . 31) ,  Hydrous Emulsifying Ointment B,P,  ( 1 , 17) ,  
wDolfat ( 1#14) ,  water as a f i v i  per cent oarboxymsthyl 
c e llu lo se  g e l ( 1 , 00 ) .
4 $ S a l ic y l ic  a c id , sulpbsm llam ldc, copper a c e ty l-a c e to n a te
Bjïà coppor su lp h a te  were re s p e c tiv e ly  in co rpo ra ted  in  la r d ,  
Kinulsifying Ointnent 3.P. ami w ater as a  f iv e  per cen t 
oarbojrv'nethyl cellulose gel, sM  th e  blood le v e ls  of th e  
drugs noted# Salicylic acid and su lphanilam ide were 
respectively five and four tim es more e f f i c i e n t  th a n  th e  
two compounds of coprer# The r e s u l t 's  o f  a l l  experim ents 
væ re statistically analysed end th e  s ig n i f ic a n t  sources 
of variance noted.
5# The vehicle or base in flu en ces th e  blood level
attained by the incorporated drug but sin ce  th e  amount 
absorbed throu^ the intact skSn i s  so sm a ll, these d if fe re n c e s  
in efficiency are of little i% o rta n o e . The ability of 
different drugs to ponotr vbe in ta c t  sk in  and be absorbed 
systemic ally varies considorably. The Interaction of a 
drug rd-th the vehicle or base in  which i t  i s  incorporated 
may either hinder or promote Wie percutaneous absorption 
of that drug#
